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Introduction 
 
Chapter 1: Conformationally Constrained Peptidomimetics 
 
1.1 Peptidomimetics 
Peptidomimetic is a term of broad meaning, often invariably referred to modified peptides 
(“peptide-derived peptidomimetics”) and to other molecules lacking a close structural 
relationship to natural peptides (“non-peptide peptidomimetics”).1 Generally speaking, 
peptidomimetics are compounds designed to mimic natural peptides or protein segments, 
retaining the capacity to interact with their biological targets, possibly with an improved 
activity and a better selectivity; depending on the agonistic or antagonistic behaviour of the 
specific peptidomimetic, the native peptide effects can be increased or inhibited. Moreover, 
peptidomimetics can prevent some of the problems usually associated with the 
pharmacological use of their natural correspondents: sensitivity to proteolysis and poor 
bioavailability. Therefore, this class of compounds can potentially express optimal drug 
candidates.2 
One of the main issue concerning the design of peptide-derived peptidomimetics is the 
conformational behaviour, especially for those meant to mimic a small portion of a protein 
structure, lacking the intramolecular interactions characteristic of the protein. In fact, small 
peptides, especially those composed by less than twelve amino acids, are usually characterized 
by a certain flexibility due to the multiple conformations that are energetically accessible for 
each of their residues; in most cases they exist in numerous dynamically interconverting 
conformations. This flexibility tends to be a major problem in getting a good ligand-receptor 
interaction, since usually only one specific conformer is recognized by the binding site of the 
target. A mixture of interconverting conformers inevitably exhibits a lower concentration of 
the active one, not to mention the unfavourable entropic contribution associated with the 
forcing of a flexible molecule in a geometrically organized binding site; all this results in a 
reduction of the biological activity of the compound. 
Therefore, the incorporation of conformational constraints into peptidomimetics is a well-
established approach for enhancing their efficacy and selectivity. Obviously, such restrictions 
have to be designed to make the compound to assume a matching conformation for the 
binding site, otherwise the activity can be lost completely. 
Chemists have available several methods to obtain a reduction of the conformational space in 
a molecule; in the next section we address the most widely adopted. 
 
1.2 Global and Local Constrains 
Cyclization, N-methylation and incorporation of conformationally restricted building blocks are 
all valid strategies to introduce conformational constrains into a peptide. While the first 
method leads to a global restriction in the molecule, the others can be used to constrain a 
portion of the peptide sequence, blocking the rotation of specific dihedral angles.3 Obviously, 
it is also possible to effectively combine the two approaches in the design of a cyclic 
peptidomimetic. 
 
Peptides can be cyclized in different fashions: head-to-tail, by connecting the N- with the C-
terminus of the sequence (figure 1, A); backbone-to-side chain, by binding either the N- or the 
C-terminus with one of the side chains (figure 1, B); or side chain-to-side chain, by coupling 
Introduction: Chapter 1 
 
4 
 
two side chains with each other (figure 1, C). In most of the cases, the side-chain-to-side chain 
cyclization is obtained introducing amide bonds or disulphide bridges between suitable side 
chains. In any case, the global conformational space of the peptide is drastically reduced, 
especially concerning the backbone angles. Independent rotations become strictly limited and 
a strong hydrogen-bond network is usually enabled to arise.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Examples of peptide cyclization: (A) head-to-tail, (B) backbone-to-side chain, (C) side 
chain-to-side chain. 
 
On the other hand, local constrains can be obtained by introducing unnatural rigid amino 
acids, often synthesized by modifying natural amino acids to a certain extent. One of the 
simplest and most broadly adopted modifications is the replacement of the α-hydrogen with 
another residue, generating Cα-tetrasubstituted amino acids, characterized by a reduction of 
the rotational freedom of the peptide dihedral angles, due to the increased steric hindrance. 
One important representative of this class of compounds, the rare naturally occurring achiral 
α-aminoisobutyric acid (Aib), can be obtained by replacing the α-hydrogen on alanine with a 
methyl group (figure 2); this amino acid is a strong helix former and it is widely adopted in the 
synthesis of peptidomimetics.4 
 
 
 
 
 
 
 
Figure 2. 
 
Introducing extra cycles of various sizes is another efficient strategy to limit the possible 
conformations of a given amino acid, since this modification can constrain simultaneously the 
backbone dihedral angles (ψ and φ) and the side chain angles (χn) (figure 3).  
 
 
 
 
Aa1 Aa2 Aa3 Aa4 Glu Aa6
Aa1 Lys Aa3 Aa4 Aa5 Aa6
Aa1 Cys Aa3 Aa4 Cys Aa6
SS
Aa1 Lys Aa3 Aa4 Glu Aa6
COHN
Aa1 Aa2 Aa3 Aa4 Aa5 Aa6A
B
C
H2N COOH
H3C H
H2N COOH
H3C CH3
1
Alanine
2
α-aminoisobutyric acid (Aib)
Introduction: Chapter 1 
 
5 
 
 
 
 
 
 
 
Figure 3. Peptide torsional angles. 
 
In case extra cycles contain the amino group of the molecule, an entire category of 
azacycloalcane carboxylic acids can arise, comprehending aziridinecarboxylic acids, 
azetidinecarboxylic acids, pyrrolidinecarboxylic acids (proline derivatives), piperidinecarboxylic 
acids (pipecolic acid derivatives), indolinecarboxylic acids, polycyclic prolines, 
indolizidinonecarboxylic acids, octahydroindolecarboxylic acids, 
tetrahydroisoquinolinecarboxylic acids and many others (figure 4).5-7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Azacycloalcane carboxylic acids. 
 
The proline derivatives (also referred to as “proline chimeras”8 when the side chain of a 
natural amino acid is incorporated in the pyrrolidine ring) doubtless represent the largest of 
these families (figure 4, 5); they have been extensively synthesized and employed to prevent 
α-helix formation and to encourage the formation of β-turn in peptidomimetics, thanks to the 
strong constrain experienced by the rotation of the N-Cα bond. Moreover, proline analogues, 
exhibiting a low barrier to cis/trans isomerism about the peptide bond, can be exploited to 
orient this equilibrium towards a preferred geometry, due to its importance in peptide 
folding.9 
On the other hand, pipecolic acid (figure 4, 6), being a non-proteinogenic amino acid, can be 
used itself as a proline substitute in peptides or proteins, especially to investigate the role of 
ring size in structure and function.10-12 Moreover, many functionalized pipecolic acids have 
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been prepared and used as constrained analogues of other amino acids, in a similar fashion to 
proline.5,13 The most relevant examples are the constrained aromatic amino acids 1,2,3,4-
tetrahydroisoquinoline-3-carboxylic acid (Tic) (figure 4, 11), 1,2,3,4-tetrahydro-7-
hydroxyisoquinoline-3-carboxylic acid (Htc) (figure 4, 12), 3-carboxy-1,2,3,4-tetrahydro-2-
carboline (Tcc) (figure 4, 13) and spinacine (Spi) (figure 4, 14), where the aromatic rings of 
phenylalanine, tyrosine,  tryptophan and histidine are fused with the piperidine moiety, 
resulting in a simultaneous restriction of backbone and side chain angles.14 Another still poorly 
explored class of further constrained pipecolic acid derivatives is constituted by the 
cyclopropane pipecolic acids (or methanopipecolic acids), where two contiguous carbon atoms 
of the piperidine ring are tethered together by a methylene bridge (figure 4, 15). Such 
molecules are part of the central topic of this work and will be addressed in a dedicated 
chapter (see section 2.3). 
 
Regarding the cycles not involving the amino group, there are again examples of rigid amino 
acids incorporating all-carbon rings of any size.5 However, the most relevant place is by far 
occupied by the just mentioned cyclopropane moiety, since the three-membered ring is one of 
the most appealing structural unit for the preparation of restricted building blocks, due to its 
rigidity and its partial unsaturated character.5,15 Therefore, aside from being widely 
incorporated in constrained amino acids (cyclopropane amino acids will be addressed in 
chapter 2), this moiety has been also selected to be embedded in the target molecules of this 
work. 
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Chapter 2: Cyclopropane Amino Acids 
 
2.1 Monocyclic Cyclopropane Amino Acids 
The simplest cyclopropane α-amino acid is 1-Aminocyclopropane-1-carboxylic acid (ACC, 2,3-
methanoalanine) (figure 1, 1), a natural intermediate in the conversion of methionine to 
ethylene, compound extensively utilized as hormone by plants. ACC was also the first 
cyclopropane amino acid incorporated in a peptide sequence, specifically an analogue of Leu5-
enkephalin, in which ACC replaced a glycine residue (figure 1, 4).1 This amino acid, together 
with other two natural secondary metabolites, coronamic acid (figure 1, 2) and norcoronamic 
acid (figure 1, 3), constituted the paradigm for a large number of artificial monocyclic 
quaternary α-amino acids, where the Cα and the Cβ are tethered in a cyclopropane ring. 
Following this model, many “cyclopropylogues” of natural amino acids have been synthesized, 
not to mention numerous other molecules bearing functionalities not strictly connected with 
natural correspondents (figure 1, 5).2-4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. 
 
These amino acids have been employed for the synthesis of either model and biologically 
active peptidomimetics, showing interesting structural features.5-11 Combined NMR and 
computational studies have demonstrated how the presence of the cyclopropane moiety may 
deeply reduce the conformational space accessible to the peptidomimetics incorporating 
cyclopropylogues. On one side, the χ1 angle results locked by tethering Cα to Cβ, leading to a 
rigid control on the orientation of the side chain of the single cyclopropylogue; on the other 
hand, the large steric hindrance of the cyclopropane ring restricts also the proximal backbone 
torsion angles, influencing the conformation of the vicinal amino acids. Accordingly, the 
presence of cyclopropylogues has been seen promoting the formation or augmenting the 
stability of different secondary structure elements, especially γ-turn, even in very short 
peptides.5-7  
Other important and numerous monocyclic cyclopropane α-amino acids are those bearing the 
cyclopropane ring on the side chain, not involving any backbone atom (figure 2). The 
prototype of this class is the cyclopropylglycine (figure 2, 6), but many other differently 
functionalized derivatives have been synthesized and studied; the cyclopropane moiety can 
either involve only one carbon atom of the side chain or comprise two contiguous positions 
tethering them together by a methylene bridge.12 Among the second type, the most important 
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derivatives are the various stereoisomers of 2-(carboxycyclopropyl)glycine (CCG) (figure 2, 8), 
in which the cyclopropane ring tethers together Cβ and Cγ of a glutamic acid side chain. These 
constrained analogues of glutamic acid, found as secondary metabolites in plants,13 are not so 
relevant for peptide synthesis, but they are extremely active agonists of the glutamic acid 
receptors in the mammalian central nervous system (CNS).14 Since their considerable 
pharmacological significance, many variously substituted versions of these amino acids have 
been synthesized, yielding also to a new class of selective and potent mGLUr receptors 
antagonists (figure 2, 9).15,16 
 
 
 
 
 
 
 
 
Figure 2. 
 
More recently, also cyclopropane β-amino acids have attracted attentions as constituents of 
peptidomimetics. Whereas there is an univocal way to build a cyclopropane ring on the 
backbone of an α-amino acid, in the case of β-amino acids there are three different 
possibilities. Starting from the simple linear structure of β-alanine, the cyclopropyl group can 
be placed like two geminal substituents in the α- or β-position (figure 3, 11 and 12), as 
similarly illustrated for α-cyclopropylogues; otherwise, the cyclopropane ring can incorporate 
both the positions, linking theme by a methylene bridge (figure 3, 13).17  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Cyclopropyl β-alanines. 
 
The simplest representative of the first group, α-cyclopropyl-β-alanine (figure 3, 11 R=H), has 
been used for the synthesis of mimetics of natural depsipeptides belonging to the family of 
cryptophycins, which exhibit high activity against a broad spectrum of tumours (figure 4).18 The 
augmented steric hindrance, due to the cyclopropane ring, proved to be suitable for 
protecting the ester bond of these depsipeptides from hydrolysis, increasing their stability and 
antitumor activity against leukaemia.19 
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Figure 4. Cyclopropyl analogues of cryptophycins. 
 
In another study, homooligomers of α-cyclopropyl-β-alanine (11, R=H) have been crystalized 
and studied by X-ray diffraction, revealing the formation of boatlike eight-membered H-
bonded rings. This peculiar geometry, confirmed to be present even in solution, made 
hypothesize a “pleated ribbon” or a “flight of stairs” structure as a possible motif for a β-
peptide consisting of α-cyclopropyl-β-alanine; such arrangement has no correspondents in the 
realm of α-peptides and proteins.20 
The second group, composed by the β-cyclopropyl-β-amino acids, has been probably even 
more expanded, and several analogues, incorporating the side chains of natural amino acids, 
have been synthesized. For instance, a common synthetic route to serine, cysteine, arginine 
and lysine mimics have been developed; the latter two have been used for the synthesis of 
analogues of the antibiotics TAN-1057 A (16) and B (17) (figure 5).21 
 
 
 
 
 
 
Figure 5. Cyclopropyl analogues of antibiotics TAN-1057 A and B. 
 
Whereas these first two families of molecules are characterized by similar properties, those 
where the α and β-positions are tethered together are slightly different. The bridging of these 
two positions creates the most severely conformationally constrained β-alanine analogues 
possible, making these 2-aminocyclopropanecarboxylic acids (β-ACCs) extremely attractive as 
constituents of peptides. However, their utilization results pretty challenging, since β-ACCs 
belong to the class of vicinally donor-acceptor substituted cyclopropanes, which are extremely 
prone to undergo ring opening, resulting in their degradation. Nonetheless, adopting special 
synthetic strategies, this obstacle has been overcome and some β-ACCs-containing 
peptidomimetics have been obtained.17 Among these products are the shortest known linear 
ligands with nanomolar affinity and good selectivity for the Neuropeptide Y1 receptor (figure 
6, 18 and 19), not to mention the potent nanomolar cyclopeptide ligand cyclo-(-Arg-Gly-Asp-
(‒)-β-Acc-Val-) (20) selective for integrin αvβ3 (see chapter 3 for a more detailed description of 
integrin ligands).22,23 
β-ACCs derivatives demonstrated to produce strongly defined and stable conformations even 
in very short linear peptidomimetics; studies performed on oligomers of various sizes 
alternating units of β-ACCs and alanine indicated the formation of defined structures starting 
from the pentapeptides, while the extension of the sequence to seven residues resulted 
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enough to develop helical structures.24 Therefore, β-ACCs can be acknowledged as building 
blocks for foldamers, behaving complementarily to the turn-inducer proline derivatives.  
 
 
 
 
 
 
 
 
 
 
 
Figure 6. β-ACCs-containing biologically active peptidomimetics. 
 
2.2 Cyclopropane Proline Derivatives 
Cyclopropane Prolines, commonly referred to as methanoprolines, represent another class of 
interesting constrained amino acids. By building the cyclopropane moiety on a proline 
heterocycle is possible to obtain three different regioisomers, namely 2,3-methanoproline, 
3,4-methanoproline and 4,5-methanoproline (figure 7).  
 
 
 
 
 
 
 
Figure 7. Methanoprolines. 
 
The second regioisomer (22) is the only naturally occurring of the series; its cis form was 
discovered in 1969 in the fresh seeds of the american horse chestnut, Aesculus parviflora,25 
and successively found also in other plants as secondary metabolite.13 Therefore, 3,4-
methanoproline has also been the most investigated and the first synthesized;26 subsequently, 
several different strategies for the synthesis of either its racemic mixture and its enantiopure 
forms have been proposed.27-30 Early studies showed how this molecule was effective as male 
plant gametocide,31 a useful tool to accomplish heterosis in crop plants, as well as inhibitor of 
the proline metabolism.32 Moreover, 3,4-methanoproline has been utilized as model structure 
to design a wide variety of analogues with different functionalities bound to the methylene 
bridge. Derivatives bearing carboxyl groups on this position have been evaluated as 
constrained analogues of glutamic acid; one of them showed interesting activity towards 
NMDA kainate and mGLUr receptors (figure 8, 24).33,34  
On the other hand, the amino derivative 25 can be a new interesting rigid scaffold for peptide 
chemistry, able to work as an α- or γ- amino acid, exploiting the orthogonality of the 
protecting groups.35 Finally, 3,4-methanoproline analogues of leucine (26), lysine (27), 
ornithine (28) and arginine (29) have been synthesised and efficiently employed for the 
construction of poly-L-proline type-II (PPII) secondary structure mimics (30), perfectly 
matching the conformational requirements.36-42 This particular spatial arrangement, 
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characteristic of polyproline, is frequently exhibited also by recognition portions of proteins 
and by peptidic ligands, and is fundamental for binding with associated receptors.43  Since, 
usually, nonprolyl amino acids, especially basic ones, present in PPII regions are critical for 
recognition mechanisms, these functionalized analogues can be very useful tools for the 
synthesis of active PPII mimics.44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. 3,4-Methanoproline derivatives. 
 
The first artificial regioisomer, 2,3-methanoproline, was synthesised in 1989 and subsequently 
incorporated in a model dipeptide to investigate its conformational behaviour, showing a 
greater preference for the cis peptide bond at the ring nitrogen atom in comparison to the 
proline-containing correspondent (figure 9) (see chapter 7 for a similar comparative study we 
conducted on a cyclopropane pipecolic acid derivative).11,45,46 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. cis/trans isomerism in a dipeptide containing 2,3-methanoproline or proline. 
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Finally, also the last regioisomer, 4,5-methanoproline, was efficiently synthesised in 
enantiopure forms for both the possible diasteroisomers.47,48 These compounds, 
conformationally characterized by a prominent flattening of the 5-membered pyrrolidine ring, 
were employed for the synthesis of constrained analogues of captopril, a proline-derived 
angiotensin-converting-enzyme (ACE) inhibitor, resulting more active than captopril itself 
(figure 10).49 Moreover, they showed to possess a catalytic activity for some of the reactions 
catalysed also by proline, exhibiting in some cases an outstanding enantioselectivity, 
exceeding the one obtained with proline.50-52 
 
 
 
 
 
 
 
 
Figure 10. Angiotensin-converting-enzyme (ACE) inhibitors. 
 
Further differently substituted derivatives were also prepared to mimic the structure of kainic 
acids, natural ligands of glutamate receptors (figure 11); their biological activity, however, 
resulted low probably lacking the structural requirements needed.53 
 
 
 
 
 
 
 
 
Figure 11. Cyclopropyl analogues of kainic acids. 
 
2.3 Cyclopropane Pipecolic Acid Derivatives 
L-Pipecolic acid (figure 12, 42) is a cyclic, naturally occurring non-proteinogenic α-amino acid, 
diffusely isolated in plants, fungi, microorganisms and human physiological fluids.54 It is the 
major product of the degradation of lysine in human brain and it accumulates in the body 
fluids causing pipecolic acidemia in subjects suffering from Zellweger syndrome,55 neonatal 
adrenoleukodystrophy,56 and infantile Refsum disease.57 Pipecolic acid and hydroxypipecolic 
acids (see chapter 8 for the synthesis of enantiopure trans 3-hydroxypipecolic acid) are also 
components of a wide range of pharmacologically active compounds, such as the 
immunosuppressive agents rapamycin (figure 12, 43)58 and FK506 (44),59 the antitumor 
antibiotics sandramycin (45)60, quinaldopeptine61 and tetrazomine (46),62 the 
cyclodepsipeptide antibiotic virginiamycin S1 (47)63 and the serotonin receptor antagonist 
damipipecoline (48),64 just to report some representative examples. 
As already mentioned in chapter 1, pipecolic acid and pipecolic acid derivatives have been also 
extensively exploited for the construction of peptidomimetics. However, among the possible 
constrained derivatives, cyclopropane pipecolic acids have not received much attention so far 
and only few syntheses have been reported. 
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Figure 12. Bioactive compounds embedding pipecolic acids. 
 
Hanessian’s group described in 1997 the synthesis of both cis and trans 5,6-methanopipecolic 
acids in enantiopure forms, employing the same method used for the already cited 4,5-
methanoprolines (see section 2.2).48 This procedure exploits, as key step for the cyclopropane 
ring introduction, an intramolecular diasteroselective nucleophilic attack on the iminium ion, 
obtained by acid catalysis from a suitable hemiaminal intermediate formed in situ (scheme 1). 
As already accounted for 4,5-methanoprolines, these products were incorporated in captopril 
rigid analogues too, which resulted, likewise the 4,5-mathanoproline derivatives, more active 
than captopril itself as angiotensin-converting-enzyme (ACE) inhibitors (see section 2.2).49 
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Scheme 1. Cyclopropane introduction in Hanessian’s synthesis of 4,5-methanopipecolic acid. 
Reagents and conditions: a) LiEt3BH, THF; b) pTsOH, MeOH/CH2Cl2; c) Bu4NF, THF; d) RuCl3, 
NaIO4, CCl4/CH3CN/H2O.  
 
More recently, some fluorinated 4,5-methanopipecolic methyl ester derivatives have been 
synthesised in a racemic form by Dixneuf’s group, exploring the scope of a peculiar ruthenium-
catalysed tandem carbene addition/bicyclization of enynes (scheme 2).65,66 
 
 
 
 
 
 
 
 
Scheme 2. Synthesis of fluorinated 4,5-methanopipecolic methyl ester derivatives. Reagents 
and conditions: a) [RuCl(cod)(Cp*)], Et2O or dioxane or MeOH. 
 
De Kimpe’s group proposed the synthesis of a tricyclic cyclopropane derivative of Tic (see 
section 1.2), resulting in a doubly constrained analogue of phenylalanine (figure 13, 56).67 In 
this case, the three-membered ring was introduced by a cyclopropanation via 
dimethylsulfoxonium methylide of a suitable 1,2-dihydroisoquinoline derivative.  
Subsequently, the same group reported the synthesis of a regioisomer of the first product, 
which can be considered a doubly constrained analogue of ACC (see section 2.1) (figure 13, 
57).68 
 
 
 
 
 
 
 
 
Figure 13. Tricyclic cyclopropane pipecolic acid derivatives. 
 
Regarding 2,3-methanopipecolic acid, the model of which we chose to design the derivatives 
presented in this work, the first synthesis of the optically active form was presented in 1996 by 
Hercouet (scheme 3).69 
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Scheme 3. First synthesis of optically active 2,3-methanopipecolic acid. Reagents and 
Conditions: a) BH3·Me2S, CHCl3, 78%; b) SOCl2, CCl4, 72%; c) NaIO4, RuCl3 cat., 96%; d) 
PhCH=NCH2CO2Me, NaH, DME, 99%; e) 1N HCl/Et2O, 86%; f) 1N NaOH, then 6N HCl, 59%. 
 
The cyclopropane moiety was introduced by a diasteroselective alkylation of 
methylbenzylideneglycinate with chiral sulfate 62, obtained starting from L-glutamic acid. 
Hydrolysis of imine 63 and subsequent treatment of the hydrochloride amino ester 64 with 
stoichiometric NaOH led to cyclization and obtainment of the desired product. 
A second approach for the synthesis of optically active 2,3-methanopipecolic acid was 
proposed by Matsumura in 2000, starting from a diprotected L-lysine (scheme 4).70  
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 4. Matsumura’s synthesis of enantiopure 2,3-methanopipecolic acid. Reagents and 
conditions: a) electrochemical oxidation, MeOH, then H2SO4, 47%; b) KHMDS, PhSSPh, 90%; c) 
m-CPBA, 92%; d) Me3SOI, NaH, DMSO, 73%; e) NaBH4, HCO2H, 75%; f) Me3SiI, CHCl3, 50%. 
 
The starting material was cyclized into the piperidine moiety by exploiting an electrochemical 
oxidation, followed by a diasteroselective acid-catalysed cyclization. Intermediate 67 was 
converted to 2,3-didehydropipecolate 68 employing a phenylthiolation of position 2, followed 
by oxidation. Then, the double bond was cyclopropanated by treatment with 
dimethylsulfoxonium methylide with a remarkable diasteroselection, explained in term of the 
steric hindrance exerted by the quasi-axial oriented 6-methoxy group. Finally, this chiral 
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auxiliary methoxy group was removed by reduction with NaBH4 in formic acid, affording the 
protected desired product. 
Considering that the syntheses listed above constitute an almost exhaustive survey of the 
efforts devoted to cyclopropane pipecolic acids so far, it is clear how, compared to proline 
analogues, this chemical space needs to be further explored, especially for what concerns 
substituted and diasteromerically and enantiomerically pure products. Moreover, to our 
knowledge, there were no reports about cyclopropane pipecolic acids embedded in peptides. 
To enlarge the scope of these unnatural amino acids in the design and synthesis of highly 
selective and potent peptidomimetics, recently our group addressed the synthesis of both cis 
and trans enantiopure 4-hydroxy-2,3-methanopipecolic acids (or 5-hydroxy cyclopropane 
pipecolic acids, according to IUPAC numbering: see note at the end of the section) as new 
conformationally constrained homoserine analogues (figure 14, 71 and 72).71 Subsequently, 
also other polyhydroxylated derivatives have been prepared (figure 14, 73 and 74), employing 
the same key reactions, which will be discussed later in this thesis (see chapters 4 and 5).72 
 
 
 
 
 
 
 
 
Figure 14. Hydroxylated 2,3-methanopipecolic acid derivatives synthesized by our group. 
 
In this thesis we aimed to further increase the number of 2,3-methanopipecolic acids (or 
cyclopropane pipecolic acids: see note at the end of the section), introducing new hydroxy- 
and amino-substituted derivatives. Moreover, we tackled the synthesis of the first 
cyclopropane pipecolic acid-containing peptidomimetics; specifically, we designed new 
peptide ligands to target some representatives of the integrin family, a group of protein which 
will be discussed in the next chapter (see chapter 3). 
 
Note: In this work, we will refer to our 2,3-methanopipecolic acids as CPAs, cyclopropane 
pipecolic acids, using the standard IUPAC numeration (figure 14), so that the positions 
tethered by the methylene bridge will be, actually, positions 1 and 6 (e.g. 4-hydroxy-2,3-
methanopipecolic acid 71 will be referred to as 5-hydroxy cyclopropane pipecolic acid or, 
following entirely the IUPAC nomenclature, 5-hydroxy-2-aza-bicyclo[4.1.0]heptane-1-
carboxylic acid). 
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Chapter 3: Integrins 
 
3.1 Integrins as Therapeutic Targets 
The name integrin was attributed in 1986 to the first characterised representative of this large 
protein family to denote its role of integrating the extracellular and intracellular environments 
by the transmembrane association between the extracellular matrix (ECM) and the 
cytoskeleton (figure 1).1,2 Actually, integrins are the major cell adhesion transmembrane 
receptors for ECM proteins (e.g. vitronectin and fibronectin) in animals, but they are also 
involved in cell-cell adhesion processes, as well as in the activation of intracellular signalling 
pathways mediated by growth factors, immunoglobulins, cytokines and matrix-degrading 
proteases. Integrin-mediated events are fundamental to modulate many aspects of cell 
behaviour, including proliferation, survival/apoptosis, shape, polarity, motility, gene 
expression and differentiation. Hence, every representative of the integrin family plays a key 
role in organism development (formation and remodelling of tissues and organs), immune 
response and haemostasis.3-5 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Integrin heterodimer. 
(Adapted from “The Science Creative Quarterly”, www.scq.ubc.ca, Jen PhilPott) 
 
This group of receptors is composed by heterodimers of non-covalently associated α and β 
subunits. Each subunit is composed by an extracellular domain, a transmembrane domain and 
a short cytoplasmatic tail (figure 1). There are 24 known heterodimers, obtained by variously 
combining 18 α and 8 β different subunits, and characterised by different binding properties 
and different tissue distribution (figure 2). 6 
Integrins can be divided in 4 main subgroups, depending on the nature of their ligands, which 
usually contain short peptidic recognition sequences in their active sites. One subgroup 
comprehends those integrins which recognise ligands containing the short peptidic sequences 
LDV (lysine-aspartic acid-valine) or LDV-related (limited variability around a definable 
consensus sequence L/I-D/E-S/T/V was observed). Such proteins are typically expressed in 
leukocytes and regulate many aspects of immune response mechanisms (figure 2, circles).2,7 
Then, there are two smaller families, one of which is composed by integrins binding highly 
selectively to laminin (figure 2, hexagons), while the other one is constituted by 
collagen/laminin dual receptors, usually recognising the GFOGER peptidic sequence (figure 2, 
pentagons). Finally, the largest subgroup comprehends those integrins which recognise 
proteins containing an RGD (arginine-glycine-aspartic acid) tripeptide active site which, 
contrary to LDV, is invariant in all the related ligands (figure 2, triangles). The five αV integrins 
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(including αVβ3 and αVβ5), α5β1, α8β1 and αIIbβ3 are all part of this subgroup.6 They bind to a 
large number of ECM proteins and soluble vascular ligands and they are usually widely 
expressed in many different cells, such as platelets (αIIbβ3), osteoclasts (αVβ3), activated 
endothelial and epithelial cells, being involved in several physiological processes, such as 
platelet aggregation, bone resorption and angiogenesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Known integrin subunit 24 combinations. Triangles: RGD receptors; pentagons: 
collagen/laminin dual receptors; hexagons: laminin receptors; circles: leukocyte integrins. β1 is 
present in many subgroups, depending on the associated counterpart. 
(Adapted from ref. [3]) 
 
Being involved in numerous physiological processes, integrins can also play a key role in many 
diseases, due to deficient or excessive expression and activity. Hence, integrin inhibition can 
be considered a valid therapeutic strategy to cope with several pathological conditions. This 
goal can be achieved developing suitable recombinant monoclonal antibodies, but also 
designing valuable peptide-derived or non-peptide peptidomimetic antagonists, containing or 
mimicking the appropriate short amino acid sequence.7 
Integrin αIIbβ3 is responsible for platelets aggregation, by binding to soluble divalent 
fibrinogen; its importance in normal haemostasis is demonstrated by the genetic bleeding 
disorder, Glanzmann’s thrombasthenia, characterized by uncontrolled bleeding and caused by 
a lack of, or mutations in, this integrin.8 On the other hand, uncontrolled or aberrant platelet 
aggregation is a primary cause of arterial thrombosis, so that αIIbβ3 blocking can be a valid 
strategy to achieve a broad spectrum antithrombotic therapy to reduce the risk of acute 
cardiac ischemic events. Various drugs have been developed with this purpose, exhibiting an 
adequate efficacy; three of them have reached the market and are prescribed in case of acute 
coronary syndrome or during percutaneous coronary intervention: the recombinant antibody 
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abciximab (ReoPro),9 the cyclic heptapeptide eptifibatide (Integrilin) (figure 3, 1)10 and the non-
peptide mimetic tirofiban (Aggrastat) (figure 3, 2).11 
Leukocyte integrins, especially α4β1, α4β7 and αLβ2, are involved in the “extravasation” process 
of leukocytes from the blood stream to the sites of injury or infection, playing a fundamental 
role in immune response. As a matter of fact, mutations that block expression of the β2 
integrins are known to lead to severe immunodeficiency.12 However, uncontrolled or excessive 
leukocyte migration can lead to a number of inflammatory disorder, such as rheumatoid 
arthritis, asthma, multiple sclerosis and other autoimmune diseases. Hence, inhibition of 
α4 integrins has been proposed as therapeutic strategy for these pathologies, leading to the 
development of natalizumab (Tysabri, former Antegren), a monoclonal antibody inhibitor, 
marketed as drug for the treatment of multiple sclerosis and Crohn’s disease.13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Anti-αIIbβ3 marketed drugs. 
 
Finally, α5β1, various αV integrins and, again, αIIbβ3, all part of the RGD-binding subgroup, are 
receiving an increasing attention, due to their strategic role in progression and dissemination 
of several types of cancer. No related drug has reached the market yet, but huge efforts have 
been dedicated to the comprehension of their mechanisms of action and to the development 
of suitable drug candidates for cancer treatment.14 Since some of these receptors, specifically 
α5β1 and αVβ3, are also the biological targets we chose to aim for with our CPA-containing 
peptidomimetics (CPA: cyclopropane pipecolic acid), they will be addressed separately in the 
next section. 
 
3.2 Inhibition of αVβ3  and α5β1 for Cancer Treatment 
Together with  αIIbβ3, α5β1 and αVβ3 are, by far, the most studied proteins of the RGD-binding 
subgroup and a remarkable number of artificial antagonists has been designed for their 
inhibition.15 
Integrin αVβ3 is mostly expressed in osteoclasts, where it participates to bone resorption 
process, and on active endothelial cells, where it mediates vascular angiogenesis. Normal 
angiogenesis is an essential process of foetal development, wound healing, ovulation, growth 
and development. On the other hand, αVβ3 is also widely overexpressed in several types of 
tumour cells and in the vascular tissue of the tumour microenvironment, promoting 
angiogenesis, which is a fundamental process also for solid tumours growth. Expanding solid 
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tumours reach a density point where the increased interstitial pressure inhibits the diffusion of 
metabolites, nutrients and oxygen, slowing down drastically this progression. Subsequently, 
many factors, such as metabolic and mechanical stress, inflammatory response and genetic 
mutations, can trigger the, so called, “angiogenic switch”. This event, starting with a signalling 
cascade, culminates with the formation of new stable blood vessels, which permit tumour to 
leave its “dormancy state” and start expanding rapidly. Among all integrins, αVβ3 is the most 
strongly involved in this mechanism, playing a key role in every step of the process: the 
degradation of old endothelial cell basement membrane, proliferation and migration of new 
endothelial cells out of the original blood vessel, and stabilization of new blood vessels 
branching towards the tumour.16,17 
Furthermore, αVβ3, together with αIIbβ3, promotes metastasis diffusion through lymphatic and 
haematogenous dissemination, and allows the metastatic deposit to become established 
through adhesion to ECM proteins. Again, αVβ3 is involved in the entire process, promoting 
extravasation from the primary tumour, cell adhesion, intravasation and tumour growth at the 
metastatic site.18,19 
Accordingly, inhibition of αVβ3 has been considered a valid strategy for developing new 
anticancer therapies and many efforts have been dedicated to this goal.20 Such result can be 
obtained blocking the RGD-binding site of the protein with an adequate ligand, which can be a 
monoclonal antibody, an RGD-based peptide or peptidomimetic, or a non-RGD-based 
antagonist mimicking the RGD sequence.14 Countless examples of such products have been 
published in the last decades and we will focus on some of them later (see section 3.3); several 
exhibited a remarkable affinity towards αVβ3 and some reached clinical trials as antitumor 
chemotherapy.21 
 
Tumours often overexpress, along with αVβ3, also α5β1, the so called fibronectin receptor due 
to its high affinity towards this ECM protein, which has a similar proangiogenic function to 
αVβ3.22 These two integrins seem to act synergistically, since  αVβ3 has been shown to regulate 
the function of α5β1 and vice versa via trans-dominant inhibition; so that blocking the activity 
of one of the two often demonstrated to trigger the overexpression and the overactivity of the 
other. This mechanism could be related with the ambiguous results obtained in clinical trials 
with many selective antagonists.15  Usually, lack of selectivity towards a specific biological 
target is considered a safety issue, possibly leading to toxic effects. However, both selective 
and multi-integrin antagonists demonstrated to be generally safe, and the latter appeared 
more efficient.23,24 These agents are probably non-toxic because the targeted integrins are 
only expressed or activated in remodelling tissues such as tumours.25 
Therefore, a dual affinity towards both αVβ3 and α5β1, as well as a multi-affinity towards a 
wider range of integrins, can be a desirable feature to obtain in an artificial ligand. Since the 
two integrins recognise the same RGD sequence and their binding sites are very similar (see 
section 3.3), this should not be a goal too difficult to achieve. 
 
Besides antagonism, integrin artificial ligands can found also other applications relatively to 
cancer treatment. Their high affinity towards receptors overexpressed in cancer cells can be a 
valuable tool to build drug delivery systems. Artificial ligands can be linked to suitable 
cytotoxic molecules, directing the action of non-specific chemotherapy on cancer cells 
increasing their efficacy and reducing drastically their toxicity.14 
The same principle can be applied in diagnostic field, delivering to the tumour radionuclides or 
dyes embedded in integrin targeting systems. 
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Therefore, highly decorated scaffolds are particularly useful for the construction of RGD-based 
ligands, since the functionalities not involved in the peptidic bonds can be exploited to 
covalently bind drugs or imaging devices, as well as to modulate the physical and chemical 
characteristics of the final products. 
 
3.3 αVβ3 Ligands for Antagonism, Targeted Drug Delivery and Diagnostic 
Since the first discovery in the early 1970s of the RGD sequence as a cell attachment site in 
fibronectin and its subsequent identification as the minimal integrin-binding sequence in many 
other ECM ligands, the structural basis of this recognition mechanism have been deeply 
investigated.26,27 
It was observed that although many integrins recognize the RGD motif, they are also able, to a 
certain extent, to discriminate between different ligands. This behaviour was correlated with 
the ability of recognising only certain conformations of the RGD moiety, imposed by the 
surrounding secondary and tertiary structures of the different proteins. Lacking further 
indications, at first, artificial antagonists were designed in a “ligand-oriented” fashion, 
rationally exploring the conformational space (with the additional aid of NMR and molecular 
dynamics) and screening the activity of libraries of RGD-based peptides (“spatial screening”). 
In such a way Kessler’s group developed Cilengitide (figure 4), the first small-molecule high 
affinity ligand for angiogenic integrins, starting from simple RGD-containing cyclic 
pentapeptides and proceeding with small modifications (D-amino acids introduction and N-
methylations).28-32  
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Cilengitide: first RGD-based subnanomolar ligand for angiogenic integrins. 
 
In fact, only antibodies and disintegrins (a family of RGD-containing cysteine-rich peptides 
derived from viper venoms) had shown such biological activity before; anti-αVβ3 monoclonal 
antibodies hLM609 (etaracizumab, Vitaxin-2, Abegrin) and CNTO-95 (intetumumab, Centocor) 
were the first integrin related products to reach clinical trials as anticancer treatment.25,33 
Cilengitide exhibited a remarkable nanomolar affinity towards αVβ5 and α5β1, and an 
outstanding subnanomolar affinity towards αVβ3.15 It was the only integrin-related antitumor 
drug candidate to have reached phase III clinical trials, specifically as treatment against 
glioblastoma.34 Surprisingly, these trials did not furnish positive results and were suspended, 
demonstrating how much is still to be undisclosed about the role of integrins in cancer. On the 
other hand, phase II trials concerning the use of Cilengitide in combination with other 
chemotherapy are still ongoing. 
Finally, in 2001, the crystal structure of the extracellular portion of αVβ3 was obtained; one 
year later also the crystal structure of αVβ3 complexed with Cilengitide was determined.35,36 
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These results help to elucidate the structural characteristics of αVβ3 binding pocket and a 
rational structure-based design of new ligands could arise. RGD binds at an interface between 
the α and β subunits, with the basic guanidinium residue fitting into a cleft in the α subunit 
and the acidic carboxylate residue pointing in the opposite direction and coordinating a cation 
bound in the β subunit (figure 5). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Key features of the RGD binding site. 
(Adapted from ref. [15]) 
 
Arg and Asp act like an “electrostatic clamp” attaching to charged regions of the two subunits 
of the protein. Specifically, Arg forms salt-bridges with Asp150 and Asp218 of the α subunit, 
while Asp coordinates a variable divalent cation contained in a MIDAS (metal ion dependent 
adhesion site) in the β subunit. Moreover, in the case of Cilengitide a further hydrophobic 
interaction between D-Phe and  β-Tyr122 was observed. Afterward, docking simulations, 
performed on complexed αVβ3 X-ray structure, allowed to establish some set parameters for 
affinity, such as the optimal distance between the pharmacophoric groups, helping in the 
design of both RGD-based and non-RGD-based ligands.37 Previously, potent αVβ3 non-RGD-
based ligands, such as SC-68448 (figure 6, 4),38 SCH221153 (5),39 S-137 (6) and S-247 (7),40 were 
identified only through the screening of large libraries of peptidomimetics, rationally refined 
accordingly to the structures of known ligands. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Potent non-RGD-based ligands for angiogenic integrins. 
 
The other RGD-binding integrins α5β1 and  αIIbβ3 displayed the same mechanism of interaction 
of αvβ3, differing only in binding site size and the identity of the arginine-binding residues 
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(figure 5).41,42 Therefore, it is possible to obtain both selective and multi-integrin antagonists, 
depending on the specific structural features of the candidates. 
Regarding conformational behaviour and selectivity, an interesting study was conducted 
cyclizing an RGD sequence together with the two enantiomers of  cyclopropane amino acid β-
Acc (see chapter 2) (figure 7), obtaining two diasteroisomers, one of which selective for αvβ3 
(8), and the other exhibiting comparable affinity towards αvβ3 and α5β1 (9).43 
Following Kessler’s Cilengitide example, many ligands have been designed as conformationally 
constrained cyclopeptidomimetics to ensure a drastic reduction of the conformational space 
and guarantee a higher affinity (see chapter 1). Usually, these structures contain the native 
RGD sequence bound to a rigid central core of various nature, mainly a conformationally 
constrained artificial amino acid. 
In this work we adopted the same concept to design our own RGD-based integrin ligands (see 
Scope of the work), following the path traced by many other research groups, which in the last 
years published a plethora of new ligands of this typology, often exhibiting nanomolar and 
subnanomolar activities. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Potent RGD-based ligands for angiogenic integrins. 
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In 2000, Kessler’s group itself developed new RGD-based ligands constructed on a sugar-
derived core (figure 7, 10), exhibiting high affinity towards αvβ3 and αIIbβ3.44 Moreover, in the 
same work, several variously decorated carbohydrates were embedded in cilengitide-like 
compounds in place of the valine side chain, with the aim of modulating the activity of the 
final products. 
In 2001, Scolastico’s group designed new ligands incorporating fused bicyclic lactams, one of 
which (ST1646) (figure 7, 11) resulted active in the low nanomolar range towards αvβ3 and 
αvβ5 and showed remarkable antiangiogenic properties.45-47 
Afterward, Casiraghi and Zanardi developed two libraries of products based on γ-
aminocyclopentane carboxylic acids (Acpca) and 4-aminoproline as central scaffolds; the two 
families contained respectively subnanomolar and low nanomolar ligands for αvβ3 (figure 7, 12 
and 13).48-49 In the case of aminoproline derivatives the ring nitrogen, which at first was bound 
to activity-modulating groups, was also successfully employed for targeted delivery of imaging 
molecules (fluoresceine and DOTA) and cytotoxic drugs (paclitaxel).50-51 
Another paclitaxel-containing drug delivery system was developed by Gennari’s group 
employing a family of RGD-based ligands embedding bifunctional diketopiperazines (DKP) 
(figure 7, 14); these paclitaxel conjugates were tested in vitro and in vivo, showing greater 
antitumor activity and lower toxicity than free paclitaxel.52-54 
Finally, Guarna and co-workers established new morpholine-based RGD ligands (figure 7, 15) 
as radiolabelled molecular imaging probe for angiogenesis, introducing a 125I-containing 
tyrosine derivative in the peptidic sequence (figure 7, 16).55,56 
Besides the directly conjugated delivery systems designed by Zanardi and Gennari, another 
fascinating alternative is the use of nanocarriers as connection between integrin ligands and 
drugs or imaging molecules (figure 8).  
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Nanocarriers for drug delivery. 
(Adapted from R. Solaro, F. Chiellini, A. Battisti, Materials, 2010, 3, 1928) 
 
Basically, a nanocarrier (liposome, nanoparticle, micelle, etc.) can be loaded with a certain 
quantity of the selected drug and grafted on its surface with many copies of an integrin ligand. 
This way in a single event a larger amount of the drug can be delivered to its target. Moreover, 
nanocarriers offer other advantages; their size (20-400 nm) leads to a further “passive 
targeting” of tumours via the so called enhanced permeability and retention effect (EPR); in 
addition, because of the size of these systems, renal filtration is avoided, leading to prolonged 
blood circulation times and longer accessibility to target receptors within the tissue.57,58 Lately, 
many efforts have been dedicated to the construction of such devices and a large number of 
clinical trials are ongoing.14 
Introduction: Chapter 3 
 
27 
 
Our research was framed in this scenario and we hope that our contribution could be of use to 
progress in the field. As already mentioned, we tackled the synthesis of new RGD-based 
integrin ligands containing our cyclopropane pipecolic acids (CPAs) as central scaffolds and, 
because of the obvious structural similarities between aminoproline and CPAs, we chose 
Zanardi’s work50 as model for the design of the synthetic strategy for the construction of these 
CPA-containing peptidomimetics (see chapter 6). 
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Scope of the Work 
 
In the previous chapters we described how conformationally constrained amino acids are 
emerging privileged structures involved in many important applications, in particular as 
constituents of biologically active compounds, as well as conformational probes. 
Although many efforts have been dedicated to the synthesis of constrained proline 
derivatives, the introduction of additional conformational restrictions in pipecolic acids by 
merging the piperidine with a cyclopropane ring has concerned very few examples. Extending 
this approach to other differently decorated cyclopropane pipecolic acids (CPAs) would 
certainly enlarge the scope of these unnatural amino acids in the design and synthesis of 
highly selective and potent peptide analogues in peptide-receptor recognition. To this aim, as 
already mentioned (see section 2.3), our group has recently published the synthesis of all four 
stereoisomers of 5-hydroxy-CPA as new conformationally constrained homoserine analogues 
to be employed as conformational probes and in the discovery of new drugs. 
In this thesis we report our efforts to enlarge the series of CPAs by introducing hydroxy or 
amino groups at different positions of the piperidine ring (figure 1). 
 
 
 
 
 
 
 
Figure 1. New CPAs synthesized within this thesis. 
 
In addition, since to our knowledge there were no reports on cyclopropane pipecolic acids 
embodied in peptides, we wish to demonstrate that these new amino acid analogues are 
actually suitable templates for the preparation of both acyclic and cyclic peptidomimetics. In 
particular, we show that cyclopeptides can be built by exploiting the carboxylic group and a 
cis-amino functionality on the ring (figure 2, A), whereas acyclic peptides could be built on the 
α-amino acid moiety as in unconstrained pipecolic acids (figure 2, B). 
 
 
 
 
 
 
 
 
Figure 2. General structures of CPA-containing cyclic and acyclic peptides. 
 
In view of possible applications of these templates in medicinal chemistry, the presence of the 
additional hydroxy (or amino) group can either provide further interactions with the active site 
of the target protein or be functionalized to attain higher potency and selectivity, and improve 
pharmacokinetics. 
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To prove the suitability of these compounds for preparing cyclic peptidomimetics, we chose to 
synthesize novel artificial ligands for RGD-binding angiogenic integrins (see chapter 3) by 
introducing suitable 4-amino- and 5-amino-CPA into an Arg-Gly-Asp (RGD) sequence (figure 3, 
4 and 5). 
In this specific case, besides the above mentioned features, the additional amino group could 
also provide an anchoring position to build drug delivery systems (see section 3.3). 
 
 
 
 
 
 
 
Figure 3. RGD-based integrin ligands. 
 
Whereas the cis relative configuration of the carboxylic group and the amino functionality on 
the ring in the candidate scaffolds 2 and 3 was necessary to build a cyclopeptide, the particular 
absolute configurations (1R,4R,6S for 2 and 1S,5R,6S for 3) were chosen on the basis of 
preliminary molecular modeling studies which showed that the RGD sequence in 4 and 5 best 
overlapped with that of potent 4-aminoproline derivative 6 (see section 3.3). 
In addition, starting from 1 we designed a model linear tripeptide (figure 4, 7) to investigate 
the conformational features offered by CPAs. Specifically, we evaluated the cis/trans 
isomerism about the pipecolic acid peptide bond and we compared this conformational 
behavior with that of published similar model tripeptides containing proline or pipecolic acid 
(figure 4, 8 and 9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Cis/trans isomerism in CPA-containing and model tripeptides 
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Finally, we also designed a new synthetic strategy to obtain both enantiomers of trans 3-
hydroxypipecolic acid (figure 5, 10), which constitutes a non-natural variant of a structural 
motif often encountered in a variety of biologically active natural compounds. Additionally, 
being an artificial mono-substituted conformationally restricted amino acid (a constrained 
serine analogues), 10 could be employed for the construction of further RGD-based ligands as 
well as other biologically active peptidomimetics. 
 
 
 
 
 
 
Figure 5. Trans 3-hydroxypipecolic acid. 
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Results and Discussion 
 
Chapter 4: Synthesis of 4-Substituted Cyclopropane Pipecolic Acids (4-R-
CPAs) 
 
4.1 General Synthetic Strategy 
Our primary synthetic strategy towards 4-substituted-CPAs (scheme 1) entails the conversion 
of a suitably functionalized enantiopure lactam IV into the corresponding enecarbamate ester 
III by means of Pd-catalyzed methoxycarbonylation of the lactam-derived vinyl phosphate,1 
followed by the stereoselective OH-directed cyclopropanation of the double bond to give the 
cyclopropane pipecolic acid derivative II. Finally, functional groups manipulation can lead from 
the hydroxy derivative II to the amino-CPA I with a contemporary inversion of position 4 
configuration. 
As it will be illustrated later, slight modifications of this general procedure were employed for 
the synthesis of every CPA. 
 
 
 
 
 
 
 
Scheme 1. Retrosynthetic Analysis for 4-R-CPAs. 
 
Enantiopure 5-hydroxy-δ-valerolactam can be prepared from a lactone of which both 
enantiomers are commercially available, following the procedure reported by Herdeis in 1986 
(scheme 2).2 Accordingly, both enantiomers of the final products can be prepared in principle. 
On the other hand, as already mentioned (see Scope of the Work), at first we were interested 
in the synthesis of a selected specific enantiomer which is obtainable starting from (S)-(+)-γ-
hydroxymethyl-γ-butyrolactone (1), the cheaper enantiomer derived from natural L-glutamic 
acid.2 
 
 
 
 
 
 
 
Scheme 2. Synthesis of enantiopure 5-hydroxy-lactam. Reagents and conditions: a) MsCl, Et3N, 
CH2Cl2; b) NaN3, [15]crown-5, CH3CN, reflux; c) H2, Pd/C, MeOH. 
 
Hence, hydroxy-lactam 4 was obtained after reduction of azide 3 and subsequent spontaneous 
rearrangement of the resulting amine intermediate. With lactam 4 in hand, different 
protection schemes have been implemented for the hydroxy and the amide groups to enlarge 
the versatility of the final products. 
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4.2 Synthesis of N-CO2Me Protected 4-R-CPAs 
Initially, following a procedure already reported by our group,3 enecarbamate ester 8 was 
obtained in four steps starting from lactam 4 (scheme 3). At first, the hydroxy group was 
protected as tert-butyldimethylsilyl ether and the ring nitrogen as methyl carbamate, resulting 
in diprotected intermediate 6, which was quantitatively converted into the corresponding 
vinyl phosphate 7 by treatment with potassium bis(trimethylsilyl) amide (KHMDS) at –78 °C in 
tetrahydrofuran (THF), followed by the addition of diphenylchlorophosphate. Pd-catalysed 
methoxycarbonylation reaction of the phosphate in anhydrous DMF and at atmospheric 
pressure was carried out at 65 °C in the presence of an excess of MeOH to give key ester 
intermediate 8 in 44% yield after four steps. 
Afterward, deprotection of the 5-OH group was accomplished to set the stage for the OH-
directed stereoselective cyclopropanation of 9.4 Hydroxy group deprotection was performed 
experimenting two possible procedures. At first, it was carried out by using 
tetrabutylammonium fluoride (TBAF), but a partial elimination of tert-butyldimethylsilanol 
lowered the yield to 70%. As here reported, better results were obtained by using 3N HCl in 
acetonitrile, leading to a remarkable 92% yield.5 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3. Synthesis of 4-hydroxy-CPA. Reagents and conditions: a) TBSCl, Imidazole, DMF, 40 
°C; b) MeOCOCl, n-BuLi, THF, –78 °C; c) KHMDS, (PhO)2P(O)Cl, THF, –78 °C; d) Pd(OAc)2, Ph3P, 
CO, MeOH, Et3N, DMF, 65 °C; e) 3N HCl, CH3CN, 45 min; f) Et2Zn, CH2I2, CH2Cl2, reflux. 
 
The OH-directed cyclopropanation of homoallylic alcohol 9, as expected, required a longer 
reaction time than what is usually required for allylic alcohols, such as the one previously used 
by our group for the synthesis of 5-OH-CPA (see section 2.3, 5.1 and 5.2).6 We first 
investigated the use of Charette’s zinc carbenoid (2,4,6-Cl3C6H2OZnCH2I),
7 which had provided 
the best results for 5-OH-CPA, but the reaction was sluggish at room temperature and never 
reached completion. Despite the low conversion rate, we were glad to observe that the 
hydroxy group still exerted a complete stereocontrol, thus leading to the cis-isomer 10 only. 
To attain complete conversion, we increased the temperature by carrying out the reaction in 
CH2Cl2 under reflux conditions and with two equivalents of the Wittig–Furukawa zinc 
carbenoid (Zn(CH2I)2).
8 Under these conditions, the reaction ended in 18 h to provide 10 still 
with complete stereoselectivity and in 71% yield after chromatography.4 
With the 4-hydroxy-2-azabicyclo-[4.1.0]heptane-1-carboxylic acid derivative 10 in hand, the 
stage was set for the synthesis of the corresponding 4-amino- derivative 14 (scheme 4). The 
synthesis of 14, which, as a δ-amino acid, is a dipeptide mimic, entailed O-mesylation (86%) 
followed by nucleophilic substitution with sodium azide to provide azido derivative 12 (83%) 
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with the correct cis stereochemistry of the two groups on the ring as required for the 
construction of a cyclopeptide. After hydrolysis of the ester group (93%) carried out with 1N 
NaOH in MeOH, hydrogenation over Pd/C at room temperature and atmospheric pressure 
provided, after 16 h, pure amino acid 14 in 70% yield.4 
 
 
 
 
 
 
 
 
 
 
 
Scheme 4. Synthesis of 4-amino-CPA. Reagents and conditions: a) MsCl, Et3N, CH2Cl2, –30 °C to 
25 °C, 1 h; b) NaN3, [15]crown-5, CH3CN, reflux, 6 h; c) 1N NaOH, MeOH, RT, 24 h; d) H2 (1 
atm), 10% Pd/C, MeOH, RT, 16 h. 
 
This approach allowed us to obtain, in a single run, almost 200 mg of pure 14, which we used 
for the synthesis of the first cyclopeptide integrin ligand, as we report later (see section 6.2). 
 
4.3 Stereochemical and Conformational Investigation on CPAs 
The relative stereochemistry and preferred conformation of compounds 10 and 14 are easily 
assigned by the analysis of the coupling constants in the 1H NMR spectra and by nuclear 
Overhauser effect (NOE) studies with the support of a molecular modelling study (figure 1).9 
 
 
 
 
 
 
 
Figure 1. Stereochemical and conformational analysis of CPAs. 
 
From the molecular modelling, it appears that the cyclopropane ring imposes a slightly 
distorted half-chair conformation on the piperidine ring with the 4-OH group axially oriented 
in compound 10. In fact, 4-H resonates as a broad singlet at about δ=4.04 ppm owing to very 
small vicinal coupling constants, in accordance with its equatorial position. Moreover, the 
absence of any NOE between the same proton and the endo proton of the cyclopropane ring is 
in accordance to the cis-relative position of the OH and the cyclopropane ring. This is 
confirmed by the NOE correlation observed between 4-H and the endo proton of the 
cyclopropane ring in compound 12 obtained by SN2 on 10 after its mesylation. In this 
compound, 4-H is axially oriented as suggested by the structured multiplet at about δ=3.45 
ppm (two trans-diaxial 3J couplings), and the observed NOE correlation with the cyclopropane 
proton that resonates at δ=0.8 ppm as a doublet of doublets is consistent with a trans-relative 
position between the cyclopropane and the azido group. The calculated distance between 4-H 
N CO2Me
HO
10
a
N CO2Me
MsO
11 (86%)
CO2MeCO2Me
b
N CO2Me
N3
12 (83%)
CO2Me
c
N CO2H
N3
13 (98%)
CO2Me
d
N CO2H
H2N
14 (70%)
CO2Me
N
OH
HMeO2C
MeO2C
10
H
N N3MeO2C
MeO2C H
12
H
NOE
4 47
H
N NH2MeO2C
HO2C H
14
H
47
H
d = 2.48 Å
d = 5.65 Å
Results and Discussion: Chapter 4 
 
38 
 
and the cyclopropane endo proton, in its amino derivative 14, is about 2.5 Å. Also for this 
compound, a molecular modelling analysis resulted in the half-chair conformation being the 
less energetic, and because of the equatorial position of the amino group, proton 4-H 
resonates at δ=3.1 ppm as a structured multiplet. 
 
4.4 Synthesis of N-CO2Bn- and N-CO2tBu-Protected 4-OH-CPAs 
Since our CPAs were meant to be employed in peptide synthesis, we wanted to obtain final 
products the most versatile possible, where all the functional groups could be exploited for 
the further decoration of these scaffolds. Concerning this issue, it is fundamental to obtain 
CPA derivatives containing easily cleavable and possibly orthogonal protecting groups. 
Accordingly, protecting the ring nitrogen as methyl carbamate cannot be considered an 
optimal strategy, due to the harsh conditions necessary for its cleavage. 
Therefore, we decided to tackle the synthesis of differently N-protected CPAs to guarantee the 
possibility of exploiting also the ring nitrogen either for peptide coupling or as anchoring point 
for other chemical entities (activity-modulating groups,  physicochemical properties-
modulating groups, drugs or imaging molecules). 
At first, we tried to follow the same reaction sequence already successfully applied, 
introducing in place of the methyl carbamate alternatively a benzyl carbamate or a tert-butyl 
carbamate. Unfortunately, this approach resulted surprisingly quite troublesome because of 
two different and unexpected side reactions, leading to the premature partial or total loss of 
these protecting groups (scheme 5). 
Initial conversion of lactam 5 into the N-Cbz- and N-Boc-protected vinyl phosphates 17 and 18, 
which was carried out, as already reported, by treatment with potassium 
bis(trimethylsilyl)amide (KHMDS) at –78 °C and then trapping the enolates with 
diphenylchlorophosphate, was uneventful. However, whereas the Pd-catalyzed 
methoxycarbonylation of 17 carried out at 60 °C proceeded very well to give 20 in good yield 
(70%), after performing the same reaction on N-Boc-protected compound 18, we observed the 
formation of carbonylated product 19, which lacked the tert-butoxycarbonyl group, as the 
main product together with a minor amount of desired compound 21. Under the best 
conditions, in the presence of a strong excess amount of MeOH (130 eq.) and at 75 °C, 
compound 21 was obtained in a 3:1 ratio with 19 and in 40% yield after chromatography on 
neutral alumina, whereas using the usual lower amount of MeOH (42 eq.) the yield was below 
20% both at 55 °C and 75°C. Compound 19 was quite labile (it decomposed on standing at 
room temperature), and an attempt to protect its nitrogen atom to obtain again the 
corresponding tert-butyl carbamate 21 caused complete decomposition. It is worth to notice 
that our group described in the past a Pd-catalyzed process that leads to Weinreb amides in 
which the N-Boc protection was perfectly compatible with the carbonylative conditions, even 
if in that case the substrate was a more reactive triflate, the nucleophiles were amines and, 
above all, the reactions were conducted at room temperature.10 On the other hand, Pd-
catalyzed alkoxycarbonylations of lactam-derived vinyl phosphates were never been carried 
out with N-Boc-protected lactams but only with N-Ts-, N-Cbz-, N-acyl-, and N-CO2Me-
protected ones.1,11  
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Scheme 5. Synthesis of N-CO2Bn and N-CO2tBu protected 4-OH-CPAs. Reagents and 
conditions: a) BnOCOCl, n-BuLi, THF, –78 °C; b) Boc2O, Et3N, 4-dimethylaminopyridine (DMAP), 
CH2Cl2, reflux, 5 h; c) KHMDS, (PhO)2P(O)Cl, THF, –78 °C; d) Pd(OAc)2, Ph3P, CO, MeOH, Et3N, 
DMF, 60 or 75 °C, 1.5 h; e) 3N HCl, CH3CN, 1.5 h; f) TBAF, THF, 30 min; g) Et2Zn, CH2I2, CH2Cl2, –
15 °C to reflux, 16 h; h) H2 (1 atm), 10% Pd/C, EtOAc, RT, 4 h; i) Boc2O, Et3N, MeOH, reflux, 4 h. 
 
We proposed a possible mechanism for this undesired decarboxylation process (scheme 6). 
Following oxidative addition and subsequent CO insertion, the tert-butyl group should be lost 
concurrently to carbonyl attack to the PdII in the acyl–palladium complex 28 to produce 
intermediate 29. Reductive elimination after addition of MeOH generated carbamic acid 30, 
which underwent rapid decarboxylation to provide 19. Increasing the relative amount of 
MeOH favoured coordination of MeOH to palladium in complex 28, speeding up the rate of 
reductive elimination of 28 and thus the formation of desired compound 21, although the 
yield was far from satisfactory. 
Despite the low yield in compound 21, we proceeded with the deprotection of the 5-OH group 
which, in this case, was necessarily carried out using TBAF, due to the presence of the acid 
labile N-Boc. As expected, we registered the formation of a certain amount of elimination 
product, but the yield in compound 23 was a more than satisfactory 76%. Unfortunately, when 
we tried its cyclopropanation by using the Wittig-Furukawa zinc carbenoid in refluxing CH2Cl2, 
another side reaction took place. Cyclopropanation of 23 occurred only in part accompanied 
by the complete loss of the Boc group to give an approximately 3:1 mixture of 25 and 26 after 
16 h. As observed for 19, also side product 26 resulted extremely unstable and decomposed 
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completely in an attempt to protect again its nitrogen atom. We conducted the 
cyclopropanation also at room temperature, but the outcome was even worse due to a slower 
rate of cyclopropanation and yet the contemporary complete loss of the Boc group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 6. Possible mechanism for decarboxylation of N-Boc-protected derivative. 
 
This was another unexpected result, since the N-Boc does seem perfectly tolerant to the 
Wittig–Furakawa cyclopropanation conditions,12,13 but the longer reaction times and probably 
the relative position of the OH group with respect to the N protection, could account for our 
results. It is possible that coordination of both the 4-OH and Boc carbonyl groups to the Zn 
atom in a seven-membered cycle could facilitate loss of the tert-butyl cation from the N-
protecting group. Actually, we found at least one case in which N-Boc loss was reported in the 
cyclopropanation of an N-Boc-protected tetrahydropyridine bearing a coordinating hydroxy 
group.14 
We encountered the same complication, although to a lesser extent, in the cyclopropanation 
of N-Cbz-protected compound 22, carried out according to the same procedure, which 
provided cyclopropane derivative 24 but only in 38% yield, when increasing the relative 
amount of zinc carbenoid to four equivalents.4 Again, since cyclopropanation of the 
corresponding N-Cbz-protected allylic alcohol and 4,5-dihydroxy derivatives proceeded 
uneventfully at room temperature,6,4 the same aforementioned reasons could account for this 
degradation process. 
In any case, N-Boc-protected compound 27 could be prepared from 24 by removal of the Cbz 
group by hydrogenation (96% yield), followed by N protection with di-tert-butyl dicarbonate in 
25, which provided N-Boc-protected cyclopropane pipecolic acid derivative 27 in 70% yield.4 
 
4.5 Further Attempts for the Synthesis of Differently N-Protected 4-OH-CPAs 
Being obviously not completely satisfied with the above mentioned procedures, we decided to 
investigate alternative routes for the synthesis of differently N-protected CPAs. 
At first, having already in hand an optimized strategy for the synthesis of N-CO2Me-protected 
CPA 10, we decided to start again from it and try the deprotection of this methyl carbamate. 
Previous attempts of acidic hydrolysis had led to complete decomposition of 10, due to the 
reported lability to strong acid conditions of cyclopropyl amino acids.15 Therefore, we tried a 
basic hydrolysis (KOH 25 eq. in refluxing EtOH) (scheme 7), knowing that the methyl ester 
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would be hydrolysed as well, but confident to be able to selectively and orthogonally protect 
again all the functional groups at a later stage. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 7. Basic hydrolysis of N-CO2Me-protected CPA. Reagents and conditions: a) NaOH 25 
eq., EtOH, reflux, 8h or 48h; b) Boc2O, Et3N, MeOH, reflux. 
 
Refluxing the reaction for 8 h led to complete disappearance of 10, but the expected product 
31 was obtained in an inseparable approximately 1:1 mixture with the side product 32, 
originated by the nucleophilic attack of the solvent on the carbamate. Retaining 32 an 
intermediate in desired product formation, we tried to apply longer reaction times and we 
observed that 48 h of reflux were necessary for the total disappearance of 32. On the other 
hand, NMR of the crude showed that a certain amount of degradation products has been 
accumulated, whereas NMR of the first reaction crude (8 h attempt) was extremely clean 
except for the presence of the main side product. Our concerns found confirmation when we 
performed the selective N-protection of 31 to the corresponding tert-butyl carbamate 33 and 
we were able to isolate this product with only a 32% yield. Since nothing suggested that the 
protection had been troublesome, it is very likely that the low yield was caused by degradation 
in the hydrolysis step. 
Along the way, we demonstrated that 31 can be selectively protected even if in a mixture with 
32, obtaining a new easily separable mixture of 33 and 32. Therefore, 8 h hydrolysis, 
protection and separation could be employed in an iterative way to convert both 10 and 32 to 
33 without degradation, but the procedure would be certainly time- and resource-consuming. 
Subsequently, we tried a different approach, screening other possible more exotic protecting 
groups for the ring nitrogen to verify their compatibility with our synthetic strategy towards 
CPAs, using unsubstituted δ-valerolactam as model substrate. 
Initially, we protected the lactam as trifluoroacetamide (-NCOCF3) (scheme 8), since this group 
cannot undergo decarboxylation during the cyclopropanation step, and it is easily cleaved in 
aqueous basic conditions.16 
Following a reported procedure,17 the protection was performed with trifluoroacetic 
anhydride (TFAA) in toluene, giving pure protected known lactam 35 with excellent yield, 
although it resulted too unstable to be chromatographed. We tried to convert 35 in the 
correspondent vinyl phosphate 36 with the usual procedure, but degradation took place and 
the yield resulted very low (20% before purification). Probably, the basic conditions of the 
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reaction and the work-up were harsh enough to cause protecting group loss and subsequent 
degradation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 8. Protection of nitrogen ring as trifluoroacetamide. Reagents and conditions: a) TFAA, 
Toluene; b) KHMDS, (PhO)2P(O)Cl, THF, –78 °C; c) Tf2O, DTBMP, CH2Cl2. 
 
Alternatively we attempted to convert 35 in the correspondent vinyl triflate 37 employing 
trifluoromethanesulfonic anhydride (Tf2O) and di-tert-butyl-methylpyridine  (DTBMP) in 
CH2Cl2. Unfortunately, in this case the conversion resulted very low and protecting group loss 
occurred at a certain extent anyway. 
Therefore, being trifluoroacetamide not suitable for our synthetic strategy, we proceeded with 
the screening of a completely different protecting group, namely an ortho-
nitrobenzenesulfonyl amide (scheme 9); this group should guarantee orthogonality, since it is 
removed under mild basic conditions only in the presence of thiols, being otherwise stable in 
both acidic and basic media.18,19 
 
 
 
 
 
 
 
 
 
Scheme 9. Protection of nitrogen ring as ortho-nitrobenzenesulfonyl amide. Reagents and 
conditions: a) n-BuLi, oNBSCl, THF, –78 °C; b) KHMDS, (PhO)2P(O)Cl, THF, –78°C. 
 
Known protected lactam 3820 was obtained applying the standard procedure with n-BuLi and 
ortho-nitrobenzenesulfonyl chloride (oNBSCl) in THF at –78 °C but, surprisingly, even in this 
case the formation of vinyl phosphate 39 resulted troublesome. The reaction was conducted 
according to the usual procedure, but formation of degradation products was readily indicated 
by the almost black colour of the solution and then confirmed by the low yield (40% before 
purification). 
Hence, we discarded also ortho-nitrobenzenesulfonyl amide as possible alternative N-
protecting group and we proceeded with a further last attempt protecting the ring nitrogen as 
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formamide (scheme 10). This protecting group, similarly to N-CO2Me, can be cleaved only in 
harsh acid or basic conditions but, analogously to dimethylformamide,21 in principle it should 
be convertible in various functional groups, including amides.22 Accordingly, linkers or peptide 
bond could be introduced without even deprotecting the amine. 
 
 
 
 
 
 
 
Scheme 10. Protection of nitrogen ring as formamide. Reagents and conditions: a) POCl3, DMF, 
CH2Cl2, reflux; b) MeOH, CO, Pd(OAc)2, Ph3P, Et3N, DMF, 75°C. 
 
Following a reported procedure based on the Vilsmeier-Haack reaction,23 upon treatment with 
POCl3 and DMF in refluxing CH2Cl2 lactam 34 was protected and converted into the 
correspondent known vinyl chloride 40 in only one step.24 Unfortunately, despite the sparing 
of a reaction step, this procedure resulted to hide a drawback, since vinyl chloride 40, 
notwithstanding its low stability, demonstrated to be extremely less reactive than phosphate 
for the following methoxycarbonylation reaction. Complete conversion was obtained only 
augmenting temperature, reaction time and MeOH quantity (5 h at 75 °C with 70 eq. of 
MeOH), but in this conditions the yield resulted low anyway (25%), probably due to starting 
material degradation. 
Therefore, even if this procedure resulted very useful in synthetic strategies including different 
Pd-catalyzed couplings, such as Suzuki or Sonogashira,24 it is hardly applicable in the case of 
our Pd-catalyzed alkoxycarbonylation. 
 
4.6 Optimised Synthesis of Differently N-Protected 4-OH-CPAs 
Having obtained poor results concerning the aforementioned protecting groups screening, we 
decided to go back to benzyl carbamate and change, instead, the conditions for the only 
troublesome cyclopropanation step (scheme 11). 
Since the double bond in enecarbamate esters such 45 is conjugated to a carboxylic group, it is 
possible to perform the cyclopropanation even by exploiting Michael-type reactions of sulfur 
methylides;25 such procedures are conducted in transition metals-free basic media, ensuring 
the compatibility of benzyl carbamate. Obviously, OH-directed cis stereoselectivity would not 
be possible anymore, lacking the coordinating Zn-carbenoid. On the other hand, a bulky 
homoallylic protecting group, such as tri-isopropyl silyl ether (-OTIPS), could direct the 
cyclopropanation onto the opposite face of the double bond providing a trans selectivity, as 
already reported for OTBS-protected allylic alcohols in the synthesis of trans-5-OH-CPA.6 
To investigate this possibility, we synthesized known protected lactam 4226 and we 
transformed it into the correspondent enecarbamate ester 45 employing the usual 
procedures. 
The cyclopropanation step was conducted in dry DMSO, preforming in situ the reactive 
dimethylsulfoxonium methylide upon treatment of trimethylsulfoxonium iodide (TMSOI) with 
NaH. In this case the synthesis worked fine (total yield: 75%),27 even if almost no facial 
selectivity was observed, whereas in the synthesis of 5-OH-CPA a 7:1 trans/cis ratio had been 
obtained.6 We hypothesized that this lack of selectivity had to be ascribed to the larger 
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distance from the double bond of the homoallylic bulky group, despite its axial disposition 
(confirmed by NMR). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 11. Optimised synthesis of N-CO2Bn protected 4-OH-CPAs. Reagents and conditions: 
a) TIPSCl, Imidazole, DMF, 40 °C; b) n-BuLi, CbzCl, THF, –78 °C; c) KHMDS, (PhO)2P(O)Cl, THF,    
–78 °C; d) MeOH, CO, Pd(OAc)2, Ph3P, Et3N, DMF, 65 °C; e) NaH, TMSOI, DMSO. 
 
Nonetheless, trans product 46 and cis product 47 resulted surprisingly easy to separate by 
column chromatography, so that this procedure can be considered an efficient method for the 
simultaneous synthesis of trans-4-OH-CPA 46 and cis-4-OH-CPA 47 which can be both 
subsequently employed as conformationally constrained amino acids for peptide synthesis, as 
we report later for compound 47 (see chapter 7).  
The relative cis stereochemistry of 47 was readily assigned because of its identity to the 
compound obtained by protecting as tri-isopropyl silyl ether the 4-OH of compound 24; 
consequently, the opposite trans stereochemistry was assigned to 46. The preferred 
conformation of both 46 and 47 were assigned by nuclear Overhauser effect (NOE) studies 
(figure 2). 
 
 
 
 
 
 
 
Figure 2. NOE studies on CPAs 
 
In compound 46 the NOE correlation observed between 4-H and the endo proton of the 
cyclopropane ring is in accordance with an axial orientation of 4-H and a trans-relative position 
between the OTIPS and the cyclopropane ring. On the contrary, no NOE was observed 
between 4-H and the endo proton of the cyclopropane ring in compound 47, demonstrating an 
equatorial orientation of 4-H and a cis-relative position of the OTIPS and the cyclopropane 
ring. In both the compounds, as usual, the methyl ester is forced in an axial orientation to 
remove the A(1,3) strain with the N-protecting group.  
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Additionally, to enlarge the scope of this synthetic strategy, we demonstrated even in this case 
the possibility to easily obtain also the N-CO2tBu-protected derivative 49 in two steps starting 
from 47 (scheme 12) by applying the same procedure already described for 27.28 
 
 
 
 
 
 
 
 
Scheme 12. Synthesis of N-CO2tBu protected 4-OH-CPA. Reagents and conditions: a) H2 (1 
atm), 10% Pd/C, EtOAc, RT, 4 h; b) Boc2O, Et3N, MeOH, reflux. 
 
Finally, starting from trans diasteroisomer 46 we tackled the protection of the amino group as 
N-9-fluorenylmethyloxycarbonyl (N-Fmoc) (scheme 13), which is, besides N-Boc, the other 
protecting group of choice for solid-phase peptide synthesis (SPPS). 
In this case we wanted to obtain a product readily utilizable for peptide synthesis, exhibiting 
contemporarily an N-Fmoc-protected amino group and a free carboxylic acid accessible for 
peptide coupling. 
Accordingly, methyl ester of 46 was selectively hydrolysed in a mixture of 1 N NaOH and 
MeOH, which had to be heated to 50 °C for 24 h, since differently than in other cases (see 
sections 4.2, 5.3 and 7.1), the reaction did not proceed at room temperature. This was 
probably due to the low solubility of the substrate in the reaction mixture or to the 
remarkable steric hindrance experienced by the methyl ester, possessing a cis stereochemistry 
relative to the bulky –OTIPS group. Nonetheless, product 50 was obtained with a high yield 
(88%) and converted to free amino acid 51 by means of the usual hydrogenation. Finally, 
amino group was protected as N-Fmoc by treating 51 with N-(9-fluorenylmethoxycarbonyloxy)
succinimide (FmocOSu) in a mixture of aqueous Na2CO3 and THF, affording final product 52 in 
81% yield.29 
 
 
 
 
 
 
 
 
Scheme 13. Synthesis of N-Fmoc protected 4-OH-CPA. Reagents and conditions: a) 1 N NaOH, 
MeOH, 50 °C, 24 h; b) H2 (1 atm), 10% Pd/C, EtOAc, RT; c) FmocOSu, Na2CO3 aq. THF. 
 
The strategies depicted in scheme 11, 12 and 13 represent the most efficient way, designed so 
far, to obtain versatile 4-substituted-CPAs. Rigid amino acid scaffolds 46 and 47, bearing three 
all orthogonally protected functional groups, were obtained straightforwardly in five steps 
starting from enantiopure hydroxy-lactam 4 and affording almost half a gram of each 
diasteroisomer in a single run. Moreover, as demonstrated above, 46 and 47 can be further 
modified according to the current synthetic needs. 
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4.7 Experimental 
 
General 
Chromatographic separations were performed under pressure on silica gel 60 (Merck, 70–230 
mesh), unless otherwise stated, using flash column techniques; Rf values refer to thin-layer 
chromatography (TLC) carried out on 0.25 mm silica gel plates with the same eluent indicated 
for column chromatography. 1H (400 and 200 MHz) and 13C (50.33 and 100.4 MHz) NMR 
spectra were recorded using Varian Inova and Mercury spectrometers in CDCl3 at 25 °C unless 
otherwise stated. Mass spectra were carried out by direct inlet using an LCQ Fleet Ion Trap 
LC/MS system (Thermo Fisher Scientific) with an ESI interface in the positive mode. 
Microanalyses were carried out with a Perkin-Elmer 2400/2 elemental analyser. Optical 
rotations were determined with a JASCO DIP-370 instrument. Anhydrous solvents were either 
commercial or prepared according to standard techniques. 
 
 
N CO2Me
HO
CO2Me  
Dimethyl (5S)-5-hydroxy-5,6-dihydropyridine-1,2(4H)-dicarboxylate [(–)-9] 
Compound 83 (1.04 g, 3.16 mmol) was dissolved in CH3CN (130 mL) and, after cooling to 0 °C, a 
3 N solution of HCl (130 mL) was added dropwise. The cooling bath was removed and the 
mixture was left under stirring for 45 min. Afterward, a satd. solution of NaHCO3 (420 mL) was 
slowly added until pH 7 was reached, the mixture was extracted with EtOAc (5 x 280 mL) and 
the combined extractions were dried over Na2SO4. After filtration and evaporation of the 
solvent, the crude was purified by flash chromatography (n-hexane/EtOAc, 1:3; Rf 0.26), to 
afford pure 9 (681 mg, 92%) as a white solid. 
M.p. 101.5-104.0 °C. [α]D
25 –25.0 (c 0.40, CHCl3). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 6.08 (t, J = 
3.9 Hz, 1 H, 3-H), 4.18–4.14 (m, 1 H, 5-H), 3.81–3.76 (m, 4 H, 6-Heq + OCH3), 3.73 (s, 3 H, OCH3), 
3.53 (dd, J = 13.1, 2.1 Hz, 1 H, 6-Hax), 2.54 (ddd, J = 19.8, 5.6, 3.9 Hz, 1 H, 4-H), 2.22 (dt, J = 19.8, 
3.9 Hz, 1 H, 4-H’), 2.01 (bs, 1 H, OH). 13C NMR (CDCl3, 100.4 MHz) δ (ppm): 164.7 (CO), 155.6 
(NCO), 132.0 (C-2), 121.4 (C-3), 64.1 (C-5), 53.5 (OCH3), 52.4 (OCH3), 49.5 (C-6), 32.2 (C-4). 
MS/MS (ESI of [M + Na]+) m/z (%): 238 (5) [M + Na]+, 194 (100). Elemental analysis calcd. (%) 
for C9H13NO5 (215.20): C, 50.23; H, 6.09; N, 6.51. Found: C, 50.15; H, 6.21; N, 6.62. 
 
 
N CO2Me
HO
CO2Me  
Dimethyl (1R,4S,6R)-4-hydroxy-2-azabicyclo[4.1.0]heptane-1,2-dicarboxylate [(+)-10] 
Et2Zn (6.32 mL of a 1M solution in hexane, 6.32 mmol) and CH2I2 (1.01 mL, 12.6 mmol) were 
added dropwise under an N2 atmosphere to a solution of 9 (681 mg, 3.16 mmol) in anhydrous 
CH2Cl2 (30 mL) cooled to –10 °C. After 1 h the cooling bath was removed and the reaction 
mixture was left under stirring for 1 h at room temperature, then heated to reflux for 18 h. 
The suspension was then cooled in an ice bath and a satd. solution of NH4Cl (30 mL) was added 
dropwise under vigorous stirring. The cooling bath was removed and when the solution 
became clear, the layers were separated, the aqueous layer was extracted with CH2Cl2 (3 × 30 
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mL) and the combined organic layers were dried over Na2SO4. After filtration and evaporation 
of the solvent, the residue was purified by flash chromatography (n-hexane/EtOAc, 1:3; Rf 
0.24), to afford pure 10 (514 mg, 71%) as a colourless oil. 
[α]D
21 +27.8 (c 1.36, CHCl3). 
1H NMR (400 MHz, CDCl3) (2.5:1 mixture of rotamers) δ (ppm): 
4.04–3.96 (m, 2 H, 4-H both rotamers + 3-Heq major rotamer), 3.81 (dd, J = 13.6, 4.1 Hz, 1 H, 3-
Heq, minor rotamer), 3.72 (s, 3 H, OCH3, minor rotamer), 3.70 (s, 3 H, OCH3, minor rotamer), 
3.69 (s, 3 H, OCH3, major rotamer), 3.67 (s, 3 H, OCH3, major rotamer), 3.04 (dd, J = 13.6, 2.3 
Hz, 1 H, 3-Hax, minor rotamer), 2.87 (dd, J = 13.3, 1.4 Hz, 1 H, 3-Hax, major rotamer), 2.40 (bs, 1 
H, OH, major rotamer), 2.32 (bs, 1 H, OH, minor rotamer), 2.14–2.00 (m, 1 H, 5-H, both 
rotamers), 1.93–1.88 (m, 1 H, 5-H’, both rotamers), 1.82 (dd, J = 10.1, 4.6 Hz, 1 H, 7-H, both 
rotamers), 1.69–1.59 (m, 1 H, 6-H, both rotamers), 1.22 (dd, J = 8.0, 4.6 Hz, 1 H, 7-H’, major 
rotamer), 1.19–1.17 (m, 1 H, 7-H’, minor rotamer). 13C NMR (100.4 MHz, CDCl3) (major 
rotamer) δ (ppm): 173.0 (CO), 158.5 (NCO), 64.8 (C-4), 53.1 (OCH3), 52.3 (OCH3), 46.7 (C-3), 
38.3 (C-1), 27.8, 23.9, 22.5. MS (ESI) m/z (%): 481 (76) [2M + Na]+, 252 (100) [M + Na]+. 
Elemental analysis calcd. (%) for C10H15NO5 (229.23): C, 52.40; H, 6.60; N, 6.11. Found: C, 
52.33; H, 6.74; N, 5.99. 
 
 
N CO2Me
N3
CO2Me  
Dimethyl (1R,4R,6S)-4-azido-2-azabicyclo[4.1.0]heptane-1,2-dicarboxylate [(–)-12] 
MsCl (195 µL, 2.47 mmol) was added dropwise to a solution of 10 (436 mg, 1.90 mmol) and 
triethylamine (343 µL, 2.47 mmol) in anhydrous CH2Cl2 (10 mL) cooled to –30 °C. After 5 min 
the cooling bath was removed and the reaction mixture was left under stirring for 1 h at room 
temperature. Then a 0.5 N solution of HCl (1 mL) was added dropwise and after 10 min the 
mixture was extracted with CH2Cl2 (3 x 5 mL). The combined organic layers were washed with 
water (3 x 5 mL) and dried over Na2SO4. After filtration and evaporation of the solvent, the 
crude was purified by flash chromatography (n-hexane/EtOAc 1:2, Rf 0.24) to afford compound 
11 (502 mg, 86%) as a colourless oil. 
1H NMR (400 MHz, CDCl3) (2:1 mixture of rotamers) δ (ppm): 5.00-4.97 (m, 1 H, 4-H, major 
rotamer), 4.95-4.90 (m, 1 H, 4-H, minor rotamer), 4.32 (dd, J = 14.3, 3.7 Hz, 1 H, 3-Heq, major 
rotamer), 4.18 (dd, J = 14.3, 4.0 Hz, 3-Heq, minor rotamer), 3.75 (s, 3 H, OCH3, minor rotamer), 
3.74 (s, 3 H, OCH3, minor rotamer), 3.73 (s, 3 H, OCH3, major rotamer), 3.71 (s, 3 H, OCH3, 
major rotamer), 3.09 (dd, J = 14.3, 2.0 Hz, 1 H, 3-Hax, minor rotamer), 3.02 (s, 3 H, SCH3, major 
rotamer), 2.98 (s, 3 H, SCH3, minor rotamer), 2.94 (dd, J = 14.3, 1.6 Hz, 1 H, 3-Hax, major 
rotamer), 2.34–2.15 (m, 2 H, 5-H + 5-H’, both rotamers), 1.97 (dd, J = 9.9, 5.2 Hz, 1 H, 7-H, 
minor rotamer), 1.91 (dd, J = 10.0, 5.1 Hz, 1 H, 7-H, major rotamer), 1.76–1.66 (m, 1 H, 6-H, 
both rotamers), 1.16-1.11 (m, 1 H, 7-H’, both rotamers). 
Mesylate 11 was dissolved in anhydrous acetonitrile (10 mL) and [15]crown-5 (65 μL, 0.33 
mmol) and NaN3 (159 mg, 2.45 mmol) were added to the resulting solution under an N2 
atmosphere. The mixture was heated to reflux for 6 h and then stirred at room temperature 
for 12 h. Afterward, the mixture was filtered through a silica/celite 1:1 pad and the filtrate 
concentrated under vacuum. The residue was purified by flash chromatography (n-
hexane/EtOAc, 3:1; Rf 0.21) affording pure 12 (344 mg, 83%) as a colourless oil. 
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[α]D
22 –18.4 (c 0.68, CHCl3). 
1H NMR (400 MHz, CDCl3) (1.8:1 mixture of rotamers) δ (ppm): 
4.08 (dd, J = 13.1, 4.7 Hz, 1 H, 3-Heq, major rotamer), 3.92 (dd, J = 13.1, 4.6 Hz, 3-Heq, minor 
rotamer), 3.73 (s, 3 H, OCH3, minor rotamer), 3.70 (s, 3 H, OCH3, major rotamer), 3.69 (s, 3 H, 
OCH3, major rotamer), 3.68 (s, 3 H, OCH3, minor rotamer), 3.51-3.42 (m, 1 H, 4-H, both 
rotamers), 2.83 (dd, J = 13.1, 8.6 Hz, 1 H, 3-Hax, minor rotamer), 2.76 (dd, J = 13.1, 8.2 Hz, 1 H, 
3-Hax, major rotamer), 2.02-1.94 (m, 3 H, 5-H + 5-H’ both rotamers + 7-H minor rotamer), 1.89 
(dd, J = 9.8, 4.9 Hz, 1 H, 7-H, major rotamer), 1.85-1.80 (m, 1 H, 6-H, both rotamers), 0.86-0.80 
(m, 1 H, 7-H’, both rotamers). 13C NMR (100.4 MHz, CDCl3) (major rotamer) δ (ppm): 172.2 
(CO), 156.9 (NCO), 55.1 (C-4), 53.1 (OCH3), 52.5 (OCH3), 44.9 (C-3), 37.7 (C-1), 27.2, 23.6, 22.6. 
MS (ESI) m/z (%): 277 (100) [M + Na]+. Elemental analysis calcd. (%) for C10H14N4O4 (254.24): C, 
47.24; H, 5.55; N, 22.04. Found: C, 47.01; H, 5.31; N, 22.43. 
 
 
N CO2H
N3
CO2Me  
(1R,4R,6S)-4-Azido-2-(methoxycarbonyl)-2-azabicyclo[4.1.0]heptane-1-carboxylic acid [(–)-
13] 
A 1 N solution of NaOH (2 mL) was added to a solution of 12 (344 mg, 1.35 mmol) in methanol 
(3 mL) and the resulting mixture was vigorously stirred for 24 h at room temperature. 
Afterward, the methanol was evaporated, the remaining aqueous layer was acidified to pH 3 
by adding a 1 N solution of HCl, and the product was extracted with CHCl3 (5 x 5 mL). Then the 
aqueous layer was further acidified to pH 1 and the product was extracted again with CHCl3 (5 
x 5 mL). The combined organic layers were dried over Na2SO4 and after filtration and 
evaporation of the solvent, compound 13 (302 mg, 93%) was obtained as a thick colourless oil. 
[α]D
27 –17.9 (c 0.75, CHCl3). 
1H NMR (400 MHz, CDCl3) (1.6:1 mixture of rotamers) δ (ppm): 
8.70 (bs, 1 H, COOH), 4.10-4.06 (m, 1 H, 3-Heq, major rotamer), 3.93-3.90 (m, 1 H, 3-Heq, minor 
rotamer), 3.74 (s, 3 H, OCH3, both rotamers), 3.52-3.47 (m, 1 H, 4-H, both rotamers), 2.88-2.76 
(m, 1 H, 3-Hax, both rotamers), 2.02-1.87 (m, 4 H, 5-H + 5-H’ + 6-H + 7-H, both rotamers), 0.89-
0.86 (m, 1 H, 7-H’, both rotamers). 13C NMR (100.4 MHz, CDCl3) (major rotamer) δ (ppm): 
177.7 (COOH), 157.0 (NCO), 55.3 (C-4), 53.4 (OCH3), 45.3 (C-3), 37.6 (C-1), 27.5, 24.5, 24.1. 
MS/MS (ESI of [M + Na]+) m/z (%): 263 (23) [M + Na]+, 220 (46), 206 (100), 187 (57). Elemental 
analysis calcd. (%) for C9H12N4O4 (240.22): C, 45.00; H, 5.04; N, 23.32. Found: C, 45.35; H, 4.88; 
N, 23.63. 
 
 
N CO2H
H2N
CO2Me  
(1R,4R,6S)-4-Amino-2-(methoxycarbonyl)-2-azabicyclo[4.1.0]heptane-1-carboxylic acid (14) 
Pd/C (10%, 40 mg) was added to a solution of 13 (302 mg, 1.26 mmol) in anhydrous methanol 
(25 mL) under an N2 atmosphere. The resulting suspension was stirred vigorously under a H2 
atmosphere (balloon) at room temperature for 16 h. After filtration through a celite layer and 
evaporation of the solvent, pure 14 (189 mg, 70%) was obtained as a white solid directly used 
in the next step without purification. 
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1H NMR (400 MHz, CD3OD) (2.1:1 mixture of rotamers) δ (ppm): 4.16 (dd, J = 12.5, 3.1 Hz, 1 H, 
3-Heq, major rotamer), 4.08 (dd, J = 13.0, 3.8 Hz, 1 H, 3-Heq, minor rotamer), 3.73 (s, 3 H, OCH3, 
major rotamer), 3.71 (s, 3 H, OCH3, minor rotamer), 3.10-3.03 (m, 1 H, 4-H, both rotamers), 
2.92-2.84 (m, 1 H, 3-Hax, minor rotamer), 2.79 (dd, J = 12.5, 10.5 Hz, 1 H, 3-Hax, major rotamer), 
2.27 (dd, J = 13.6, 5.4 Hz, 1 H, 5-H, major rotamer), 2.23-2.20 (m, 1 H, 5-H, minor rotamer), 
1.98-1.89 (m, 1 H, 5-H’, both rotamers), 1.87-1.70 (m, 2 H, 6-H + 7-H, both rotamers), 0.75 (dd, 
J = 7.03, 4.3 Hz, 1 H, 7-H’, major rotamer), 0.70-0.67 (m, 1 H, 7-H’, minor rotamer). MS/MS (ESI 
of [M]+) m/z (%): 214 (11) [M]+, 182 (100), 154 (16). 
 
 
N O
TBSO
Cbz  
(5S)-Benzyl 5-(tert-butyldimethylsilanyloxy)-2-oxopiperidine-1-carboxylate [(+)-15] 
n-BuLi (306 μL of a 1.6 M solution in hexane, 0.49 mmol) was added dropwise, under an N2 
atmosphere, to a solution of lactam 52 (112 mg, 0.49 mmol) in anhydrous THF (5 mL) cooled to 
–78 °C, keeping the temperature below –70 °C during the addition. The mixture was stirred for 
15 min and then benzyl chloroformate (77 μL, 0.54 mmol) was added dropwise. After 10 min 
the cooling bath was removed and the temperature was allowed to reach 0 °C. Keeping the 
reaction flask in an ice bath, a satd. solution of NaHCO3 (2 mL) was added and the mixture was 
stirred for 10 min. Afterward, the layers were separated, the aqueous layer was extracted with 
CH2Cl2 (3 x 2 mL) and the combined organic layers were dried over Na2SO4. After filtration and 
evaporation of the solvent, the residue was purified by flash chromatography (n-
hexane/EtOAc, 4:1; Rf 0.21), to afford pure 15 (125 mg, 70%) as a white solid. 
M.p. 35.6-36.8 °C. [α]D
22 +12.2 (c 0.68, CHCl3). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 7.44-7.41 (m, 
2 H, Ph), 7.38-7.29 (m, 3 H, Ph), 5.29 (s, 2 H, CH2Ph), 4.19-4.15 (m, 1 H, 5-H), 3.75 (ddd, J = 
13.3, 4.7, 1.6 Hz, 1 H, 6-H), 3.68 (dd, J = 13.3, 3.7 Hz, 1 H, 6-H’), 2.76 (ddd, J = 17.2, 9.4, 6.6 Hz, 
1 H, 3-H), 2.46 (ddd, J = 17.2, 6.2, 5.7 Hz, 1 H, 3-H’), 2.00-1.92 (m, 1 H, 4-H), 1.90-1.82 (m, 1 H, 
4-H’), 0.86 [s, 9 H, SiC(CH3)3], 0.07 [s, 3 H, Si(CH3)2], 0.06 [s, 3 H, Si(CH3)2]. 
13C NMR (CDCl3, 
100.4 MHz) δ (ppm): 170.7 (CO), 154.1 (NCO2Bn), 135.5 (Carom), 128.5 (2 C, Carom), 128.2 (Carom), 
128.0 (2 C, Carom), 68.5 (CH2Ph), 64.2 (C-5), 52.9 (C-6), 30.9 (C-3), 28.9 (C-4), 25.6 [3 C, 
SiC(CH3)3], 18.0 [SiC(CH3)3], –4.9 [2 C, Si(CH3)2]. MS/MS (ESI of [M + Na]
+) m/z (%): 386 (37) [M 
+ Na]+, 342 (100). Elemental analysis calcd. (%) for C19H29NO4Si (363.52): C, 62.78; H, 8.04; N, 
3.85. Found: C, 62.40; H, 7.67; N, 3.98. 
 
 
N O
TBSO
Boc  
(5S)-tert-Butyl 5-(tert-butyldimethylsilanyloxy)-2-oxopiperidine-1-carboxylate [(+)-16] 
Triethylamine (1.14 mL, 8.15 mmol), Boc2O (1.64 g, 7.41 mmol) and DMAP (91 mg, 0.741 
mmol) were added to a solution of lactam 52 (1.70 g, 7.41 mmol) in anhydrous CH2Cl2 (45 mL), 
under an N2 atmosphere. The resulting reaction mixture was heated to reflux for 5 h, adding 
further Boc2O (2.46 g, 11.1 mmol) portionwise over the first 3 h. Afterward, water (55 mL) was 
added, the layers were separated and the aqueous one was extracted with CH2Cl2 (3 x 25 mL). 
The combined organic layers were washed with a 5% solution of KHSO4 (55 mL), a satd. 
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solution of NaHCO3 (55 mL), water (55 mL) and brine (55 mL) and then dried over Na2SO4. 
After filtration and evaporation of the solvent, the residue was purified by flash 
chromatography (n-hexane/EtOAc, 5:1; Rf 0.23), affording pure 16 (1.95 g, 80%) as a white 
solid. 
M.p. 34.0-36.0 °C. [α]D
24 +7.8 (c 0.99, CHCl3). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 4.17-4.12 (m, 
1 H, 5-H), 3.68-3.59 (m, 2 H, 6-H + 6-H’), 2.71 (ddd, J = 17.2, 9.0, 6.7 Hz, 1 H, 3-H), 2.42 (dt, J = 
17.2, 6.2 Hz, 1 H, 3-H’), 1.99-1.91 (m, 1 H, 4-H), 1.86-1.78 (m, 1 H, 4-H’), 1.52 [s, 9 H, OC(CH3)3], 
0.88 [s, 9 H, SiC(CH3)3], 0.08 [s, 6 H, Si(CH3)2]. 
13C NMR (CDCl3, 100.4 MHz) δ (ppm): 170.9 (CO), 
152.5 (NCO2tBu), 82.9 [OC(CH3)3], 64.4 (C-5), 52.4 (C-6), 31.1 (C-3), 29.0 (C-4), 28.0 [3 C, 
OC(CH3)3], 25.7 [3 C, SiC(CH3)3], 18.0 [SiC(CH3)3], –4.9 [2 C, Si(CH3)2]. MS/MS (ESI of [M + Na]
+) 
m/z (%): 352 (15) [M + Na]+, 252 (100). Elemental analysis calcd. (%) for C16H31NO4Si (329.51): 
C, 58.32; H, 9.48; N, 4.25. Found: C, 57.89; H, 9.95; N, 4.75. 
 
 
N OP(O)(OPh)2
TBSO
Cbz  
(3S)-Benzyl 6-[(diphenoxyphosphoryl)oxy]-3-(tert-butyldimethylsilanyloxy)-3,4-
dihydropyridine-1(2H)-carboxylate (17) 
A solution of 15 (125 mg, 0.34 mmol) in anhydrous THF (840 μL) was added dropwise to a 
solution of KHMDS (850 μL of a 0.5 M solution in toluene, 0.425 mmol) in anhydrous THF (2.2 
mL) cooled to –78 °C, under an N2 atmosphere, and the resulting mixture was stirred for 1.5 h 
at –78 °C. Afterward, a solution of diphenyl chlorophosphate (88 μL, 0.425 mmol) in 
anhydrous THF (650 μL) was added dropwise and the reaction was left under stirring for 1 h at 
–78 °C, before allowing the temperature to reach 0 °C. Then a 5% NaOH aqueous solution (6.5 
mL) was slowly added and the product was extracted with Et2O (3 × 4 mL). The combined 
organic layers were washed with 5% NaOH (5 mL) and dried over anhydrous K2CO3 for 30 min. 
After filtration and evaporation of the solvent (without heating and leaving a small volume of 
solvent), the crude phosphate was chromatographed (n-hexane/EtOAc, 4:1 with 1% Et3N; Rf 
0.22), affording 17 (201 mg, 99%) as a pale yellow oil, which was immediately used in the next 
step. 
1H NMR (CDCl3, 400 MHz) δ (ppm): 7.36-7.24 (m, 10 H, Ph), 7.20-7.15 (m, 5 H, Ph), 5.10-5.02 
(m, 3 H, AB system CH2Ph + 5-H), 4.04-3.99 (m, 1 H, 3-H), 3.76 (dd, J = 12.7, 6.1 Hz, 1 H, 2-H), 
3.44 (dd, J = 12.7, 2.1 Hz, 1 H, 2-H’), 2.38 (dq, J = 18.2, 4.3 Hz, 1 H, 4-H), 2.07 (dq, J = 18.2, 3.9 
Hz, 1 H, 4-H’), 0.85 [s, 9 H, SiC(CH3)3], 0.05 [s, 3 H, Si(CH3)2], 0.04 [s, 3 H, Si(CH3)2]. 
13C NMR 
(CDCl3, 100.4 MHz) δ (ppm): 154.6 (NCO2Bn), 150.3 (2 C, Carom), 139.5 (C-6), 135.8 (Carom), 129.7 
(4 C, Carom), 128.4 (2 C, Carom), 128.0 (2 C, Carom), 127.9 (Carom), 125.2 (2 C, Carom), 120.1 (4 C, 
Carom), 98.5 (C-5), 67.9 (CH2Ph), 64.7 (C-3), 51.5 (C-2), 32.0 (C-4), 25.7 [3 C, SiC(CH3)3], 18.0 
[SiC(CH3)3], –5.0 [2 C, Si(CH3)2]. MS (ESI) m/z (%): 1213 (100) [2M + Na]
+, 596 (20) [M + 1]+. 
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N OP(O)(OPh)2
TBSO
Boc  
(3S)-tert-Butyl 6-[(diphenoxyphosphoryl)oxy]-3-(tert-butyldimethylsilanyloxy)-3,4-
dihydropyridine-1(2H)-carboxylate (18) 
Prepared as reported for 17, starting from 16 (1.95 g, 5.92 mmol). After flash chromatography 
(n-hexane/EtOAc, 4:1 with 1% Et3N; Rf 0.46), compound 18 (3.29 g, 99%) was obtained as a 
pale yellow oil, which was immediately used in the next step. 
1H NMR (CDCl3, 400 MHz) δ (ppm): 7.36-7.17 (m, 10 H, Ph), 5.04-5.01 (m, 1 H, 5-H), 4.01-3.96 
(m, 1 H, 3-H), 3.59-3.49 (m, 2 H, 2-H + 2-H’), 2.43-2.35 (m, 1 H, 4-H), 2.06 (dq, J = 18.1, 4.2 Hz, 1 
H, 4-H’), 1.42 [s, 9 H, OC(CH3)3], 0.89 [s, 9 H, SiC(CH3)3], 0.08 [s, 6 H, Si(CH3)2]. 
13C NMR (CDCl3, 
100.4 MHz) δ (ppm): 153.4 (NCO2tBu), 150.5 (2 C, Carom), 140.1 (C-6), 129.9 (4 C, Carom), 125.6 (2 
C, Carom), 120.3 (4 C, Carom), 98.0 (C-5), 81.8 [OC(CH3)3], 65.3 (C-3), 51.2 (C-2), 32.3 (C-4), 28.3 [3 
C, OC(CH3)3], 26.0 [3 C, SiC(CH3)3], 18.4 [SiC(CH3)3], –4.6 [2 C, Si(CH3)2]. 
 
 
N CO2Me
TBSO
Cbz  
(5S)-1-Benzyl 2-methyl 5-(tert-butyldimethylsilanyloxy)-5,6-dihydropyridine-1,2(4H)-
dicarboxylate [(+)-20] 
Pd(OAc)2 (7.6 mg, 0.034 mmol) and Ph3P (19.7 mg, 0.075 mmol) were added to a solution of 
phosphate 17 (201 mg, 0.34 mmol) in anhydrous DMF (860 μL), under an N2 atmosphere. The 
flask was flushed and saturated with carbon monoxide and the mixture was vigorously stirred 
for 10 min at 25 °C under carbon monoxide atmosphere. Afterward, Et3N (92 μL, 0.68 mmol) 
and anhydrous methanol (578 μL, 14.3 mmol) were added and the mixture was stirred at 60 °C 
(external bath) for 1.5 h under carbon monoxide atmosphere (balloon). After cooling, water (8 
mL) was added, the product was extracted with Et2O (4 × 8 mL) and the combined organic 
extracts were dried over Na2SO4. After filtration and evaporation of the solvent, the crude was 
purified by flash chromatography (n-hexane/EtOAc, 6:1; Rf 0.17), to afford pure 20 (97 mg, 
70%) as a thick colourless oil. 
[α]D
19 +10.8 (c 0.99, CHCl3). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 7.37-7.29 (m, 5 H, Ph), 6.04 (t, J 
= 3.9 Hz, 1 H, 3-H), 5.12 (AB system, 2 H, CH2Ph), 4.05-4.03 (m, 1 H, 5-H), 3.60-3.55 (m, 5 H, 6-H 
+ 6-H’ + OCH3), 2.45 (ddd, J = 19.3, 5.5, 3.9 Hz, 1 H, 4-H), 2.14 (dt, J = 19.3, 3.9 Hz, 1 H, 4-H’), 
0.86 [s, 9 H, SiC(CH3)3], 0.06 [s, 6 H, Si(CH3)2]. 
13C NMR (CDCl3, 100.4 MHz) δ (ppm): 164.7 (CO), 
154.6 (NCO2Bn), 135.8 (Carom), 132.0 (C-2), 128.4 (2 C, Carom), 128.3 (2 C, Carom), 128.2 (Carom), 
121.5 (C-3), 68.0 (CH2Ph), 64.6 (C-5), 51.9 (C-6), 49.8 (OCH3), 33.3 (C-4), 25.7 [3 C, SiC(CH3)3], 
18.0 [(SiC(CH3)3], –4.9 [2 C, Si(CH3)2]. MS (ESI) m/z (%): 833 (100) [2M + Na]
+, 406 (20) [M + 1]+. 
Elemental analysis calcd. (%) for C21H31NO5Si (405.56): C, 62.19; H, 7.70; N, 3.45. Found: C, 
62.32; H, 7.44; N, 3.38. 
 
 
 
Results and Discussion: Chapter 4 
 
52 
 
N CO2Me
TBSO
Boc  
(5S)-1-tert-Butyl 2-methyl 5-(tert-butyldimethylsilanyloxy)-5,6-dihydropyridine-1,2(4H)-
dicarboxylate [(+)-21] 
Prepared as reported for 20, starting from 18 (3.29 g, 5.86 mmol), using a triple amount of 
anhydrous methanol (29.9 mL, 738 mmol) and carrying out the reaction at 75 °C. The crude 
was purified by flash chromatography on neutral aluminium oxide of activity II (prepared from 
Fluka, 100-125 mesh, Brockmann Activity I) (n-hexane/EtOAc, 20:1; Rf 0.31), affording pure 21 
(871 mg, 40%) as a colourless oil. 
[α]D
23 +22.8 (c 0.76, CHCl3). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 5.93 (t, J = 3.9 Hz, 1 H, 3-H), 
4.03-3.95 (m, 1 H, 5-H), 3.77 (s, 3 H, OCH3), 3.64-3.38 (m, 2 H, 6-H + 6-H’), 2.44 (ddd, J = 19.3, 
5.7, 3.9 Hz, 1 H, 4-H), 2.12 (ddd, J = 19.3, 5.2, 3.9 Hz, 1 H, 4-H’), 1.42 [s, 9 H, OC(CH3)3], 0.87 [s, 
9 H, SiC(CH3)3], 0.08 [s, 6 H, Si(CH3)2]. 
13C NMR (CDCl3, 100.4 MHz) δ (ppm): 165.2 (CO), 153.3 
(NCO2tBu), 132.4 (C-2), 120.1 (C-3), 81.3 [OC(CH3)3], 64.8 (C-5), 51.9 (C-6), 49.1 (OCH3), 33.3 (C-
4), 28.0 [3 C, OC(CH3)3], 25.8 [3 C, SiC(CH3)3], 18.1 [(SiC(CH3)3], – 4.9 [2 C, Si(CH3)2]. MS/MS (ESI 
of [M + Na]+) m/z (%): 394 (12) [M + Na]+, 338 (100), 294 (57). Elemental analysis calcd. (%) for 
C18H33NO5Si (371.54): C, 58.19; H, 8.95; N, 3.77. Found: C, 58.50; H, 9.21; N, 3.82. 
 
 
N CO2Me
HO
Cbz  
1-Benzyl 2-methyl (5S)-5-hydroxy-5,6-dihydropyridine-1,2(4H)-dicarboxylate [(–)-22] 
Prepared as reported for 9, starting from 20 (97 mg, 0.24 mmol) and carrying out the reaction 
for 1.5 h. After flash chromatography (n-hexane/EtOAc, 1:1; Rf 0.19), pure 22 (58 mg, 83%) 
was obtained as a white solid. 
M.p. 87.8-89.2 °C. [α]D
25 –14.6 (c 0.65, CHCl3). 
1H NMR (400 MHz, CDCl3) δ (ppm): 7.38-7.29 (m, 
5 H, Ph), 6.06 (t, J = 3.9 Hz, 1 H, 3-H), 5.19 (part A of an AB system, J = 12.1 Hz, 1 H, CH2Ph), 
5.12 (part B of an AB system, J = 12.1 Hz, 1 H, CH2Ph), 4.17-4.16 (m, 1 H, 5-H), 3.82 (dd, J = 
12.9, 6.1 Hz, 1 H, 6-H), 3.58-3.54 (m, 4 H, 6-H’ + OCH3), 2.53 (ddd, J = 19.7, 5.0, 3.9 Hz, 1 H, 4-
H), 2.22 (dt, J = 19.7, 3.9 Hz, 1 H, 4-H’). 13C NMR (100.4 MHz, CDCl3) δ (ppm): 164.5 (CO), 154.9 
(NCO2Bn), 135.7 (Carom), 132.1 (C-2), 128.5 (2 C, Carom), 128.3 (2 C, Carom), 128.2 (Carom), 121.0 (C-
3), 68.2 (CH2Ph), 64.1 (C-5), 52.0 (OCH3), 49.4 (C-6), 32.1 (C-4). MS (ESI) m/z (%): 292 (100) [M 
+ 1]+. Elemental analysis calcd. (%) for C15H17NO5 (291.30): C, 61.85; H, 5.88; N, 4.81. Found C, 
62.11; H, 5.62; N, 4.62. 
 
 
N CO2Me
HO
Boc  
1-tert-Butyl 2-methyl (5S)-5-hydroxy-5,6-dihydropyridine-1,2(4H)-dicarboxylate [(–)-23] 
TBAF (2.67 mL of a 1 M solution in THF, 2.67 mmol) was slowly added to a solution of 21 (871 
mg, 2.34 mmol) in anhydrous THF (100 mL), under an N2 atmosphere. After 30 min the solvent 
was evaporated under vacuum and the residue was taken up in Et2O (100 mL). The solvent was 
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evaporated again and the residue was purified by flash chromatography (n-hexane/EtOAc, 1:1; 
Rf 0.24), affording pure 23 (458 mg, 76%) as a white solid. 
M.p. 116.0-118.0 °C. [α]D
22 –21.0 (c 0.68, CHCl3). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 5.97 (t, J = 
3.9 Hz, 1 H, 3-H), 4.14–4.10 (m, 1 H, 5-H), 3.77 (s, 3 H, OCH3), 3.66 (dd, J = 12.9, 6.3 Hz, 1 H, 6-
Heq), 3.54 (dd, J = 12.9, 2.5 Hz, 1 H, 6-Hax), 2.51 (ddd, J = 19.7, 5.7, 3.9 Hz, 1 H, 4-H), 2.40 (bs, 1 
H, OH), 2.19 (dt, J = 19.7, 3.9 Hz, 1 H, 4-H’), 1.42 [s, 9 H, OC(CH3)3]. 
13C NMR (CDCl3, 100.4 MHz) 
δ (ppm): 165.0 (CO), 153.8 (NCO2tBu), 132.3 (C-2), 120.1 (C-3), 81.7 [OC(CH3)3], 64.1 (C-5), 51.9 
(OCH3), 48.9 (C-6), 32.0 (C-4), 27.9 [3 C, OC(CH3)3]. MS (ESI) m/z (%): 537 (100) [2M + Na]
+, 258 
(43) [M + 1]+. Elemental analysis calcd. (%) for C12H19NO5 (257.28): C, 56.02; H, 7.44; N, 5.44. 
Found: C, 56.37; H, 7.68; N, 5.45. 
 
 
N CO2Me
HO
Cbz  
2-Benzyl 1-methyl (1R,4S,6R)-4-hydroxy-2-azabicyclo[4.1.0]heptane-1,2-dicarboxylate [(+)-
24] 
Prepared as reported for 10, starting from 22 (58 mg, 0.20 mmol) and using a double amount 
of Et2Zn (800 μL of a 1 M solution in hexane, 0.80 mmol) and CH2I2 (128 μL, 1.60 mmol). After 
purification by flash chromatography (n-hexane/EtOAc, 1:1; Rf 0.21) pure 24 (23 mg, 38%) was 
obtained as a colourless oil. 
[α]D
25 +22.7 (c 0.92, CHCl3). 
1H NMR (400 MHz, CDCl3) (2.8:1 mixture of rotamers) δ (ppm): 
7.36-7.25 (m, 5 H, Ph), 5.26 (part A of an AB system, J = 12.5 Hz, 1 H, CH2Ph, major rotamer), 
5.18 (AB system, 2 H, CH2Ph, minor rotamer), 5.08 (part B of an AB system, J = 12.5 Hz, 1 H, 
CH2Ph, major rotamer), 4.06-3.99 (m, 2 H, 4-H both rotamers + 3-Heq major rotamer), 3.86 (dd, 
J = 13.6, 4.3 Hz, 1 H, 3-Heq, minor rotamer), 3.69 (s, 3 H, OCH3, minor rotamer), 3.55 (s, 3 H, 
OCH3, major rotamer), 3.07 (dd, J = 13.6, 2.5 Hz, 1 H, 3-Hax, minor rotamer), 2.92-2.88 (m, 1 H, 
3-Hax, major rotamer), 2.16-1.91 (m, 3 H, 5-H both rotamers + 5-H’ both rotamers + OH), 1.85 
(dd, J = 10.2, 4.7 Hz, 1 H, 7-H, both rotamers), 1.72-1.60 (m, 1 H, 6-H, both rotamers), 1.26 (dd, 
J = 8.0, 4.7 Hz, 1 H, 7-H’, major rotamer), 1.24-1.19 (m, 1 H, 7-H’, minor rotamer). 13C NMR 
(100.4 MHz, CDCl3) (major rotamer) δ (ppm): 172.9 (CO), 157.7 (NCO), 136.7 (Carom), 128.4 (2 C, 
Carom), 127.8 (Carom), 127.4 (2 C, Carom), 67.3 (CH2Ph), 64.9 (C-4), 52.2 (OCH3), 46.8 (C-3), 38.4 (C-
1), 27.9, 24.1, 22.5. MS/MS (ESI of [M + 1]+) m/z (%): 306 (3) [M + 1]+, 262 (100). Elemental 
analysis calcd. (%) for C16H19NO5 (305.33): C, 62.94; H, 6.27; N, 4.59. Found: C, 62.88; H, 6.39; 
N, 4.44. 
 
 
N
H
CO2Me
HO
 
Methyl (1R,4S,6R)-4-hydroxy-2-azabicyclo[4.1.0]heptane 1-carboxylate [(+)-25] 
Pd/C (5 mg, 10%) was added to a solution of 24 (23 mg, 0.075 mmol) in ethyl acetate (1.5 mL), 
under an N2 atmosphere. The resulting suspension was stirred under a H2 atmosphere 
(balloon) at room temperature for 4 h. After filtration over a celite layer and evaporation of 
the solvent, pure 25 (12 mg, 96%) was obtained as a colourless oil. 
[α]D
24 +91.0 (c 0.91, CHCl3). 
1H NMR (400 MHz, CDCl3) δ (ppm): 3.88-3.85 (m, 1 H, 4-H), 3.71 (s, 
3 H, OCH3), 2.83 (ddd, J = 12.7, 3.9, 1.4 Hz, 1 H, 3-H), 2.69-2.65 (m, 3 H, 3-H’ + OH + NH), 2.10-
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1.98 (m, 2 H, 5-H + 5-H’), 1.64-1.54 (m, 2 H, 6-H + 7-H), 1.15 (dd, J = 7.03, 3.5 Hz, 1 H, 7-H’). 13C 
NMR (100.4 MHz, CDCl3) δ (ppm): 175.4 (CO), 64.0 (C-4), 52.4 (OCH3), 47.5 (C-3), 39.5 (C-1), 
28.7, 26.1, 19.6. MS (ESI) m/z (%): 172 (100) [M + 1]+. MS/MS (ESI of [M + 1]+) m/z (%): 172 (9) 
[M + 1]+, 112 (100). Elemental analysis calcd. (%) for C8H13NO3 (171.19): C, 56.13; H, 7.65; N, 
8.18. Found: C, 56.37; H, 7.36; N, 8.01. 
 
 
N CO2Me
HO
Boc  
2-tert-Butyl 1-methyl (1R,4S,6R)-4-hydroxy-2-azabicyclo[4.1.0]heptane-1,2-dicarboxylate 
[(+)-27] 
Triethylamine (20 μL, 0.14 mmol) and Boc2O (31 mg, 0.14 mmol) were added to a solution of 
25 (12 mg, 0.070 mmol) in anhydrous methanol (2 mL), under an N2 atmosphere, and the 
resulting reaction mixture was heated to reflux for 4 h. Afterward, water (3 mL) was added 
and the product was extracted with CH2Cl2 (5 x 2 mL). The combined organic extracts were 
washed with a 5% solution of KHSO4 (3 mL), a satd. solution of NaHCO3 (3 mL), water (3 mL) 
and brine (3 mL) and then dried over Na2SO4. After filtration and evaporation of the solvent, 
the residue was purified by flash chromatography (n-hexane/EtOAc, 1:2; Rf 0.34), affording 
pure 27 (13 mg, 70%) as a white gummy solid. 
[α]D
24 +22.5 (c 0.60, CHCl3). 
1H NMR (400 MHz, CDCl3) (3.6:1 mixture of rotamers) δ (ppm): 
4.08-4.04 (m, 1 H, 4-H, major rotamer), 4.00-3.96 (m, 2 H, 3-Heq major rotamer, 4-H minor 
rotamer), 3.73-3.72 (m, 1 H, 3-Heq, minor rotamer), 3.70 (s, 3 H, OCH3, major rotamer), 3.69 (s, 
3 H, OCH3, minor rotamer), 3.06 (dd, J = 13.6, 2.6 Hz, 1 H, 3-Hax, minor rotamer), 2.84 (dd, J = 
13.7, 1.8 Hz, 1 H, 3-Hax, major rotamer), 2.06-1.99 (m, 1 H, 5-H, both rotamers), 1.96-1.92 (m, 1 
H, 5-H’, both rotamers), 1.82 (dd, J = 10.0, 4.6 Hz, 1 H, 7-H, both rotamers), 1.73-1.58 (m, 2 H, 
6-H both rotamers + OH), 1.48 [s, 9 H, OC(CH3)3, minor rotamer], 1.43 [s, 9 H, OC(CH3)3, major 
rotamer], 1.18 (dd, J = 8.0, 4.6 Hz, 1 H, 7-H’, major rotamer), 1.16-1.14 (m, 1 H, 7-H’, minor 
rotamer). 13C NMR (100.4 MHz, CDCl3) (major rotamer) δ (ppm): 173.4 (CO), 157.0 (NCO), 80.3 
[OC(CH3)3], 65.5 (C-4), 52.3 (OCH3), 46.2 (C-3), 38.9 (C-1), 28.5 [3 C, OC(CH3)3], 28.1, 24.2, 22.8. 
MS/MS (ESI of [M + Na]+) m/z (%): 294 (6) [M + Na]+, 238 (21), 194 (100). Elemental analysis 
calcd. (%) for C13H21NO5 (271.31): C, 57.55; H, 7.80; N, 5.16. Found: C, 57.81; H, 7.62; N, 4.93. 
 
 
N CO2H
HO
Boc  
(1R,4S,6R)-4-Hydroxy-2-(tert-buthoxycarbonyl)-2-azabicyclo[4.1.0]heptane-1-carboxylic acid 
[(+)-33] 
A solution of 10 (78 mg, 0.34 mmol) and KOH (477 mg, 8.5 mmol) in ethanol (4.6 mL) was 
heated to reflux for 48 h. Afterward, the mixture was allowed to reach room temperature and 
neutralized with a 1.25 M solution of HCl in MeOH. After filtration over a celite layer and 
evaporation of the solvent, the deprotected amino acid 31 was obtained as an orange solid 
directly used in the next step without purification. 
Results and Discussion: Chapter 4 
 
55 
 
1H NMR (400 MHz, CD3OD) δ (ppm): 4.09-4.07 (m, 1 H, 4-H), 3.11 (dd, J = 12.7, 3.7 Hz, 1 H, 3-
H), 2.87 (dd, J = 13.7, 1.2 Hz,  1 H, 3-H’), 2.07 (t, J = 4.0 Hz, 2 H, 5-H), 1.75-1.71 (m, 1 H, 6-H), 
1.56-1.48 (m, 1 H, 7-H), 1.30-1.22 (m, 1 H, 7-H’). MS/MS (ESI of [M + 1]+) m/z (%): 112 (100). 
Amino acid 31 was dissolved in anhydrous methanol (4 mL) and triethylamine (190 µl, 3.16 
mmol) and Boc2O (300 mg, 3.16 mmol) were added to the resulting solution, under an N2 
atmosphere. The reaction mixture was heated to reflux for 24 h, then the solvent was 
evaporated under vacuum and the residue was dissolved in H2O (5 mL). NaH2PO4·2H2O (50 mg) 
was added to the resulting solution, which was then cooled to 0 °C, acidified to pH 2, adding a 
1 N solution of HCl, and stirred for 30 min at 0 °C. Afterward, the product was extracted with 
EtOAc (6 x 5 mL) and the combined organic extracts were dried over Na2SO4. After filtration 
and evaporation of the solvent, the crude was purified by flash chromatography 
(CH2Cl2/methanol 10:1, Rf 0.25), to afford compound 33 (28 mg, 32% from 10) as a pale yellow 
oil. 
[α]D
20 +7.3  (c 0.75, CH3OH). 
1H NMR (400 MHz, CD3OD) (3:1 mixture of rotamers) δ (ppm): 
3.95-3.91 (m, 1 H, 4-H, major rotamer), 3.90-3.88 (m, 1 H, 4-H, minor rotamer), 3.69 (dd, J = 
13.0, 4.9 Hz, 1 H, 3-Heq major rotamer), 3.64 (dd, J = 12.9, 5.1 Hz, 1 H, 3-Heq, minor rotamer), 
3.10 (dd, J = 12.9, 3.3 Hz, 1 H, 3-Hax, minor rotamer), 2.97 (dd, J = 13.0, 3.0 Hz,  1 H, 3-Hax, 
major rotamer), 2.17-2.10 (m, 1 H, 5-H, both rotamers), 1.80 (dd, J = 9.8, 4.7 Hz, 7-H, minor 
rotamer), 1.75 (dd, J = 9.5, 4.3 Hz, 7-H, major rotamer), 1.70-1.59 (m, 2 H, 5-H’ + 6-H, both 
rotamers), 1.48 [s, 9 H, OC(CH3)3, minor rotamer], 1.45 [s, 9 H, OC(CH3)3, major rotamer], 1.08 
(dd, J = 7.4, 4.3 Hz, 1 H, 7-H’, major rotamer), 1.06-1.04 (m, 1 H, 7-H’, minor rotamer). 13C NMR 
(100.4 MHz, CD3OD) (major rotamer) δ (ppm): 177.2 (CO), 158.5 (NCO), 81.2 [OC(CH3)3], 66.1 
(C-4), 47.5 (C-3), 39.6 (C-1), 30.0, 28.7 [3 C, OC(CH3)3], 24.4, 23.8. MS (ESI) m/z (%): 537 (100) 
[2M + Na]+, 280 (65) [M + Na]+. 
 
 
N CO2Me
O H  
Methyl 1-formyl-1,4,5,6-tetrahydropyridine-2-carboxylate (41) 
Prepared as reported for 20, starting from 4024 (204 mg, 1.4 mmol), using a double amount of 
anhydrous methanol (4 mL, 99 mmol) and carrying out the reaction at 75 °C for 5 h. After 
purification by flash chromatography (n-hexane/EtOAc, 2:1; Rf 0.22) pure 41 (60 mg, 25%) was 
obtained as a pale yellow oil. 
1H NMR (CDCl3, 200 MHz) (5.5:1 mixture of rotamers) δ (ppm): 8.55 (s, 1 H, CHO, major 
rotamer), 8.01 (s, 1 H, CHO, minor rotamer), 6.42 (t, J = 4.0 Hz, 1 H, 3-H, major rotamer), 6.16 
(t, J = 3.8 Hz, 1 H, 3-H, minor rotamer), 3.81 (s, 3 H, OCH3, major rotamer), 3.78 (s, 3 H, OCH3, 
minor rotamer), 3.71-3.66 (m, 2 H, 6-H + 6-H’, major rotamer), 3.57-3.51 (m, 2 H, 6-H + 6-H’, 
minor rotamer), 2.34-2.26 (m, 2 H, 4-H + 4-H’, both rotamers), 1.92-1.74 (m, 2 H, 5-H + 5-H’, 
both rotamers). 13C NMR (CDCl3, 50 MHz) (major rotamer) δ (ppm): 163.5 (CO), 161.9 (CHO), 
130.1 (C-2), 125.5 (C-3), 52.4 (OCH3), 38.8 (C-6), 23.4 (C-4), 21.8 (C-5). MS/MS (ESI of [M + 1]
+) 
m/z (%): 170 (3) [M + 1]+, 142 (84), 138 (100). 
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N O
TIPSO
Cbz  
(5S)-Benzyl 5-(triisopropylsilanyloxy)-2-oxopiperidine-1-carboxylate [(+)-43] 
Prepared as reported for 15, starting from 4225 (1.46 g, 5.38 mmol). After purification by flash 
chromatography (n-hexane/EtOAc, 4:1; Rf 0.28) pure 43 (1.75 g, 80%) was obtained as a 
colourless oil. 
[α]D
20 +10.7 (c 1.00, CHCl3). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 7.42-7.40 (m, 2 H, Ph), 7.36-
7.25 (m, 3 H, Ph), 5.27 (s, 2 H, CH2Ph), 4.29-4.25 (m, 1 H, 5-H), 3.84 (ddd, J = 13.1, 4.7, 1.5 Hz, 1 
H, 6-H), 3.69 (dd, J = 13.1, 3.3 Hz, 1 H, 6-H’), 2.77 (ddd, J = 17.2, 9.9, 7.1 Hz, 1 H, 3-H), 2.46 (dt, J 
= 17.2, 5.9 Hz, 1 H, 3-H’), 2.02-1.86 (m, 2 H, 4-H + 4-H’), 1.02 {s, 21 H, Si[CH(CH3)2]3 + 
Si[CH(CH3)2]3}. 
13C NMR (CDCl3, 100.4 MHz) δ (ppm): 170.8 (CO), 154.0 (NCO2Bn), 135.4 (Carom), 
128.5 (2 C, Carom), 128.2 (Carom), 128.0 (2 C, Carom), 68.4 (CH2Ph), 64.2 (C-5), 53.0 (C-6), 30.9 (C-
3), 29.0 (C-4), 17.9 {6 C, Si[CH(CH3)2]3}, 12.1 {3 C, Si[CH(CH3)2]3}. MS (ESI) m/z (%): 833 (100) 
[2M + Na]+, 406 (26) [M + 1]+. MS/MS (ESI of [M + 1]+) m/z (%): 362 (72), 272 (100), 228 (29). 
 
 
N OP(O)(OPh)2
Cbz
TIPSO
 
(3S)-Benzyl 6-[(diphenoxyphosphoryl)oxy]-3-(triisopropylsilanyloxy)-3,4-dihydropyridine-
1(2H)-carboxylate [(–)-44] 
Prepared as reported for 17, starting from 43 (1.75 g, 4.31 mmol). After flash chromatography 
(n-hexane/EtOAc, 8:1 with 1% Et3N; Rf 0.23), pure 44 (2.06 g, 75%) was obtained as a 
colourless oil, which was immediately used in the next step. 
[α]D
23 –2.6 (c 0.70, CDCl3). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 7.35-7.24 (m, 10 H, Ph), 7.20-
7.15 (m, 5 H, Ph), 5.10-5.02 (m, 3 H, CH2Ph + 5-H), 4.13-4.11 (m, 1 H, 3-H), 3.75 (dd, J = 12.5, 
6.4 Hz, 1 H, 2-H), 3.57 (dd, J = 12.5, 2.4 Hz, 1 H, 2-H’), 2.43 (dq, J = 18.1, 4.7 Hz, 1 H, 4-H), 2.14 
(dq, J = 18.1, 4.0 Hz, 1 H, 4-H’), 1.03 {s, 21 H, Si[CH(CH3)2]3 + Si[CH(CH3)2]3}. 
13C NMR (CDCl3, 
100.4 MHz) δ (ppm): 154.4 (NCO2Bn), 150.4 (2 C, Carom), 139.5 (C-6), 135.7 (Carom), 129.7 (4 C, 
Carom), 128.4 (2 C, Carom), 128.1 (2 C, Carom), 128.0 (Carom), 125.5 (2 C, Carom), 120.1 (4 C, Carom), 
98.6 (C-5), 67.9 (CH2Ph), 64.9 (C-3), 51.6 (C-2), 32.3 (C-4) 17.9 {6 C, Si[CH(CH3)2]3}, 12.1 {3 C, 
Si[CH(CH3)2]3}. MS (ESI) m/z (%): 1298 (100) [2M + Na]
+, 638 (8) [M + 1]+. 
 
 
N CO2Me
Cbz
TIPSO
 
(5S)-1-Benzyl 2-methyl 5-(triisopropylsilanyloxy)-5,6-dihydropyridine-1,2(4H)-dicarboxylate 
[(+)-45] 
Prepared as reported for 20, starting from 44 (1.95 g, 3.06 mmol). After flash chromatography 
(n-hexane/EtOAc, 9:1; Rf 0.17), pure 45 (1.02 g, 74%) was obtained as a thick colourless oil. 
[α]D
22 +16.8 (c 0.96, CHCl3). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 7.36-7.29 (m, 5 H, Ph), 6.04 (t, J 
= 3.7 Hz, 1 H, 3-H), 5.20-5.07 (m, 2 H, CH2Ph), 4.13 (bs, 1 H, 5-H), 3.78-3.71 (m, 1 H, 6-H), 3.55 
(bs, 4 H, 6-H’ + OCH3), 2.51 (ddd, J = 19.5, 5.5, 3.9 Hz, 1 H, 4-H), 2.19 (dt, J = 19.5, 4.5 Hz, 1 H, 4-
H’), 1.03 {s, 21 H, Si[CH(CH3)2]3 + Si[CH(CH3)2]3}. 
13C NMR (CDCl3, 100.4 MHz) δ (ppm): 164.7 
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(CO), 154.4 (NCO2Bn), 135.7 (Carom), 131.9 (C-2), 128.4 (2 C, Carom), 128.3 (2 C, Carom), 128.2 
(Carom), 121.5 (C-3), 68.0 (CH2Ph), 64.7 (C-5), 52.0 (C-6), 49.9 (OCH3), 33.6 (C-4), 17.9 {6 C, 
Si[CH(CH3)2]3}, 12.1 {3 C, Si[CH(CH3)2]3}. MS (ESI) m/z (%): 917 (100) [2M + Na]
+, 448 (67) [M + 
1]+. MS/MS (ESI of [M + 1]+) m/z (%): 404 (100). Elemental analysis calcd. (%) for C24H37NO5Si 
(447.64): C, 64.39; H, 8.33; N, 3.13. Found: C, 63.67; H, 8.95; N, 3.57. 
 
 
N CO2Me
TIPSO
Cbz  
N CO2Me
TIPSO
Cbz  
2-Benzyl 1-Methyl (1S,4S,6S)-4-(triisopropylsilanyloxy)-2-azabicyclo[4.1.0]heptane-1,2-
dicarboxylate [(+)-46] and 2-Benzyl 1-Methyl (1R,4S,6R)-4-(triisopropylsilanyloxy)-2-
azabicyclo[4.1.0]heptane-1,2-dicarboxylate [(+)-47] 
NaH (60% in weight in mineral oil, 97 mg, 2.42 mmol), previously washed with dry n-hexane (2 
× 5 mL), was suspended in dry DMSO (10 mL), under an N2 atmosphere. Trimethylsulfoxonium 
iodide (709 mg, 3.22 mmol) was added to the resulting suspension in three portions and the 
mixture was stirred at room temperature for 30 min, until complete disappearance of the 
precipitate. Then, a cooling bath at 15 °C was applied and a solution of 45 (722 mg, 1.61 mmol) 
in dry DMSO (5 mL) was added dropwise to the reaction mixture. The cooling bath was 
removed and the reaction mixture was stirred at room temperature for 45 min. Afterward, a 
cooling bath at 15 °C was applied again and water (100 mL) was added to the mixture, which 
was then extracted with Et2O (5 × 75 mL). The combined organic extracts were dried over 
Na2SO4, filtered and concentrated, affording a colourless oil containing a 1.4:1 mixture of trans 
(46) and cis (47) isomers. The two isomers were separated and purified by flash 
chromatography (n-hexane/EtOAc, 9:1, Rf 0.27 and Rf 0.15), to afford pure 46 (301 mg, 40%) 
and pure 47 (264 mg, 35%) both as thick colourless oils. 
46: [α]D
21 +11.4 (c 0.95, CHCl3). 
1H NMR (CDCl3, 400 MHz) (2.3:1 mixture of rotamers) δ (ppm): 
7.36-7.27 (m, 5 H, Ph, both rotamers), 5.28 (part A of an AB system, J = 12.6 Hz, 1 H, CH2Ph, 
major rotamer), 5.16 (AB system, J = 12.3 Hz, 2 H, CH2Ph, minor rotamer), 5.06 (part B of an AB 
system, J = 12.6 Hz, 1 H, CH2Ph, major rotamer), 3.95-3.84 (m, 2 H, 4-H major rotamer + 3-Heq 
both rotamers), 3.79-3.72 (m, 1 H, 4-H minor rotamer), 3.69 (s, 3 H, OCH3, minor rotamer), 
3.52 (s, 3 H, OCH3, major rotamer), 2.93-2.84 (m, 1 H, 3-Hax, both rotamers), 2.10-2.03 (m, 1 H, 
5-H, major rotamer), 2.01-1.79 (m, 4 H, 5-H minor rotamer + 5-H’ minor rotamer + 6-H both 
rotamers + 7-H both rotamers), 1.73-1.65 (m, 1 H, 5-H’, major rotamer), 1.03 {s, 21 H, 
Si[CH(CH3)2]3 + Si[CH(CH3)2]3, major rotamer}, 0.99 {s, 21 H, Si[CH(CH3)2]3 + Si[CH(CH3)2]3, minor 
rotamer}, 0.89-0.84 (m, 1 H, 7-H’, minor rotamer), 0.81 (dd, J = 7.4, 4.7 Hz, 1 H, 7-H’, major 
rotamer). 13C NMR (100.4 MHz, CDCl3) (major rotamer) δ (ppm): 172.9 (CO), 156.5 (NCO), 
136.7 (Carom), 128.4 (2 C, Carom), 127.8 (Carom), 127.6 (2 C, Carom), 67.1 (CH2Ph), 65.8 (C-4), 52.1 
(OCH3), 49.2 (C-3), 37.4 (C-1), 31.2, 24.1, 23.3, 17.9 {6 C, Si[CH(CH3)2]3}, 12.1 {3 C, 
Si[CH(CH3)2]3}. MS (ESI) m/z (%): 945 (14) [2M + Na]
+, 462 (100) [M + 1]+. MS/MS (ESI of [M + 
1]+) m/z (%): 429 (81), 418 (58), 295 (100), 287 (63). 
47: [α]D
22 +19.5 (c 1.74, CHCl3). 
1H NMR (400 MHz, CDCl3) (2.5:1 mixture of rotamers) δ (ppm): 
7.37-7.23 (m, 5 H, Ph), 5.27-5.22 (m, 1 H, CH2Ph, both rotamers), 5.05-5.00 (m, 1 H, CH2Ph, 
both rotamers), 4.11-4.03 (m, 2 H, 4-H both rotamers + 3-Heq major rotamer), 3.95 (dd, J = 
13.2, 3.9 Hz, 1 H, 3-Heq, minor rotamer), 3.69 (s, 3 H, OCH3, minor rotamer), 3.52 (s, 3 H, OCH3, 
major rotamer), 2.92 (dd, J = 13.2, 1.6 Hz, 1 H, 3-Hax, minor rotamer), 2.88-2.78 (m, 1 H, 3-Hax, 
major rotamer), 2.04-1.96 (m, 2 H, 5-H both rotamers + 5-H’ major rotamer), 1.92-1.88 (m, 2 
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H, 5-H’ minor rotamer + 7-H minor rotamer), 1.83 (dd, J = 9.9, 4.1 Hz, 1 H, 7-H, major rotamer), 
1.69-1.59 (m, 1 H, 6-H, both rotamers), 1.36 (dd, J = 8.0, 4.1 Hz, 1 H, 7-H’, both rotamers), 1.02 
{s, 21 H, Si[CH(CH3)2]3 + Si[CH(CH3)2]3, major rotamer}, 0.96 {s, 21 H, Si[CH(CH3)2]3 + 
Si[CH(CH3)2]3, minor rotamer}. 
13C NMR (100.4 MHz, CDCl3) (major rotamer) δ (ppm): 173.4 
(CO), 157.1 (NCO), 137.1 (Carom), 128.2 (2 C, Carom), 127.7 (Carom), 127.6 (2 C, Carom), 67.0 
(CH2Ph), 65.8 (C-4), 52.2 (OCH3), 47.2 (C-3), 38.3 (C-1), 29.3, 23.7, 22.8, 18.0 {6 C, 
Si[CH(CH3)2]3}, 12.1 {3 C, Si[CH(CH3)2]3}. MS (ESI) m/z (%): 945 (100) [2M + Na]
+, 462 (12) [M + 
1]+. Elemental analysis calcd. (%) for C25H39NO5Si (461.67): C, 65.04; H, 8.51; N, 3.03. Found: C, 
65.24; H, 8.27; N, 3.37. 
 
 
N
H
CO2Me
TIPSO
 
Methyl (1R,4S,6R)-4-triisopropylsilanyloxy-2-azabicyclo[4.1.0]heptane 1-carboxylate [(+)-48] 
Prepared as reported for 25, starting from 47 (53 mg, 0.11 mmol). After filtration and 
evaporation of the solvent, compound 48 (36 mg, 95%) was obtained as a colourless oil. 
[α]D
21 +42.8 (c 1.12, CHCl3). 
1H NMR (400 MHz, CDCl3) δ (ppm): 3.82 (d, J = 3.5 Hz, 1 H, 4-H), 
3.69 (s, 3 H, OCH3), 2.75 (ddd, J = 13.6, 3.5, 1.1 Hz, 1 H, 3-Heq), 2.54 (d, J = 13.6 Hz, 1 H, 3-Hax), 
2.08-1.98 (m, 2 H, 5-H + 5-H’), 1.92 (bs, 1 H, NH), 1.60-1.51 (m, 2 H, 6-H + 7-H), 1.34-1.28 (m, 1 
H, 7-H’), 1.01 {s, 21 H, Si[CH(CH3)2]3 + Si[CH(CH3)2]3}. 
13C NMR (100.4 MHz, CDCl3) δ (ppm): 
176.0 (CO), 64.4 (C-4), 52.3 (OCH3), 48.3 (C-3), 38.2 (C-1), 29.0, 26.6, 20.4, 18.0 {6 C, 
Si[CH(CH3)2]3}, 12.0 {3 C, Si[CH(CH3)2]3}. MS (ESI) m/z (%): 677 (61) [2M + Na]
+, 328 (100) [M + 
1]+. Elemental analysis calcd. (%) for C17H33NO3Si (327.53): C, 62.34; H, 10.16; N, 4.28. Found: 
C, 62.30; H, 9.86; N, 4.07. 
 
 
 
N CO2Me
TIPSO
Boc  
2-tert-Butyl 1-methyl (1R,4S,6R)-4-triisopropylsilanyloxy-2-azabicyclo[4.1.0]heptane-1,2-
dicarboxylate [(+)-49] 
Prepared as reported for 27, starting from 48 (36 mg, 0.11 mmol). After flash chromatography 
(n-hexane/EtOAc, 8:1; Rf 0.23), pure 49 (35 mg, 74%) was obtained as a colourless oil. 
[α]D
23 +17.5 (c 1.15, CHCl3). 
1H NMR (400 MHz, CDCl3) (2.5:1 mixture of rotamers) δ (ppm): 
4.10-4.06 (m, 1 H, 4-H, major rotamer), 4.04-3.98 (m, 2 H, 3-Heq major rotamer, 4-H minor 
rotamer), 3.87-3.80 (m, 1 H, 3-Heq, minor rotamer), 3.69 (s, 3 H, OCH3, major rotamer), 3.68 (s, 
3 H, OCH3, minor rotamer), 2.89 (dd, J = 13.3, 1.8 Hz, 1 H, 3-Hax, minor rotamer), 2.74 (dd, J = 
13.0, 1.5 Hz, 1 H, 3-Hax, major rotamer), 2.01-1.90 (m, 2 H, 5-H + 5-H’, both rotamers), 1.87 
(dd, J = 9.9, 4.4 Hz, 1 H, 7-H, minor rotamer), 1.77 (dd, J = 10.0, 4.2 Hz, 1 H, 7-H, major 
rotamer), 1.63-1.55 (m, 1 H, 6-H, both rotamers), 1.46 [s, 9 H, OC(CH3)3, minor rotamer], 1.41 
[s, 9 H, OC(CH3)3, major rotamer], 1.29 (dd, J = 7.9, 4.2 Hz, 1 H, 7-H’, both rotamers), 1.03 {s, 21 
H, Si[CH(CH3)2]3 + Si[CH(CH3)2]3}. 
13C NMR (100.4 MHz, CDCl3) (major rotamer) δ (ppm): 173.7 
(CO), 156.0 (NCO), 79.5 [OC(CH3)3], 66.0 (C-4), 52.0 (OCH3), 46.1 (C-3), 38.4 (C-1), 29.2, 28.3 [3 
C, OC(CH3)3], 23.4, 22.9, 18.0 {6 C, Si[CH(CH3)2]3}, 12.0 {3 C, Si[CH(CH3)2]3}. MS (ESI) m/z (%): 
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877 (74) [2M + Na]+, 450 (36) [M + Na]+, 328 (98). MS/MS (ESI of [M + Na]+) m/z (%): 395 (27], 
351 (100). 
 
 
N COOH
TIPSO
Cbz  
(1S,4S,6S)-4-triisopropylsilanyloxy-2-(benzyl)-2-azabicyclo[4.1.0]heptane-1-carboxylic acid 
[(+)-50] 
NaOH (2 mL of a 1 N solution in water, 2 mmol) was added to a solution of 46 (418 mg, 0.91 
mmol) in methanol (4 mL) and the resulting mixture was vigorously stirred for 24 h at 50 °C. 
Afterward, the methanol was evaporated, the remaining aqueous layer was acidified to pH 3 
by adding a 1 N solution of HCl. The resulting suspension was extracted with CH2Cl2 (4 x 30 mL) 
and the combined organic layers were dried over Na2SO4. After filtration and evaporation of 
the solvent, compound 50 (355 mg, 88%) was obtained as a thick pale yellow oil. 
[α]D
25 +10.9 (c 0.65, CHCl3). 
1H NMR (CDCl3, 400 MHz) (1.7:1 mixture of rotamers) δ (ppm): 
9.02 (bs, 1 H, COOH), 7.34-7.29 (m, 5 H, Ph, both rotamers), 5.22-5.03 (m, 2 H, CH2Ph, both 
rotamers), 3.98-3.89 (m, 1 H, 3-Heq, both rotamers), 3.87-3.82 (m, 1 H, 4-H, major rotamer), 
3.69-3.60 (m, 1 H, 4-H minor rotamer), 2.83 (dd, J = 12.6, 6.8 Hz, 1 H, 3-Hax, major rotamer), 
2.79-2.72 (m, 1 H, 3-Hax, minor rotamer), 2.07-1.97 (m, 1 H, 5-H, both rotamers), 1.94-1.87 (m, 
2 H, 6-H + 7-H, both rotamers), 1.84-1.78 (m, 1 H, 5-H’, both rotamers), 1.04 {s, 21 H, 
Si[CH(CH3)2]3 + Si[CH(CH3)2]3, major rotamer}, 0.98 {s, 21 H, Si[CH(CH3)2]3 + Si[CH(CH3)2]3, minor 
rotamer}, 0.85-0.78 (m, 1 H, 7-H’, both rotamers). 13C NMR (100.4 MHz, CDCl3) (major 
rotamer) δ (ppm): 178.0 (COOH), 156.4 (NCO), 136.7 (Carom), 128.4 (2 C, Carom), 128.0 (2 C, 
Carom), 127.4 (Carom), 67.2 (CH2Ph), 65.8 (C-4), 49.0 (C-3), 37.6 (C-1), 31.3, 24.9, 24.4, 17.9 {6 C, 
Si[CH(CH3)2]3}, 12.1 {3 C, Si[CH(CH3)2]3}. MS (ESI) m/z (%): 933 (23) [2M + K]
+, 448 (100) [M + 
1]+. 
 
 
N COOH
TIPSO
Fmoc  
(1S,4S,6S)-4-triisopropylsilanyloxy-2-(9-Fluorenylmethoxycarbonyl)-2-
azabicyclo[4.1.0]heptane-1-carboxylic acid [(+)-52] 
Pd/C (87 mg, 10%) was added to a solution of 50 (355 mg, 0.79 mmol) in ethyl acetate (25 mL), 
under an N2 atmosphere. The resulting suspension was stirred under a H2 atmosphere 
(balloon) at room temperature for 18 h. Afterward, methanol (50 mL) was added and the 
mixture was filtered over a celite layer to remove the catalyst. Subsequent evaporation of the 
solvent led to 51 (233 mg, 94%) as a pale yellow solid, which was employed for the next step 
without further purification. 
1H NMR (400 MHz, CD3OD) δ (ppm): 4.02-3.96 (m, 1 H, 4-H), 2.96-2.92 (m, 1 H, 3-H), 2.91-2.86 
(m, 1 H, 3-H’), 2.13-2.06 (m, 1 H, 5-H), 2.05-1.99 (m, 1 H, 5-H’), 1.84-1.74 (m, 1 H, 6-H), 1.56 
(dd, J = 10.0, 5.8 Hz, 1 H, 7-H), 1.10 {s, 21 H, Si[CH(CH3)2]3 + Si[CH(CH3)2]3}, 0.93 (dd, J = 7.5, 5.8 
Hz, 1 H, 7-H’). MS (ESI) m/z (%): 649 (100) [2M + Na]+, 336 (43) [M + Na]+, 314 (17) [M + 1]+. 
MS/MS (ESI of [M + 1]+) m/z (%): 140 (100). 
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Amino acid 51 was suspended in THF (1.7 mL) and a 10% solution of Na2CO3 in water (2 mL) 
was added to this suspension. The resulting mixture was cooled to 0 °C and a solution of Fmoc-
OSu (275 mg, 0.81 mmol) in THF (5 mL) was added. This reaction mixture was vigorously 
stirred at room temperature for 24 h. Afterward, the solvent was evaporated under vacuum, 
the resulting residue was taken up in EtOAc (12 mL) and a satd. solution of NH4Cl (12 mL) was 
added. The mixture was extracted with EtOAc (3 x 12 mL) and the combined organic layers 
were dried over Na2SO4. After filtration and evaporation of the solvent the crude was purified 
by flash chromatography (n-hexane/EtOAc, 4:1 + 0.5% CH3COOH; Rf 0.16) to afford compound 
52 (321 mg, 81%) as a white solid. 
M.p. 58.1-60.3 °C. [α]D
24 +1.2 (c 0.82, CHCl3). 
1H NMR (CDCl3, 400 MHz) (2:1 mixture of 
rotamers) δ (ppm): 9.11 (bs, 1 H, COOH), 7.73-7.64 (m, 2 H, Fmoc), 7.58-7.50 (m, 2 H, Fmoc), 
7.37-7.28 (m, 2 H, Fmoc), 7.27-7.20 (m, 2 H, Fmoc), 4.51-4.28 (m, 2 H, CH2 Fmoc), 4.20-4.08 
(m, 1 H, CH Fmoc), 3.90 (dd, J = 12.7, 4.2 Hz, 1 H, 3-Heq, major rotamer), 3.87-3.81 (m, 1 H, 3-
Heq, minor rotamer), 3.71-3.60 (m, 1 H, 4-H, both rotamers), 2.78-2.62 (m, 1 H, 3-Hax, both 
rotamers), 1.96-1.72 (m, 3 H, 5-H + 5-H’ + 6-H, both rotamers), 1.67-1.56 (m, 1 H, 7-H, both 
rotamers), 1.01 {s, 21 H, Si[CH(CH3)2]3 + Si[CH(CH3)2]3}, 0.63-0.51 (m, 1 H, 7-H’, both rotamers). 
13C NMR (100.4 MHz, CDCl3) (major rotamer) δ (ppm): 177.7 (COOH), 156.4 (NCO), 143.8 (2 C, 
Carom), 141.2 (2 C, Carom), 127.5 (2 C, Carom), 126.9 (2 C, Carom), 125.0 (2 C, Carom), 119.8 (2 C, 
Carom), 67.4 (CH2 Fmoc), 65.8 (C-4), 48.7 (C-3), 47.3 (CH Fmoc), 37.8 (C-1), 31.4, 29.7, 25.0, 17.9 
{6 C, Si[CH(CH3)2]3}, 12.1 {3 C, Si[CH(CH3)2]3}. MS (ESI) m/z (%): 1093 (100) [2M + Na]
+, 558 (9) 
[M + Na]+. 
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Chapter 5: Synthesis of 5-Substituted Cyclopropane Pipecolic Acids (5-R-
CPAs) 
 
5.1 General Synthetic Strategy towards 5-OH-CPAs 
As previously mentioned, our group already published in 2011 the synthesis of both cis and 
trans 5-OH-CPAs as new conformationally constrained homoserine analogues (see section 
2.3).1 These compounds were obtained by applying a diastereodivergent procedure (scheme 1) 
starting from achiral commercial δ-valerolactam (V).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1. Retrosynthetic analysis for 5-OH-CPAs. 
 
Enecarbamate esters IV were synthesised by means of the usual Pd-catalyzed 
methoxycarbonylation of the lactam-derived vinyl phosphates and then oxidized on the allylic 
position to get the racemic allylic alcohols III. Afterward, a highly enantioselective lipase-
catalysed kinetic resolution provided the two enantioenriched forms of III,2 which in turn were 
cyclopropanated to obtain the cis (I) or the trans (II) products, depending on the reaction 
conditions. Under the best conditions for OH-directed cyclopropanation, Charette’s Zn-
carbenoid (2,4,6-Cl3C6H2OZnCH2I)
3 provided cis-4-OH-CPAs (I) in the highest yield (73–86%) and 
with complete facial selectivity. The trans selectivity in Michael-type addition of 
dimethylsulfoxonium methylide4 on suitably OH-protected allylic alcohols was 1:4 to 1:7 in 
DMSO and diastereopure trans isomers (II) were obtained by chromatography after OH-
deprotection in 57–73% yield. 
Hence, starting from the aforementioned published synthetic strategy, in this work we wanted 
to enlarge the series of 5-substituted cyclopropane pipecolic acids (5-R-CPAs) by introducing 
one N-CO2tBu-protected 5-OH derivative as well as completely new 5-NH2-CPAs. 
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5.2 Synthesis of N-CO2tBu-Protected 5-OH-CPA 
The synthesis of both N-CO2Me- (8) and N-CO2Bn-protected (9) cis 5-OH-CPAs were already 
effectively accomplished in 2011 (scheme 2),1 since in the case of allylic alcohols also benzyl 
carbamate protection demonstrated to be perfectly compatible with the use of Zn-carbenoids 
in cyclopropanation step. 
In these procedures, both racemic allylic alcohols 4 and 5 were obtained by allylic oxidation of 
the correspondent enecarbamate esters 2 and 3 carried out with N-bromosuccinimide (NBS) in 
the presence of a catalytic amount of azobisisobutyronitrile (AIBN), followed by hydrolysis 
with ZnCl2 in wet acetone. Subsequently, enantioenriched (S)-4 and (S)-5 were isolated by 
exploiting kinetic resolutions realized through enantioselective enzyme-catalysed 
esterification of (R)-4 and (R)-5, carried out in the presence of PS “AMANO” IM lipase as a 
catalyst and vinyl butyrate as an acylating agent. Finally, (S)-4 and (S)-5 were efficiently 
cyclopropanated using Charette’s Zn-carbenoid (2,4,6-Cl3C6H2OZnCH2I), formed in situ from 
Et2Zn and CH2I2 in the presence of 2,4,6-trichlorophenol (TCP), affording both 8 and 9 with 
remarkable yields and total diastereoselectivity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2. Synthesis of cis-5-OH-CPAs. Reagents and conditions: a) NBS, AIBN, CCl4/CHCl3 9:1, 
reflux; b) ZnCl2, aq. acetone; c) vinyl butyrate, PS-“AMANO”-IM lipase, THF, 30 °C, 6 h; d) vinyl 
butyrate, PS-“AMANO”-IM lipase, TBME, 30 °C (two sequential kinetic resolutions); e) Et2Zn, 
CH2I2, TCP, CH2Cl2, –40 °C to 25 °C. 
 
Starting from these two nicely synthesised cyclopropanated products, we wanted to 
investigate the possibility to generate further new CPAs. 
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Considering that we already demonstrated how N-CO2tBu-protected CPAs are easily accessible 
from N-CO2Bn-protected correspondent (see chapter 4), we firstly tackled such synthesis, 
applying the same procedure already described for 4-OH-CPA (scheme 3). 
 
 
 
 
 
 
 
Scheme 3. Synthesis of N-CO2tBu-Protected 5-OH-CPA. Reagents and conditions: a) H2 (1 atm), 
10% Pd/C, EtOAc, RT, 4 h; b) Boc2O, Et3N, MeOH, reflux, 4 h. 
 
Accordingly, N-Boc protected amino acid 11 was prepared in 66% yield5 after hydrogenation of 
known N-Cbz derivative 9.1 
In such a way, we established once again our amino acids as suitable building blocks for 
peptide synthesis, since their amino groups can be easily protected with those which are 
considered the protecting groups of choice in solid-phase peptide synthesis (SPPS). 
 
5.3 Synthesis of 5-NH2-CPAs 
We planned the synthesis of 5-amino-CPAs with the same purpose we did for 4-amino-CPA, 
that was the construction of CPA-containing new integrin ligands. Consequently, even in this 
case we selected the best absolute configuration for our amino acids, according to preliminary 
molecular modelling studies (see Scope of the work). Specifically, we determined that we 
needed allylic alcohol (S)-4 as starting material to obtain the stereochemistry of choice in the 
final products. 
The synthesis of racemic alcohol 4 and its enzymatic kinetic resolution (EKR) were carried out 
as already described (scheme 2). Since the resolution provided just less than 50% of the 
requisite enantiopure stereoisomer (S)-4 from the racemic alcohol, butyrate (R)-6 was 
hydrolysed and subjected to Mitsunobu reaction to invert the C-4 configuration and thus 
increase the amount of the desired 4S enantiomer (scheme 4). This procedure was conducted 
treating (R)-4 with Ph3P and diisopropyl azodicarboxylate (DIAD) in the presence of acetic acid 
as an acylating agent and final product (S)-4 was obtained in good yield (75% over two steps) 
after hydrolysis of the acetate. 
 
 
 
 
 
 
 
 
Scheme 4. Inversion of C-4 configuration in allylic alcohol 4 by means of a Mitsunobu reaction. 
Reagents and conditions: a) MeONa, MeOH, 0 °C; b) Ph3P, DIAD, CH3COOH, THF, 0°C; c) 
MeONa, MeOH, 0 °C. 
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However, as this reaction was carried out on an allylic alcohol,6 prone to stable carbocation 
formation, racemization took place to a certain extent and it furnished alcohol (S)-4 with only 
36% ee. 
Even though enzymatic kinetic resolution and Mitsunobu could be potentially employed in an 
iterative way to convert all the R enantiomer to the S correspondent, the procedure would be 
certainly time- and resource-consuming, not to mention the partial loss of material in the 
process, due to the non-quantitative yields. 
Thus, for the synthesis of 5-amino-CPA and its peptidomimetic derivative we used just the (S)-
4 directly obtained from the EKR, that is with a 94% ee (97:3 er), relying on the fact that HPLC 
purification of the final peptidomimetic product would provide a diastereopure compound. 
(S)-4 was cyclopropanated as already reported (scheme 2) and, applying the same procedure 
already described for 5-R-CPAs (see section 4.2), 4-OH-CPA (8) was converted into azido 
derivative 14 (scheme 5),5 which displays the correct cis stereochemistry of the two groups on 
the ring as required for the construction of a cyclopeptide. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 5. Synthesis of 5-amino-CPAs. Reagent and conditions: a) MsCl, Et3N, CH2Cl2, –30 to 25 
°C, 1 h; b) NaN3, [15]crown-5, CH3CN, reflux, 6 h; c) H2 (1 atm), 10% Pd/C, MeOH, 
RT, 16 h. d) 1N NaOH, MeOH; e) H2, 10% Pd/C, MeOH; f) FmocOSu, Na2CO3 aq., THF, 25 °C, 
24h. 
 
Relative stereochemistry of 14 was assigned as a consequence of the bimolecular nucleophilic 
displacement, which afforded the product from known compound 81, whereas the preferred 
conformation was assigned, as usual, by the analysis of the coupling constants in the 1H NMR 
spectra and by nuclear Overhauser effect (NOE) studies (figure 1). The 5-H proton resonates at 
about δ=4 ppm as a broad multiplet owing to very low coupling constant values in accordance 
with an equatorial position. Moreover, an NOE effect between endo 7-H and axial 4-H further 
confirms the stereochemical assignment. 
 
 
 
 
 
 
Figure 1. NOE studies on key intermediate 14 
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From 14 we synthesised two different amino derivatives (15 and 18), according to the 
subsequent coupling strategy we desired to adopt. Product 15, readily accessible with 
quantitative yield by hydrogenation of 14, exhibits a free amino group, while the carboxylic 
function is still protected as methyl ester.5  Therefore, such compound can firstly form a 
peptide bond with its amino function. On the contrary, compound 18 is protected as N-Fmoc 
on the amino group and bears a free carboxylic function, which can be promptly coupled. To 
obtain this further derivative, suitable even for solid-phase peptide synthesis (SPPS), at first we 
carried out the hydrolysis of the methyl ester of 14 that, differently from what previously 
reported (see section 4.6), occurred at room temperature in 24 h leading to intermediate 16 
with good yield (93%). Afterward, the azido group was reduced to amine by the usual 
procedure, even if in this case the resulting free amino acid 17 resulted insoluble in the 
reaction media (methanol), probably due to the formation of the zwitterion, and precipitated 
as soon as formed, mixing with the solid catalyst. Therefore, at the end of the reaction, before 
filtering off Pd/C, addition of water was necessary to dissolve 17. In such a way we managed to 
isolate this product, even if the yield of the reaction (67%) was slightly lowered by probable 
partial material loss during the process. Finally, we carried out the N-Fmoc protection with N-
(9-fluorenylmethoxycarbonyloxy)succinimide (FmocOSu) in a mixture of aqueous Na2CO3 and 
THF, affording final product 18 with 81% yield.7 
In this way we could obtain an amount of suitable protected amino acids 15 and 18 sufficient 
to accomplish peptide synthesis; in particular, 200 mg of 18 were synthesised in a single run. 
Accordingly, as we report later (see chapter 6), both the compounds were used to tackle the 
construction of a new peptidomimetic integrin ligand. 
 
 
 
5.4 Experimental 
 
 
N CO2Me
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2-tert-Butyl 1-Methyl (1S,5S,6R)-5-Hydroxy-2-azabicyclo[4.1.0]heptane-1,2-dicarboxylate [(–
)-11] 
Triethylamine (25 μL, 0.18 mmol) and Boc2O (40 mg, 0.18 mmol) were added to a solution of 
10
1 (15 mg, 0.088 mmol) in anhydrous methanol (2 mL), under an N2 atmosphere, and the 
resulting reaction mixture was heated to reflux for 4 h. Afterward, water (3 mL) was added 
and the product was extracted with CH2Cl2 (5 x 2 mL). The combined organic extracts were 
washed with a 5% solution of KHSO4 (3 mL), a satd. solution of NaHCO3 (3 mL), water (3 mL) 
and brine (3 mL) and then dried over Na2SO4. After filtration and evaporation of the solvent, 
the residue was purified by flash chromatography (n-hexane/EtOAc, 1:2; Rf 0.38), affording 
pure 11 (16 mg, 66%) as a white solid. 
M. p. 124.5-125.7 °C. [α]D
23 –31.7 (c 0.70, CHCl3). 
1H NMR (400 MHz, CDCl3) (3:1 mixture of 
rotamers) δ (ppm): 4.37-4.31 (m, 1 H, 5-H, both rotamers), 3.98 (dt, J = 13.5, 3.7 Hz, 1 H, 3-Heq, 
major rotamer), 3.81 (dt, J = 10.9, 3.6 Hz, 1 H, 3-Heq, minor rotamer), 3.71 (s, 3 H, OCH3 major 
rotamer), 3.70 (s, 3 H, OCH3, minor rotamer), 2.77 (t, J = 10.9 Hz, 3-Hax, minor rotamer), 2.66 
(td, J = 13.5, 1.9 Hz, 3-Hax, major rotamer), 2.00-1.91 (m, 2 H, 4-H + 6-H, both rotamers), 1.85 
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(dd, J = 9.9, 5.0 Hz, 1 H, 7-H, both rotamers), 1.64 (bs, 1 H, OH, both rotamers), 1.47 [s, 9 H, 
OC(CH3)3, minor rotamer], 1.42 [s, 9 H, OC(CH3)3, major rotamer], 1.27-1.15 (m, 1 H, 4-H’, both 
rotamers), 1.07 (dd, J = 6.4, 4.6 Hz, 1 H, 7-H’, minor rotamer), 1.01 (dd, J = 7.6, 5.0 Hz, 1 H, 7-
H’, major rotamer). 13C NMR (100.4 MHz, CDCl3) (major rotamer) δ (ppm): 172.6 (CO), 155.3 
(NCO), 80.4 [OC(CH3)3], 64.7 (C-5), 52.5 (OCH3), 42.0, 40.3, 31.2, 29.3, 28.5 [3 C, OC(CH3)3], 
19.7. MS/MS (ESI of [M + 1]+) m/z (%): 272 (16) [M + 1]+, 240 (55), 198 (100). Elemental 
analysis calcd. (%) for C13H21NO5 (271.31): C, 57.55; H, 7.80; N, 5.16. Found: C, 57.18; H, 7.58; 
N, 4.90. 
 
 
N CO2Me
CO2Me
OH
 
Conversion of Dimethyl (R)-4-Hydroxy-5,6-dihydropyridine-1,2(4H)-dicarboxylate [(+)-4] into 
(S)-4-Hydroxy-5,6-dihydropyridine-1,2(4H)-dicarboxylate [(–)-4] by Mitsunobu Reaction 
A solution of (R)-42 (95% ee)(105 mg, 0.49 mmol) and Ph3P (195 mg, 0.74 mmol) in dry THF (3.5 
mL) was added to a solution of diisopropyl azodicarboxylate (DIAD) (146 µL, 0.74 mmol) and 
acetic acid (42 µL, 0.74 mmol) in dry THF (3.5 mL) cooled to 0 °C. The resulting mixture was 
stirred for 1.5 h at 0 °C, then the solvent was removed under vacuum. The residue was taken 
up in a n-hexane-Et2O 1:1 mixture (5 mL), which was then filtered and evaporated under 
vacuum. The residue was chromatographed (CH2Cl2/Et2O, 50:1; Rf 0.26) to afford 12 (in a 4:1 
ratio with a residual impurity of reduced DIAD) as a colourless oil. 
Acetate 12 was hydrolysed according to published procedure,2 to afford pure (S)-4 (79 mg, 
75% over two steps) exhibiting a 36% enantiomeric excess, determined by comparison of the 
observed optical rotation with the specific rotation of the enantiopure correspondent. 
Spectroscopic data as reported in the literature.2 
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Dimethyl (1S,5R,6S)-5-Azido-2-azabicyclo[4.1.0]heptane-1,2-dicarboxylate [(+)-14] 
MsCl (31 µL, 0.39 mmol) was added dropwise to a solution of 81 (70 mg, 0.31 mmol) and 
triethylamine (54 µL, 0.39 mmol) in anhydrous CH2Cl2 (3 mL) cooled to –30 °C. After 5 min the 
cooling bath was removed and the reaction mixture was left under stirring for 2 h at room 
temperature. Then a 0.5 N solution of HCl (150 µL) was added dropwise and after 10 min the 
mixture was extracted with CH2Cl2 (3 x 1 mL). The combined organic layers were washed with 
water (3 x 1 mL) and dried over Na2SO4. After filtration and evaporation of the solvent, the 
crude was purified by flash chromatography (pure Et2O, Rf 0.34) to afford compound 13 (72 
mg, 77%) as a white solid. 
1H NMR (400 MHz, CDCl3) (2:1 mixture of rotamers) δ (ppm): 5.34-5.28 (m, 1 H, 5-H, both 
rotamers), 4.11 (dt, J = 13.6, 3.5 Hz, 1 H, 3-Heq, major rotamer), 3.95 (dt, J = 13.3, 3.7 Hz, 1 H, 
3-Heq, minor rotamer), 3.74 (s, 3 H, OCH3, minor rotamer), 3.72 (s, 3 H, OCH3, major rotamer), 
3.71 (s, 3 H, OCH3, both rotamers), 3.07 (s, 3 H, SCH3, both rotamers), 2.86 (t, J = 13.3 Hz, 3-Hax, 
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minor rotamer), 2.77 (td, J = 13.6, 1.9 Hz, 3-Hax, major rotamer), 2.17-2.11 (m, 2 H, 4-H + 6-H, 
both rotamers), 2.07 (dd, J = 9.8, 5.5 Hz, 1 H, 7-H, minor rotamer), 2.01 (dd, J = 9.8, 5.5 Hz, 1 H, 
7-H, major rotamer), 1.54-1.44 (m, 1 H, 4-H’, both rotamers), 1.26-1.18 (m, 1 H, 7-H’, both 
rotamers). 
Mesylate 13 was dissolved in anhydrous acetonitrile (2 mL) and [15]crown-5 (10 μL, 0.05 
mmol) and NaN3 (22 mg, 0.34 mmol) were added to the resulting solution under an N2 
atmosphere. The mixture was heated to reflux for 6 h and then stirred at room temperature 
for 12 h. Afterward, the mixture was filtered through a silica/celite 1:1 pad and the filtrate 
concentrated under vacuum. The residue was purified by flash chromatography (n-
hexane/EtOAc, 3:1; Rf  0.21) affording pure 14 (57 mg, 95%) as a white solid. 
M. p. 72.1-75.4 °C. [α]D
19 +28.5 (c 1.02, CHCl3). 
1H NMR (400 MHz, CDCl3) (2:1 mixture of 
rotamers) δ (ppm): 4.00 (bs, 1 H, 5-H, both rotamers), 3.87 (dt, J = 13.2, 3.9 Hz, 1 H, 3-Heq, 
major rotamer), 3.75-3.65 (m, 7 H, 3-Heq minor rotamer + 2 x OCH3 both rotamers), 3.03 (td, J 
= 13.3, 1.9 Hz, 1 H, 3-Hax, minor rotamer), 2.94 (td, J = 13.2, 2.3 Hz, 1 H, 3-Hax, major rotamer), 
2.00 (dd, J = 10.2, 5.5 Hz, 1 H, 7-Hexo, minor rotamer), 1.93 (dd, J = 10.5, 5.5 Hz, 1 H, 7-Hexo, 
major rotamer), 1.83-1.72 (m, 2 H, 4-Heq + 6-H, both rotamers), 1.58-1.49 (m, 1 H, 4-Hax, both 
rotamers), 0.87-0.79 (m, 1 H, 7-Hendo, both rotamers). 
13C NMR (100.4 MHz, CDCl3) (major 
rotamer) δ (ppm): 171.9 (CO), 156.8 (NCO), 54.7 (C-5), 53.1 (OCH3), 52.7 (OCH3), 38.4, 36.7, 
27.9, 27.8, 21.0. MS/MS (ESI of [M + 1]+) m/z (%): 255 (5) [M + 1]+, 223 (100), 212 (16). 
Elemental analysis calcd. (%) for C10H14N4O4 (254.24): C, 47.24; H, 5.55; N, 22.04. Found: C, 
47.21; H, 5.31; N, 22.41. 
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Dimethyl (1S,5R,6S)-5-Amino-2-azabicyclo[4.1.0]heptane-1,2-dicarboxylate [(+)-15] 
Pd/C (10%, 7 mg) was added to a solution of 14 (57 mg, 0.22 mmol) in anhydrous methanol (4 
mL), under an N2 atmosphere. The resulting suspension was vigorously stirred under a H2 
atmosphere (balloon) at room temperature for 24 h. After filtration over a celite layer and 
evaporation of the solvent, pure 15 (51 mg, 100%) was obtained as a colourless oil. 
[α]D
23 +14.7 (c 0.88, CHCl3). 
1H NMR (400 MHz, CDCl3) (1.5:1 mixture of rotamers) δ (ppm): 
3.75-3.57 (m, 8 H, 5-H + 3-Heq + 2 x OCH3, both rotamers), 3.23-3.17 (m, 1 H, 3-Hax, minor 
rotamer), 3.16-3.10 (m, 1 H, 3-Hax, major rotamer), 1.91 (dd, J = 10.2, 5.5 Hz, 1 H, 7-Hexo, minor 
rotamer), 1.84 (dd, J = 10.0, 5.3 Hz, 1 H, 7-Hexo, major rotamer), 1.64-1.45 (m, 3 H, 4-Heq + 4-Hax 
+ 6-H, both rotamers), 1.33 (bs, 2 H, NH2), 0.82-0.76 (m, 1 H, 7-Hendo, both rotamers). 
13C NMR 
(100.4 MHz, CDCl3) (major rotamer) δ (ppm): 173.0 (CO), 157.2 (NCO), 53.0 (OCH3), 52.5 
(OCH3), 45.0 (C-5), 38.2, 37.7, 32.8, 31.2, 21.7. MS/MS (ESI of [M + 1]
+) m/z (%): 229 (2) [M + 
1]+, 212 (44), 197 (50), 154 (100). Elemental analysis calcd. (%) for C10H16N2O4 (228.25): C, 
52.62; H, 7.07; N, 12.27. Found: C, 52.75; H, 6.84; N, 12.25. 
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(1S,5R,6S)-5-Azido-2-(methoxycarbonyl)-2-azabicyclo[4.1.0]heptane-1-carboxylic acid  [(+)-
16] 
A 1 N solution of NaOH (1.23 mL) was added to a solution of 14 (208 mg, 0.82 mmol) in MeOH 
(2 mL) and the resulting mixture was vigorously stirred for 24 h at room temperature. 
Afterward, the methanol was evaporated and the remaining aqueous layer was washed with 
Et2O (5 mL). Then, the aqueous layer was acidified to pH 3, adding a 1 N solution of HCl, and 
the product was extracted with CHCl3 (5 x 5 mL). Finally, the aqueous layer was further 
acidified to pH 1 and the product was extracted again with CHCl3 (5 x 5 mL). The combined 
organic layers were dried over Na2SO4 and after filtration and evaporation of the solvent, 
compound 16 (183 mg, 93%) was obtained as a white solid. 
[α]D
21 +30.7  (c 0.98, CHCl3) (ee 94%). 
1H NMR (400 MHz, CDCl3) (1.5:1 mixture of rotamers) δ 
(ppm): 10.21 (bs, 1 H, COOH), 4.04-4.00 (m, 1 H, 5-H, both rotamers), 3.89 (dt, J = 11.3, 4.1 Hz, 
1 H, 3-Heq, major rotamer), 3.78-3.69 (m, 4 H, 3-Heq minor rotamer + OCH3 both rotamers), 
3.07 (t, J = 11.9 Hz, 1 H, 3-Hax, minor rotamer), 2.97 (t, J = 11.3 Hz, 1 H, 3-Hax, major rotamer), 
2.06-1.87 (m, 2 H, 6-H + 7-Hexo, both rotamers), 1.82-1.75 (m, 1 H, 4-H, both rotamers), 1.60-
1.52 (m, 1 H, 4-H’, both rotamers), 0.95-0.88 (m, 1 H, 7-Hendo, both rotamers). 
13C NMR (100.4 
MHz, CDCl3) (major rotamer) δ (ppm): 177.2 (CO), 156.9 (NCO), 54.7 (C-5), 53.2 (OCH3), 38.0, 
36.7, 28.6, 27.6, 21.5. MS (ESI) m/z (%): 239 (100) [M – 1]–. Elemental analysis calcd. (%) for 
C9H12N4O4 (240.22): C, 45.00; H, 5.04; N, 23.32. Found: C, 45.21; H, 4.87; N, 23.01. 
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(1S,5R,6S)-5-Amino-2-(methoxycarbonyl)-2-azabicyclo[4.1.0]heptane-1-carboxylic acid (17) 
10% Pd/C (24 mg) was added to a solution of 16 (183 mg, 0.76 mmol) in anhydrous MeOH (15 
mL), under an N2 atmosphere. The resulting suspension was stirred vigorously under a H2 
atmosphere (balloon) at room temperature. During the reaction, the resulting product 
precipitated, due to the formation of the zwitterion. After 24 h, H2O (100 mL) was added and 
the resulting mixture was filtered over a celite layer. After evaporation of the solvent, pure 17 
(123 mg, 67%) was obtained as a white solid, directly used in the next step without further 
purifications. 
1H NMR (400 MHz, D2O) (2:1 mixture of rotamers) δ (ppm): 3.79-3.72 (m, 1 H, 3-Heq, both 
rotamers), 3.71 (s, 3 H, OCH3, minor rotamer), 3.70 (s, 3 H, OCH3, major rotamer), 3.62-3.58 
(m, 1 H, 5-H, major rotamer), 3.57-3.54 (m, 1 H, 5-H, minor rotamer), 3.20-3.07 (m, 1 H, 3-Hax, 
both rotamers), 1.84-1.77 (m, 3 H, 4-H + 4-H’ + 7-H, both rotamers), 1.69-1.61 (m, 1 H, 6-H, 
both rotamers), 0.94-0.87 (m, 1 H, 7-H’, both rotamers). MS (ESI) m/z (%): 215 (67) [M + 1]+. 
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(1S,5R,6S)-5-(9-Fluorenylmethoxycarbonylamino)-2-(methoxycarbonyl)-2-
azabicyclo[4.1.0]heptane-1-carboxylic acid  [(–)-18] 
A 10% aqueous solution of Na2CO3 (1.6 mL) was added to a suspension of amino acid 17 (120 
mg, 0.56 mmol) in THF (1.3 mL). A solution of Fmoc-OSu (189 mg, 0.56 mmol) in THF (3.8 mL) 
was added to the resulting mixture, cooled to 0 °C, which was then vigorously stirred at room 
temperature for 24 h. Afterward, the solvent was evaporated under vacuum and the residue 
was taken up in EtOAc (6 mL). Then, a satd. solution of NH4Cl (6 mL) was added and the 
mixture was extracted with EtOAc (5 x 6 mL). The aqueous layer was acidified to pH 2, adding 
a 1 N solution of HCl, and extracted again with EtOAc (5 x 6 mL). The combined organic layers 
were dried over Na2SO4 and after filtration and evaporation of the solvent the crude was 
purified by flash chromatography (MeOH/CH2Cl2 1:20, then MeOH/CH2Cl2 1:10, Rf 0.38) to 
afford compound 18 (197 mg, 81%) as a white solid. 
M.p. 171-173 °C (dec). [α]D
22 –16.1  (c 1.60, CHCl3) (ee 94%). 
1H NMR (400 MHz, CD3OD) 
(mixture of rotamers) δ (ppm):  7.76 (d, J = 7.5 Hz, 2 H, Fmoc), 7.63-7.61 (m, 2 H, Fmoc), 7.36 
(t, J = 7.5 Hz, 2 H, Fmoc), 7.28 (t, J = 7.5 Hz, 2 H, Fmoc), 4.40-4.32 (m, 2 H, CH2 Fmoc), 4.16 (bs, 
1 H, CH Fmoc), 3.81 (bs, 1 H, 5-H), 3.75-3.60 (m, 4 H, 3-Heq + OCH3), 3.09-3.00 (m, 1 H, 3-Hax), 
1.79-1.76 (m, 1 H, 7-H), 1.66-1.56 (m, 3 H, 4-H + 4-H’ + 6-H), 0.78-0.70 (m, 1 H, 7-H’). 13C NMR 
(100.4 MHz, CD3OD) (major rotamer) δ (ppm): 159.3 (Cq), 158.8 (Cq), 158.1 (Cq), 145.3 (2 C, 
Cq,arom), 142.6 (2 C, Cq,arom), 128.7 (2 C, Carom), 128.1 (2 C, Carom), 126.1 (2 C, Carom), 121.0 (2 C, 
Carom), 67.4 (CH2 Fmoc), 53.3 (OCH3), 48.5 (CH Fmoc), 46.1 (C-5), 40.5 (C-4), 39.0 (C-3), 29.2 (C-
6), 29.0 (C-4), 21.0 (C-7). MS (ESI) m/z (%): 435 (100) [M – 1]–. Elemental analysis calcd. (%) for 
C24H24N2O6 (436.46): C, 66.04; H, 5.54; N, 6.42. Found: C, 66.23; H, 5.29; N, 6.09. 
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Chapter 6: Cyclic RGD-based New Integrin Ligands Containing CPAs as Central 
Scaffolds 
 
6.1 Design of New Integrin Ligands 
To assess the suitability of CPAs for building peptidomimetics, we decided to embed selected 
4-amino-CPA (1) and 5-amino-CPA (3) (figure 1) into RGD-containing cyclic peptides (2 and 4), 
which were then evaluated as possible new ligands for angiogenic integrins αvβ3 and α5β1 (see 
chapter 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Selected CPAs as scaffolds for new integrin ligands 
 
We were in fact interested in evaluating whether the different relative position (and spatial 
orientation) of the amino and carboxylic groups on which the RGD sequence is fixed would 
affect the potency of the peptidomimetic towards the integrins αvβ3 and α5β1. In this way we 
could determine whether the two templates (1 and 3) would provide an optimal platform for 
the synthesis of integrin ligands as potential therapeutics or for targeted delivery of drugs or 
diagnostics (see section 3.3 and Scope of the work). Accordingly, after synthesis and biological 
evaluation, we also performed an accurate study (NMR experiments and molecular modelling) 
concerning the structures of both peptide candidates 2 and 4, comparing their conformational 
behaviors and trying to rationalize their biological activities. 
 
6.2 Synthesis of Cyclo[RGD-4-NHCPA] 
The synthesis of 2 (scheme 1) was carried out in solution according to the procedure reported 
by Battistini et al. for the synthesis of aminoproline-containing integrin ligands (see Scope of 
the work and section 3.3).1 
Thus, after protection of the amino group as N-Fmoc (74% yield) by the usual procedure (see 
section 5.3), carboxylic acid 5 was coupled to home-made dipeptide H-Arg(Mtr)-Gly-OBn1 (Mtr: 
4-methoxy-2,3,6,-trimethylbenzenesulphonyl), by using 3-(diethoxyphosphoryloxy)-1,2,3-
benzotriazin-4(3H)-one (DEPBT) as the coupling reagent in THF at 35 °C, which provided, after 
four days, tripeptide 6 in 71% yield (chromatographic purification). In comparison to the 
corresponding step carried out for the synthesis of the aminoproline derivative,1 which was 
complete in 12 h, in our case the reaction required much longer reaction times, probably due 
to the remarkable steric hindrance experienced by the carboxylic group of our molecule. This 
behaviour was generally always observed in every peptide coupling performed on CPAs. 
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Scheme 1. Synthesis of RGD-based integrin ligand containing 4-NH2-CPA as central scaffold. 
Reagents and conditions: a) FmocOSu, Na2CO3 aq., THF, 18 h; b) DEPBT, DIPEA, H-Arg(Mtr)-Gly-
OBn, THF, 35 °C, 4 d; c) CH2Cl2/Et2NH 1:1, 3 h; d) DEPBT, DIPEA, Z-Asp(OtBu)-OH, THF, 35 °C, 4 
d; e) H2 (1 atm), 10% Pd/C, EtOH, 24 h; f) DEPBT, DIPEA, THF, 35 °C, 4 d;  g) TFA/TIS/H2O 
95:2.5:2.5, 18 h. 
 
Deprotection of the 5-amino group in 6 was carried out in a CH2Cl2/diethylamine 1:1 mixture 
and provided uneventfully compound 7 (94% yield), which was coupled to Z-Asp(OtBu)-OH as 
above to give tetrapeptide 8 in 59% yield after chromatography. Catalytic hydrogenation over 
10% Pd/C allowed concurrent deprotection of both chain terminals to give tetrapeptide 9 in 
88% yield. With the exposed amino and carboxylic functionalities in place, the construction of 
macrocycle 10 was first attempted by exposing a slightly high-diluted solution (3.5 mM) of 9 in 
DMF to the three-component system 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-
b]pyridinium 3-oxid hexafluorophosphate (HATU)/1-hydroxy-7-azabenzotriazole 
(HOAt)/collidine at room temperature as reported by Battistini et al.1 However, after 
chromatographic separation on silica gel, we were unable to recover any fraction that 
contained a product with the right mass-to-charge ratio (checked by ESI-MS). 
Therefore, we opted for an alternative setting of the cyclization procedure, resorting to the 
initial coupling conditions by working in THF and by making use of DEPBT as the coupling 
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reagent, since it had already proved effective on our substrates. Thus compound 9 was 
(incompletely) dissolved in THF (3.5 mM) and treated with DEPBT and N,N-
diisopropylethylamine (DIPEA), which caused the complete solubilisation of the starting 
material. After 4 days at 35 °C, TLC monitoring revealed the complete disappearance of the 
starting material and the formation of a new spot. After chromatography of the crude reaction 
mixture, a major product was obtained (55% yield), the mass spectrum of which revealed a 
molecular ion at m/z 793 [M+1]+ consistent with the cyclopeptide structure of 10; its 1H and 
13C NMR spectra resulted perfectly compatible as well. Eventually, exhaustive deprotection of 
all functionalities (except the N piperidine ring), which was carried out in a 95:2.5:2.5 
trifluoroacetic acid (TFA)/triisopropylsilane (TIS)/H2O mixture, provided after semipreparative 
HPLC purification (see appendix 1 for analytical HPLC of pure 2) cyclopeptide 2 (molecular ion 
at m/z 525 [M+1]+), which was fully characterized (see appendix 1 for full characterisation) and 
tested as a new potential integrin binder.2 
 
6.3 Synthesis of Cyclo[RGD-5-NHCPA] 
Initially, we tried a different synthetic approach for the construction of peptidomimetic 4 with 
the aim of shorten the procedure applied for the first ligand. Specifically, we attempted to 
couple first the amino group of the CPA to the aspartic acid, so that to avoid the N-Fmoc 
protection/deprotection steps, exploiting the fact that the carboxylic group of CPA comes out 
from our synthetic strategy already protected as methyl ester. 
Therefore, as previously reported (see chapter 5), we converted azido derivative 11 into 5-
amino CPA methyl ester 12 and tried to use directly this as starting material for assembling the 
target compound (scheme 2). 
 
 
 
 
 
 
 
 
Scheme 2. Reagents and conditions: a) Z-Asp(OtBu)OH, DEPBT, DIPEA, THF. 
 
However, whilst the coupling of the 5-amino group with Z-Asp(OtBu)OH was successful, the 
selective hydrolysis of the methyl ester (necessary to link the Arg-Gly dipeptide) was 
troublesome. Despite the two protections (methyl and t-butyl esters) are generally considered 
orthogonal, in this molecule this proved untrue and we never managed to obtain selectively 
the free carboxylic acid on CPA. This was probably due to the unusual excessive stability 
conferred to the methyl ester by the remarkable surrounding steric hindrance, as already 
observed on another occasion (see section 4.6). Usual procedure (1 N NaOH/MeOH at room 
temperature) surprisingly led to contemporary cleavage of both methyl and t-butyl ester, 
while attempts to use porcine liver esterase (PLE) in a selective enzymatic hydrolysis afforded 
only the unchanged starting compound 13. 
Thus, we resort to the first longer procedure, which had already proven effective for the 
construction of peptidomimetic 2, and we applied it also for the synthesis of 4 (scheme 3). 
 
 
N CO2Me
NH2
CO2Me
12
a
N CO2Me
HN
CO2Me
13 (84%)
O
NHCbz
CO2tBu
N CO2Me
N3
CO2Me
11
[chap. 5]
Results and Discussion: Chapter 6 
 
 
74 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3. Synthesis of RGD-based integrin ligand containing 5-NH2-CPA as central scaffold. 
Reagents and conditions: a) DEPBT, DIPEA, H-Arg(Mtr)-Gly-OBn, THF, 35 °C, 4 d; b) 
CH2Cl2/Et2NH 1:1, 25 °C, 4.5 h; c) DEPBT, DIPEA, Z-Asp(OtBu)-OH, THF, 35 °C, 4 d; d) H2 (1 atm), 
10% Pd/C, EtOH, 25 °C, 24 h; e) DEPBT, DIPEA,THF, 35 °C, 4 d; f) TFA/TIS/H2O (95:2.5:2.5), 25 
°C, 18 h. 
 
Accordingly, the suitably N-Fmoc-protected amino acid 14 was prepared from 11 as described 
in chapter 5 and used as the starting substrate. The following coupling and deprotection steps 
were conducted exactly the same way as we did for the correspondent 4-amino-CPA 
derivative. Compared to that, only the final ring closure proved troublesome as it provided, by 
1H NMR and HPLC analysis, besides compound 19, a complex mixture of other compounds 
which we were unable to identify but which likely contained the minor diastereoisomer 
deriving from ent-14 (as reported in chapter 5, our 5-NH2-CPA are obtained with 94% ee), the 
dimers of both 19 and its aforementioned minor diasteroisomer and probably other heavier 
oligomers. This result was unexpected, since even in this case we conducted the cyclization in 
a slightly high-diluted solution (3.5 mM), demonstrating how the different position and 
orientation of the amino group and the minor size of the macrocycle can make the ring closure 
more complicated and cause the formation of undesired side products. Anyway, at this stage 
of the study, we were not interested in optimizing the procedure, so we did not carry out any 
other experiment by using other coupling methodologies and we proceeded, instead, with the 
exhaustive deprotection of the mixture containing compound 19. As we hoped, we managed 
to obtain, by semipreparative HPLC, an almost pure fraction (see appendix 2 for analytical 
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HPLC of 4) of major cyclopeptide 4 (molecular ion at m/z 525 [M+1]+, see appendix 2) with 
12% yield over the last two steps that provided sufficient material for the biological tests and 
the NMR analysis (see appendix 2 for full characterization).3 
 
6.4 Biological Evaluation 
The candidate RGD compounds 2 and 4 were firstly tested for their binding affinity towards 
M21 human melanoma cells that expressed high levels of αvβ3 heterodimer and low levels of 
αvβ5 heterodimer as shown by flow cytometry analysis (see appendix 3). The test were carried 
out in agreement with similar cell-based screening methods by using the same αvβ3 expressing 
cell line M21 as reported in the literature, in which the reference RGD ligand c[RGDf(Me)V] 
(cilengitide) showed an IC50 value of 0.4 nM (see section 3.3).
4,5 Tests were performed in the 
presence of 2 mM MnCl2 to switch integrins of tumour cells into an activated form. We were 
pleased to find that both compounds 2 and 4, when used at concentrations that ranged from 3 
µM down to 0.3 nM, demonstrated the capacity to inhibit the binding of M21 melanoma cells 
to vitronectin as an RGD-containing substrate in the nanomolar range (IC50 = 34 ± 12 nM for 
compound 22 and IC50 = 2.4 ± 1.5 nM for compound 4
3, table 1, see appendix 3 for percentage 
of inhibition plots), with compound 4 resulting ten times more active than 2 and comparable 
to the most potent antagonists reported so far (see section 3.3). As will be discussed later, 
such evidence of CPA-containing peptides as good ligands for αvβ3 integrin suggests that the 
rigid structure of CPA induces a significant conformational asset towards optimal presentation 
of the pharmacophoric groups of the ligands. 
 
Table 1. 
Entry Compound IC50 (nM) 
  αvβ3 a α5β1 b 
1 2 34 ± 12c 15 ± 10 c 
2 4 2.4 ± 1.5 c 26 ± 16 c 
a Test carried out on M21 human melanoma cells expressing high levels of αvβ3 heterodimer. The percentage of 
inhibition of the integrin-mediated M21 cell adhesion to vitronectin was measured. 
b Test carried out on human erythroleukemia cell line K562 expressing high levels of α5β1  heterodimer. The 
percentage of inhibition of the integrin-mediated K562 cell adhesion to fibronectin was measured. 
c The error was propagated from the original logarithmic value by applying the formula ∆x = x·ln(10)·∆[log(x)]. 
 
Both peptidomimetics were also screened for their capacity to compete with fibronectin for 
the binding to α5β1 integrin expressed by human erythroleukemia cell line K562 (see appendix 
4 for flow cytometry analysis). Interestingly, when both compounds were tested as α5β1 
integrin ligands, for 5-amino-CPA derivative 4 we measured an IC50 value of 26 ± 16 nM close 
to the IC50 value  obtained for the 2 isomer (IC50 = 15 ± 10 nM) (table 1, see appendix 4 for 
percentage of inhibition plots).3 
Since the activity of both compounds was in the nanomolar range towards both  integrins, 2 
and 4 can be considered as dual ligands, which could be an advantage in these compounds to 
find applications in cancer therapy. These results are encouraging in further employing these 
CPA templates for the synthesis of new integrin binders and, by exploiting the scaffold N atom 
as an anchoring point, for targeted delivery of drugs and diagnostics. 
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6.5 Conformational Analysis 
Cyclopeptides 2 and 4 were subjected to conformational analysis to assess the structural 
determinants that lead to binding activity towards αvβ3 and α5β1. 
Diluted solutions of 2 and 4 in DMSO-d6 were used for the NMR spectroscopic analysis to 
prevent aggregation. Total correlation spectroscopy (TOCSY), rotating-frame Overhauser effect 
spectroscopy (ROESY), and variable-temperature 1H NMR spectroscopic experiments were 
carried out for the NMR spectroscopic analysis. 
Furthermore, molecular modelling calculations were carried out to get more insight into the 
conformational preferences of peptides 2 and 4. 
 
Analysis of Cyclo[RGD-4-NHCPA] (2) 
1H NMR spectroscopic data of 2 showed two sets of signals in a 2:1 ratio as a consequence of 
the existence of rotamers around the N-CO2Me bond. The major rotamer showed chemical 
shift values between δ=7.6 and 8.1 ppm (table 2) for the amide protons. 
Variable-temperature 1H NMR experiments indicated low ∆δ/∆T coefficients (table 2) for Gly 
and Asp amide protons, which suggested the existence of intramolecular hydrogen bonds, 
whereas relatively high chemical shift and ∆δ/∆T values suggested that CPA and Arg amide 
protons were interacting with the solvent with equilibrating intermolecular hydrogen bonds. 
 
Table 2. Chemical shifts and temperature-dependent 1H NMR spectroscopic 
data for amide protons of peptide 2.a 
NH δ ∆δ/∆T 
CPA 7.91 – 4.8 
Arg 8.11 – 4.2 
Gly 7.39 – 0.5 
Asp 7.61 – 2.8 
a 1H NMR spectra for determining temperature coefficients were obtained at 298–323 K with increments of 5 K. 
Chemical shift (δ) values are obtained at 298 K and are in ppm. ∆δ/∆T coefficients were retrieved from linear 
regression analysis and are expressed in ppbK-1. 
 
ROESY analysis of 2 showed sequential ROESY peaks between Asp NH and Gly H-α, between 
Gly NH and Arg H-α, and between CPA NH and Asp H-α, which allowed us to propose the 
preferred conformation of 2 in solution, as shown in figure 2. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Selected ROESY peaks (left), and global minimum conformer (right) for 2 
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Moreover, ROESY peaks between Asp and Gly amide protons suggested that these atoms were 
oriented inside the cyclopeptide and in agreement with a hydrogen-bonded structure (figure 
2). Although temperature coefficient values suggested such hydrogen-bonded states to be in 
equilibrium with non-hydrogen-bonded states, the existence of a doubly hydrogen-bonded 
structure, and specifically of a conformation that displayed a γ-turn structure further stabilized 
by an equilibrating β-turn, suggested CPA nucleating a compact structure, ultimately resulting 
in a rigid conformation. As further proof, in the 1H NMR spectrum of 2 in D2O, the Gly CH2 
protons resonate as two highly separate doublets, one at δ=4.18 ppm and the other at δ=3.41 
ppm, as similarly reported for the corresponding protons in potent aminoproline-containing 
integrin antagonist (see section 3.3),1 in accordance with a rigid conformation for 2. 
 
Afterward, the conformational preferences of compound 2 were investigated by molecular 
mechanics calculations within the framework of Macromodel v6.56 by using Amber*7 as a force 
field and the implicit water GB/SA solvation model of Still et al.8 Monte Carlo energy 
minimization (MCEM)9 conformational searches of the peptide analogues that contained 
methyl groups instead of the Arg and Asp side chains were performed as the first step and 
using conformational constraints according to ROESY data. 
The global minimum conformer for compound 2 was in agreement with NMR spectroscopic 
data, which indicated the role of Gly and Asp amide protons in establishing intramolecular 
hydrogen bonds (figure 2). Specifically, Gly NH took part in a hydrogen bond with CPA C=O and 
likewise for Asp NH, although with minor strength, thus generating an inverse γ-turn (Gly NH), 
further stabilized with an equilibrating β-turn (Asp NH), within the cyclopeptide. 
The results from the conformational analysis were consistent with the IC50 value, which 
suggested a close connection between conformation and ligand-binding affinity, as the role of 
CPA in nucleating the correct conformation was due to the existence of the rigid cis 
stereochemistry of the amino and carboxylic groups, which allowed it to maintain the required 
torsional angles between Asp and Arg for a good binding to the integrin. Nevertheless, the 
calculation of the distance between the C-β atoms of Asp and Arg in the global minimum 
conformer of 2 resulted in a value of 7.2 Å, which is shorter than the optimal value of around 
8.9 Å.10 This could be a possible factor responsible for the lower αvβ3 binding activity of 2 
relative to the reference c[RGDf(Me)V] ligand (cilengitide) (see section 3.3).4,5,10 
 
Finally, a docking simulation was carried out using compound 2 with the aim of gaining further 
insight into the possible binding modes of the cyclopeptide to the αvβ3 receptor at the 
molecular level (figure 3). The crystal structure of the complex formed by c[RGDf(Me)V] and 
the extracellular fragment of the αvβ3 receptor (PDB code: 1L5G) provides a general mode of 
interaction between the integrin and its ligands.10 Specifically, as already illustrated (see 
section 3.3), Asp carboxylate and Arg guanidinium moiety of RGD-based ligands are the two 
key structural elements in the receptor recognition. In fact, the carboxylate group interacts 
with the metal-ion-dependent adhesion site (MIDAS) that consists of divalent metal ions and 
Ser121/Ser123, whereas the Arg guanidinium group is responsible for salt bridge interactions 
with the side chains of Asp218 and Asp150. 
According to similar docking calculations reported in the literature for RGD ligands,11 the 
docking program Autodock 4.0.112 was used to evaluate the binding energies of selected 
conformations of 2 as potential ligands for the αvβ3 receptor, and the docked conformations 
were analysed by taking into account the binding interactions observed in the crystal structure 
of the bound ligand–protein complex. 
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Figure 3. RGD ligand 2 (gray) docked into the binding region of αvβ3 integrin highlighting the 
protein residues (magenta) that form the key interactions: Asp218/Asp150 versus Arg, and 
Mn2+ versus Asp. The reference ligand c[RGDf(Me)V] (coordinated from PDB: 1L5G) is shown in 
red. Non polar hydrogen atoms are omitted for clarity 
 
The docking results for ligand 2 revealed the key interactions with Asp218 and the MIDAS site 
of the receptor, which suggests that all these interactions are necessary for the molecular 
recognition of the Arg-Gly-Asp-containing ligands. Specifically, the global minimum conformer 
of peptide 2 displayed a low-energy cluster that showed the canonical binding mode that 
consisted of bidentate Asp218/Arg and MIDAS/Ser121/Asp interactions (figure 3).2 
 
Analysis of Cyclo[RGD-5-NHCPA] (4) 
1H NMR data of diluted DMSO-d6 solution of 4 showed two sets of signals in a 5:1 ratio, as a 
consequence of the existence of rotamers around the N-CO2Me bond. The major rotamer 
showed amide proton chemical shift values between 7.2 and 8.9 ppm, with Asp amide proton 
being the more deshielded, thus suggesting its hydrogen-bonded status (table 3). 
 
Table 3. Chemical shifts and temperature-dependent 1H NMR spectroscopic 
data for amide protons of peptide 4.a 
NH δ ∆δ/∆T 
CPA 7.78 – 2.9 
Arg 7.51 – 2.6 
Gly 7.22 – 1.3 
Asp 8.90 – 3.4 
a 1H NMR spectra for determining temperature coefficients were obtained at 293–328 K with increments of 5 K or 10 
K. Chemical shift (δ) values are obtained at 298 K and are in ppm. ∆δ/∆T coefficients were retrieved from linear 
regression analysis and are expressed in ppbK-1. 
 
Variable-temperature 1H NMR experiments (figure 4) indicated low ∆δ/∆T coefficients for all 
amide protons (table 3), suggesting the existence of intramolecular hydrogen-bonds. 
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Figure 4. Temperature-dependent 1H chemical shifts for amide protons of 4; : CPA NH; : 
Arg NH; : Asp, NH; : Gly, NH. 
 
In contrast to 2, Asp and Arg amide protons in 4 showed an inverted profile in terms of 
chemical shift and temperature coefficients, as Asp NH possessed a more deshielded chemical 
shift value and higher ∆δ/∆T coefficient, possibly resulting from equilibrating hydrogen 
bonding species. Gly NH showed the lowest ∆δ/∆T coefficient, indicating the involvement in 
strong intramolecular hydrogen bonds. Such data suggest a different intramolecular hydrogen 
bonding network within the two cyclic peptides 2 and 4, contributing to a diverse arrangement 
of the cyclic frameworks induced by the two isomeric CPAs (figure 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. ROESY selected peaks and global minimum conformer for 2 (left) and 4 (right). 
 
Molecular modelling analysis resulted in a global minimum conformer for compound 4 which 
indicates the role of Gly, CPA and Asp amide protons in establishing equilibrating 
intramolecular hydrogen-bonds (figure 5, right). Specifically, Gly NH experiences a hydrogen-
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bond with CPA C=O, Asp NH with Arg C=O, and CPA NH with Gly C=O, although with variable 
strength, thus generating two γ-turns within the cyclopeptide. This is in contrast to the 
conformational asset of 2, which displayed a similarly Arg-centered γ-turn although stabilized 
by a β-turn having a hydrogen bond experienced by Asp NH with CPA C=O (figure 5, left).  
ROESY analysis of 4 showed a ROESY peak between CPA NH and CPA 3-Hax, and sequential 
ROESY peaks between Asp NH and Gly H-α, between CPA NH and Asp H-α, and between Gly 
NH and Arg H-α, consistent with the preferred conformation of 4 found by the modelling 
(figure 5, right), and in which the CPA NH points “inwards” below the scaffold’s six-membered 
ring. Thus, ROESY peaks together with the variable temperature experiments suggest a 
conformation of the cyclopeptide characterized by the presentation of Asp and Arg side chains 
as showed in Figure 5, right. Although temperature coefficient values indicate that the 
hydrogen-bonded states could be in equilibrium with non hydrogen-bonded states, the 
existence of a conformation displaying γ-turns suggests CPA nucleating a compact structure in 
all equilibrating conformations.3 
 
6.6 Structure-Activity Relationship 
The results of the conformational analysis and the IC50 values for 2 and 4 suggest a close 
connection between conformational preferences and ligand binding affinity. Specifically, 
higher ligand binding affinity of 4 for αvβ3 resulted from equilibrium between correct 
conformations for the RGD recognition site of the integrin, whereas 2 showed more rigid 
structure though not as optimal as the isomeric 4, producing lower affinity towards αvβ3. Such 
differences in binding affinity was not evinced for α5β1 integrin, suggesting that this integrin 
best accommodates both RGD peptidomimetics in its recognition site. In all cases, the role of 
CPA in nucleating the correct conformation is due to the existence of the rigid cis orientation 
of amino and carboxylic groups, which allows maintaining the required torsional angles 
between Asp and Arg for an optimal binding to the integrin. 
 
Based on NMR and conformational studies on integrin ligands, some prerequisites for a robust 
binding have been established amongst which the distance between Arg and Asp beta carbons 
(see section 3.3). In potent αvβ3 integrin antagonist cilengitide c(RGDf[NMe]V), for instance, 
this distance has an optimal value of 8.9 Å10 as measured in the X-ray crystal structure of the 
complex with the αvβ310,13 and which leads to an extended conformation of the RGD motif and 
a stretched arrangement of the charged side chains. 
Based on our modelling, the measured distance between the two beta C atoms in 4 is 7.9 Å,3 
that is longer than that calculated for 2 (7.1 Å)2 and closer to the optimal value, which could 
account for, or contribute to, the higher activity of 4. Additionally, the potency of both 2 and 4 
towards α5β1 integrin is justified by the fact that the binding mode is the same as in αVβ3 and 
that the requisite distance between the beta C atoms for an optimal binding with α5β1 is in the 
same range.14-18 
 
It is worth to notice that αVβ3 vs. α5β1 selectivity is observed in many RGD-containing cyclic 
peptides and peptidomimetics. For example cyclo-(-Arg-Gly-Asp-D-Phe-Val-),19 bicyclic lactam-
containing ligand ST1646,20 and cyclo-(-Arg-Gly-Asp-(+)-β-Acc-Val-)21 (see section 3.3) are all 
αVβ3 selective antagonists, and the same Cilengitide cyclo-[-Arg-Gly-Asp-D-Phe-(N-Me)Val-] 
shows sub-nanomolar (0.65 nM) antagonistic activity for the αVβ3 receptor and nanomolar 
(13.2 nM) affinity  for α5β1. Extra N-methylation of Cilengitide further increases the αVβ3/α5β1 
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selectivity by 2-3 orders of magnitudes.22 In all these cases the selectivity has been shown to 
depend on the overall conformation of the cyclopeptide. 
Our compounds are instead not selective, as they display a nanomolar potency toward both 
integrins. 
For cyclopeptides like cyclo-(-Arg-Gly-Asp-(+)-β-Acc-Val-) incorporating a β-aminocyclopropane 
amino acid, αVβ3 selectivity has been explained on the basis of a less stretched conformation 
of the RGD sequence as suggested by a shorter distance between the C-α atoms of Arg and 
Asp (from 5.25 to 6.50 Å). In the non-selective isomer cyclo-(-Arg-Gly-Asp-(–)-β-Acc-Val-), this 
distance is 6.00-7.00 Å corresponding to a more stretched conformation for the RGD 
sequence.21 On the other hand, for 2 and 4 the distances between the C-α atoms of Arg and 
Asp are 6.01 and 6.07 Å which are at the borderline of the two ranges above mentioned and 
therefore the lack of selectivity cannot be correlated with such a parameter. 
 
6.7 Experimental 
 
Chemistry 
Chromatographic separations were performed under pressure on silica gel 60 (Merck, 70-230 
mesh) using flash column techniques; Rf values refer to TLC carried out on 0.25 mm silica gel 
plates with the same eluent indicated for column chromatography. 1H NMR (500, 400 and 200 
MHz) and 13C NMR (50.33 and 100.4 MHz) spectra were recorded on Bruker Avance II 500 MHz 
Ultrashield,  and Varian Inova and Mercury spectrometers in CDCl3 at 25 °C unless otherwise 
stated. Mass spectra were carried out by direct inlet on a LCQ FleetTM Ion Trap LC/MS system 
(Thermo Fisher Scientific) with an ESI interface in the positive mode. Ligand 2 and 4 was 
purified by Beckman-Gold HPLC system equipped with a reverse-phase semi-preparative 
column (Alltima C18 10 μm, 250 mm × 10 mm, Alltech). Analytical HPLC analyses were 
performed on Dionex Ulltimate 3000 system equipped with a reverse-phase column (Acclaim 
120, C18, 5 μm , 4.6-250 mm). Anhydrous solvents were either commercial or prepared 
according to standard techniques. 
 
Biological Assays 
Cell Lines and Culture Conditions: The M21 human melanoma cell line (for αvβ3 binding 
assays) was obtained from the American Type Culture Collection (ATCC, Rockville, MD). 
Melanoma cells were grown in Dulbecco’s modified Eagle medium, containing 4500 mg/L 
glucose (DMEM 4500, GIBCO) supplemented with 10% foetal calf serum (FCS) at 37 °C in a 
humidified incubator containing 10% CO2. 5.0x10
5 melanoma cells were seeded in 100 mm 
Sarstedt dishes and propagated every 3 days by incubation with a trypsin−EDTA soluhon. The 
human erythroleukemia cell line K562 (for α5β1 binding assays) was maintained in Iscove's 
Modified Dulbecco's Medium (IMDM, GIBCO) supplemented with 10% FCS in T25 culture flasks 
(Sarstedt) in humidified incubator at 37°C, 5% CO2. When cultures reached a cell density 
between 1x105 and 1x106 cells/ml cells were re-suspended in warm fresh media at a volume to 
yield a density of 2x105 cells/ml. Both M21 and K562 cultures were periodically monitored for 
mycoplasma contamination. 
Citofluorimetric Assays: M21 cells were detached by gentle treatment with Accutase (Lonza), 
a 0.5 mM EDTA solution. K562 cells were removed from culture flasks and re-suspended in 
fresh medium. Cells were then washed, and incubated for 1 h at 4°C in the presence of anti-
αvβ3 monoclonal antibody (1 μg/50 μL, anti-integrin αvβ3, clone LM609, Millipore), anti-αvβ5 
monoclonal antibody (1 μg/50 μL, anti-integrin αvβ5, Santa Cruz 13588) and anti-α5β1 
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monoclonal antibody (1 μg/50 μL, anti-integrin α5β1, Abcam ab75472) . Cells were then 
washed and incubated for 1 h at 4 °C with a specific secondary antibody, 5 μg/mL goat anti-
mouse IgG conjugated with FITC (Santa Cruz Biotecnology, Inc., Santa Cruz, CA). Integrin-
Positive cells were analysed at 488 nm on the flow cytometer FACScan system (BD-FACS 
Canto). 
Cell Adhesion Assay: Plates (96 wells) were coated with vitronectin (for αvβ3 binding assays, 
10 μg/mL) or fibronectin (for α5β1 binding assays, 10 μg/mL)  (both from Sigma) by overnight 
incubation at 4 °C. Plates were washed with PBS and then incubated at 37 °C for 1 h with 
PBS−1% BSA. Ajer being washed cells were counted and re-suspended in serum free medium, 
and exposed to compound (final concentration was 10 nM, 0.1, 1, or 10 μM) at 37 °C for 30 
min to allow the ligand-receptor equilibrium to be reached. Assays were performed in the 
presence of 2 mmol/L MnCl2. Cells were then plated (4−5x10
4 cells/well) and incubated at 37 
°C for 1 h. All the wells were washed with PBS to remove the non-adherent cells, and 0.5% 
crystal violet solution in 20% methanol was added. After 2 h of incubation at 4 °C, plates were 
examined at 540 nm in a counter ELX800 (Bio TEK Instruments). Experiments were conducted 
in triplicate and were repeated at least three times. The values are expressed as % inhibition ± 
SEM of cell adhesion relative to untreated cells. 
Data Analysis: The IC50 values were determined by fitting binding inhibition data by non-linear 
regression using GraphPad Prism 4.0 Software Package (GraphPad Prism, San Diego, CA). 
 
NMR Methods 
NMR experiments on diluted DMSO-d6 solutions of 2 and 4 were performed at a temperature 
of 298 K on a Varian Mercury 400 MHz NMR spectrometer and on a Bruker Avance II 500 MHz 
Ultrashield. All proton chemical shifts were assigned unambiguously for 2 and 4. Variable 
temperature 1D, and 2D experiments (TOCSY, gCOSY, ROESY) were carried out at the sample 
concentration of 3 mM for 2 and 4. One-dimensional 1H NMR spectra for determining 
temperature coefficients were obtained at 298-323 K with increments of 5 K for 2 and at 293–
328 K with increments of 5 K or 10 K for 4. Sample temperatures were controlled with the 
variable-temperature unit of the instrument. Proton signals were assigned via TOCSY spectra, 
and ROESY spectra provided the data discussed in the conformational analysis. TOCSY spectra 
were recorded with 2048 points in t1, 200 points or 256 points in t2, and 16 scans per t2 
increment and using a mixing time of 80 ms. ROESY spectra were recorded with a similar 
number of t1 and t2 points unless otherwise noted, and 64 scans per t2 increment, and using a 
spinlock of 0.5 s or 0.2 s. 
 
Molecular Modelling 
Molecular modelling calculations were carried out within the framework of Macromodel v6.5,6 
using Amber*7 as a force field and the implicit water GB/SA solvation model of Still et al.8 
Monte Carlo energy minimization (MCEM)9 conformational searches of the peptide analogue 
containing methyl groups instead of the Arg and Asp side chains were performed as the first 
step. The torsional space of each AGA cyclopeptide was randomly varied with the usage-
directed Monte Carlo conformational search. Ring-closure bonds were defined in the CPA ring 
and in the cyclopeptide ring. Amide bonds were included among the rotatable bonds. For each 
search, at least 1000 starting structures for each variable torsion angle were generated and 
minimized until the gradient was less than 0.05 kJ/Åmol using the truncated Newton-Raphson 
method implemented in Macromodel. Duplicate conformations and those with an energy 
greater than 6 kcal/mol above the global minimum were discarded. 
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Docking Calculations 
Automated docking studies were carried out by the Autodock 4.0.1 program12 by using the 
Lamarckian genetic algorithm (LGA) as a search engine. The AutoDockTools 1.4.5 (ADT) 
graphical interface23 was used to prepare the receptor and the ligands PDBQT files. The 
coordinates of the ligand 2 were retrieved from the lowest energy conformers that resulted 
from calculation using NMR spectroscopic data, whereas the coordinates of αvβ3 receptor was 
retrieved from the Protein Data Bank (PDB code: 1L5G), and the ligand–protein complex was 
unmerged for achieving free receptor structure. Water molecules were removed. For the 
protein receptor and ligand 2, all hydrogen atoms were added, Gasteiger charges were 
computed, and non-polar hydrogen atoms were merged. A charge value of +2.0 to each Mn 
atom of the protein receptor was successively added. Three-dimensional energy scoring grids 
of 0.375 Å resolution and 40 Å x 40 Å x 40 Å dimensions were computed. The centre of the grid 
was set to be coincident with the mass centre of the ligands preliminary fitted on the X-ray 
structure of c[RGDf(Me)V] in the αvβ3 complex (1L5G). A total of 50 runs with a maximum of 2 
500000 energy evaluations were carried out for each ligand, using the default parameters for 
LGA. Cluster analysis was performed on the docked results using a root-meansquare (rms) 
tolerance of 1.5 Å. The analysis of the binding mode, the calculation of the binding energy and 
the prediction of the binding activity of the docked conformations were carried out using 
PyMol Autodock Tools plugin within PyMol software.24 
 
 
N CO2H
FmocHN
CO2Me  
(1R,4R,6S)-4-(9-Fluorenylmethoxycarbonylamino)-2-(methoxycarbonyl)-2-
azabicyclo[4.1.0]heptane-1-carboxylic acid [(–)-5] 
A 10% solution of Na2CO3 (2.5 mL) was added to a suspension of amino acid 1
[chap. 4]
 in THF (2 
mL). The resulting mixture was cooled to 0 °C and a solution of Fmoc-OSu (297 mg, 0.88 mmol) 
in THF (6 mL) was added. The reaction mixture was vigorously stirred at room temperature for 
18 h. Afterward, the solvent was evaporated under vacuum and the residue was taken up in 
EtOAc (10 mL), a satd. solution of NH4Cl (10 mL) was then added and the mixture was 
extracted with EtOAc (5 x 10 mL). The aqueous layer was acidified to pH 2 by adding a 1 N 
solution of HCl and extracted again with EtOAc (5 x 10 mL). The combined organic layers were 
dried over Na2SO4. After filtration and evaporation of the solvent the crude was purified by 
flash chromatography (pure EtOAc; Rf 0.14) to afford compound 5 (282 mg, 74%) as a white 
solid. 
M.p. 95-100 °C (dec.). [α]D
24 –6.5 (c 0.40, CHCl3). 
1H NMR (400 MHz, CDCl3) (mixture of 
rotamers) δ (ppm): 7.75 (d, J = 7.5 Hz, 2 H, Fmoc), 7.56-7.55 (m, 2 H, Fmoc), 7.39 (t, J = 7.5 Hz, 
2 H, Fmoc), 7.30 (t, J = 7.5 Hz, 2 H, Fmoc), 4.96 (bs, 1 H, NH), 4.58-4.30 (m, 2 H, CH2 Fmoc), 
4.25-4.15 (m, 2 H, CH Fmoc + 3-Heq major rotamer), 4.10-3.98 (m, 1 H, 3-Heq, minor rotamer), 
3.73 (s, 3 H, OCH3, minor rotamer), 3.71 (s, 3 H, OCH3, major rotamer), 3.61-3.48 (m, 1 H, 4-H, 
major rotamer), 3.46-3.40 (m, 1 H, 4-H, minor rotamer), 2.88-2.60 (m, 1 H, 3-Hax, both 
rotamers), 2.10-1.55 (m, 3 H, 5-H + 5-H’ + 7-H), 1.42-1.10 (m, 1 H, 6-H), 1.0-0.78 (m, 1 H, 7-H’). 
13C NMR (100.4 MHz, CDCl3) (major rotamer) δ (ppm): 177.3 (COOH), 157.0 (NCO), 155.7 
(NCO), 143.7 (2 C, Carom), 141.3 (2 C, Carom), 127.7 (2 C, Carom), 127.1 (2 C, Carom), 125.0 (2 C, 
Carom), 120.0 (2 C, Carom), 66.7 (CH2 Fmoc), 53.1 (OCH3), 47.2 (CH Fmoc), 46.4, 45.7, 33.6, 29.7, 
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24.8, 21.0. MS (ESI) m/z (%): 895 (100) [2M + Na]+, 459 (80) [M + Na]+. Elemental analysis calcd 
(%) for C24H24N2O6 (436.46): C, 66.04; H, 5.54; N, 6.42. Found: C, 66.27; H, 5.29; N, 6.08. 
 
 
N
FmocHN
CO2Me
O
HN
NHO
N
H
NHMtr
NH
CO2Bn  
4-Fmoc-[2-(methoxycarbonyl)-4-NHCPA]-Arg(Mtr)-Gly-OBn [(–)-6] 
DEPBT (108 mg, 0.36 mmol) and DIPEA (63 μL, 0.36 mmol) were added under an N2 
atmosphere to a solution of 5 (79 mg, 0.18 mmol) in anhydrous THF (1.5 mL), cooled at 0 °C, 
and the resulting mixture was allowed to warm to room temperature. After 15 min the 
reaction was cooled again to 0 °C and a solution of H-Arg(Mtr)-Gly-OBn (144 mg, 0.27 mmol) in 
anhydrous THF (1.5 mL) was added. The resulting reaction mixture was stirred at 35 °C for 4 
days. Afterward, EtOAc (30 mL) was added and the mixture was washed with a satd. solution 
of NH4Cl (2 x 7.5 mL), a satd. solution of NaHCO3 (2 x 7.5 mL) and H2O (2 x 7.5 mL). The organic 
layer was dried over Na2SO4, filtered and evaporated under vacuum. The residue was purified 
by flash chromatography (pure EtOAc; Rf 0.40) affording pure 6 (122 mg, 71 %) as a white 
solid. 
M.p. 165.6-169.9 °C (dec.). [α]D
26 –6.4 (c 0.70, CHCl3). 
1H NMR (400 MHz, CDCl3) (major 
rotamer) δ (ppm): 7.85-7.72 (m, 3 H, NH + Fmoc), 7.57-7.55 (m, 2 H, Fmoc), 7.40-7.36 (m, 2 H, 
Fmoc), 7.34-7.27 (m, 7 H, Fmoc + Ph), 7.22-7.05 (m, 1 H, NH), 6.50 (s, 1 H, CH Mtr), 6.33 (bs, 3 
H, NHε Arg), 5.22 (bs, 1 H, NH), 5.11-5.09 (m, 2 H, CH2Ph), 4.65-4.55 (m, 1 H, Hα Arg), 4.42-4.25 
(m, 2 H, CH2 Fmoc), 4.20-4.18 (m, 1 H, CH Fmoc), 4.13-4.11 (m, 1 H, 3-Heq), 4.06 (dd, J = 17.7, 
5.3 Hz, 1 H, Hα Gly), 3.93 (dd, J = 17.7, 5.3 Hz, 1 H, Hα Gly), 3.79 (s, 3 H, OCH3 Mtr), 3.67 (bs, 3 
H, OCH3), 3.46-3.40 (m, 1 H, 4-H), 3.31-3.15 (m, 2 H, Hδ Arg), 2.82-2.40 (m, 7 H, 3-Hax + 2 x CH3 
Mtr), 2.10 (s, 3 H, CH3 Mtr), 1.89-1.42 (m, 7 H, 5-H + 5-H’ + 7-H + Hβ Arg + Hγ Arg), 1.28-1.22 (m, 
1 H, 6-H), 0.80-0.60 (m, 1 H, 7-H’). 13C NMR (100.4 MHz, CDCl3) (major rotamer) δ (ppm): 172.5 
(Cq), 169.8 (Cq), 158.5 (Cq), 157.3 (Cq), 156.4 (Cq), 155.8 (Cq), 155.6 (Cq), 143.8 (2 C, Cq,arom), 
141.2 (2 C, Cq,arom), 138.5 (Cq,arom), 136.6 (Cq,arom), 135.2 (Cq,arom), 133.2 (Cq,arom), 128.5 (2 C, 
CHarom), 128.4 (CHarom), 128.2 (2 C, CHarom), 127.7 (2 C, Carom), 127.0 (2 C, Carom), 125.0 (2 C, 
Carom), 124.8 (Cq,arom), 119.9 (2 C, Carom), 111.7 (CHarom), 67.1 (CH2Ph), 66.8 (CH2 Fmoc), 55.4 
(OCH3 Mtr), 53.4 (OCH3), 52.5 (Cα Arg), 47.1 (CH Fmoc), 45.7 (C-3), 45.5 (C-4), 41.2 (Cα Gly), 
40.3 (Cδ Arg), 30.0 (CH2), 29.6 (CH2), 27.7 (CH2), 24.9 (CH2), 24.8, 24.1 (CH3 Mtr), 21.0, 18.3 (CH3 
Mtr), 11.9 (CH3 Mtr). MS (ESI) m/z (%): 954 (23), 953 (51), 952 (100) [M + 1]
+. Elemental 
analysis calcd (%) for C49H57N7O11S (952.08): C, 61.81; H, 6.03; N, 10.30. Found: C, 61.66; H, 
6.28; N, 10.02. 
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N
H
N
CO2Me
O
HN
NHO
N
H
NHMtr
NH
O
CbzHN
t-BuO2C
CO2Bn  
4-[Z-Asp(OtBu)]-2-(methoxycarbonyl)-4-NHCPA-Arg(Mtr)-Gly-OBn [(–)-8] 
Compound 6 (122 mg, 0.13 mmol) was dissolved in a 1:1 CH2Cl2/diethylamine mixture (1.5 mL) 
under an N2 atmosphere. The resulting solution was stirred at room temperature for 3 h, 
meanwhile additional 1:1 CH2Cl2/diethylamine mixture (1 mL) was added. Afterward, the 
solution was concentrated under vacuum, the residue was taken up in CH2Cl2 (4 mL) and then 
concentrated again. The crude was purified by flash chromatography (pure EtOAc, then 
MeOH/EtOAc 1:1; Rf 0.38), affording pure 7 (88 mg, 94 %) as a white solid. 
1H NMR (400 MHz, CDCl3) (major rotamer) δ (ppm): 7.76-7.73 (m, 1 H, NH), 7.32-7.28 (m, 5 H, 
Ph), 7.20-7.16 (m, 1 H, NH), 6.50 (s, 1 H, CH Mtr), 6.38-6.10 (m, 3 H, NHε Arg), 5.13-5.11 (m, 2 
H, CH2Ph), 4.62-4.50 (m, 1 H, Hα Arg), 4.25-3.86 (m, 5 H, NH2 CPA + 3-Heq + Hα Gly), 3.80 (s, 3 H, 
OCH3 Mtr), 3.72-3.58 (m, 4 H, 4-H + OCH3), 3.31-3.12 (m, 2 H, Hδ Arg), 2.85-2.70 (m, 1 H, 3-Hax), 
2.66 (s, 3 H, CH3 Mtr), 2.59 (s, 3 H, CH3 Mtr), 2.11 (s, 3 H, CH3 Mtr), 1.96-1.45 (m, 7 H, 5-H + 5-
H’ + 7-H + Hβ Arg + Hγ Arg), 1.28-1.22 (m, 1 H, 6-H), 0.72-0.65 (m, 1 H, 7-H’). MS (ESI) m/z (%): 
753 (43), 752 (100) [M + Na]+, 731 (38), 730 (83) [M + 1]+. 
DEPBT (79 mg, 0.27 mmol) and DIPEA (47 μL, 0.27 mmol) were added under an N2 atmosphere 
to a solution of Z-Asp(OtBu)-OH monohydrate (62 mg, 0.18 mmol) in anhydrous THF (1.5 mL), 
cooled at 0 °C, and the resulting mixture was allowed to warm to room temperature. After 15 
min this solution was slowly added to a solution of compound 7 (88 mg, 0.12 mmol) in 
anhydrous THF (500 μL) precooled at 0 °C. The resulting reaction mixture was stirred at 35 °C 
for 4 days. Afterward, EtOAc (20 mL) was added and the mixture was washed with a satd. 
solution of NH4Cl (2 x 5 mL), a satd. solution of NaHCO3 (2 x 5 mL) and H2O (2 x 5 mL). The 
organic layer was dried over Na2SO4, filtered and evaporated under vacuum. The residue was 
purified by flash chromatography (pure EtOAc; Rf 0.38) affording pure 8 (74 mg, 59 %) as a 
white solid. 
M.p. 102-109 °C (dec.). [α]D
25 –4.4 (c 0.75, CHCl3). 
1H NMR (400 MHz, CDCl3) (major rotamer) δ 
(ppm): 7.65 (bs, 1 H, NH), 7.32-7.28 (m, 10 H, 2 x Ph), 7.05 (bs, 1 H, NH), 6.75 (bs, 1 H, NH), 
6.50 (s, 1 H, CH Mtr), 6.31 (bs, 3 H, NHε Arg), 6.06 (bs, 1 H, NH), 5.10-5.02 (m, 4 H, 2 x CH2Ph), 
4.60-4.57 (m, 1 H, Hα Asp), 4.49-4.40 (m, 1 H, Hα Arg), 4.06 (dd, J = 17.8, 5.6 Hz, 1 H, Hα Gly), 
3.93 (dd, J = 17.8, 4.9 Hz, 1 H, Hα Gly), 3.90-3.82 (m, 1 H, 4-H), 3.84-3.72 (m, 4 H, 3-Heq + OCH3 
Mtr), 3.66 (bs, 3 H, OCH3), 3.60-3.58 (m, 1 H, 3-Hax), 3.31-3.17 (m, 2 H, Hδ Arg), 2.82-2.68 (m, 2 
H, Hβ Asp), 2.66 (s, 3 H, CH3 Mtr), 2.59 (s, 3 H, CH3 Mtr), 2.10 (s, 3 H, CH3 Mtr), 2.00-1.46 (m, 7 
H, 5-H + 5-H’ + 7-H + Hβ Arg + Hγ Arg), 1.40 [s, 9 H, OC(CH3)3], 1.28-1.22 (m, 1 H, 6-H), 0.80-0.60 
(m, 1 H, 7-H’). 13C NMR (100.4 MHz, CDCl3) (major rotamer) δ (ppm): 172.5, 170.5, 170.4, 
169.8, 158.4, 157.3, 156.4, 156.1, 138.5 (Carom), 136.5 (Carom), 136.4 (Carom), 136.0 (Carom), 135.2 
(Carom), 133.4 (Carom), 128.6 (2 C, Carom), 128.5 (2 C, Carom), 128.4 (Carom), 128.3 (2 C, Carom), 128.2 
(2 C, Carom), 128.1 (Carom), 124.8 (Carom), 111.7 (Carom), 81.7 [OC(CH3)3], 67.2 (CH2Ph), 67.1 
(CH2Ph), 55.4 (OCH3 Mtr), 53.4 (OCH3), 52.4 (Cα Arg), 51.3 (Cα Asp), 46.1 (C-3), 43.8 (C-4), 41.2 
(Cα Gly), 40.3 (Cδ Arg), 37.7 (Cβ Asp), 30.2, 29.6, 28.0 [3 C, OC(CH3)3], 27.1, 25.7, 24.8, 24.1 (CH3 
Mtr), 22.6, 18.3 (CH3 Mtr), 11.9 (CH3 Mtr). MS (ESI) m/z (%): 1057 (55) [M + Na]
+, 1036 (58), 
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1035 (100) [M + 1]+. Elemental analysis calcd (%) for C50H66N8O14S (1035.17): C, 58.01; H, 6.43; 
N, 10.82. Found: C, 57.77; H, 6.35; N, 10.59. 
 
 
N
HN H
O
NH
O NH
CO2t-Bu
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O
NH
MtrHN NH
CO2Me
 
Cyclo[Arg(Mtr)-Gly-Asp(OtBu)-2-(methoxycarbonyl)-4-NHCPA] [(–)-10] 
Pd/C (35 mg, 10%) was added to a solution of 8 (74 mg, 0.07 mmol) in ethanol (4 mL), under 
an N2 atmosphere. The resulting suspension was stirred under a H2 atmosphere (balloon) at 
room temperature for 24 h. After filtration over a celite layer and evaporation of the solvent, 
compound 9 (51 mg, 88%) was obtained as a white solid. This crude was suspended in THF (20 
mL) under an N2 atmosphere. The suspension was cooled to 0 °C and DEPBT (63 mg, 0.21 
mmol) and DIPEA (37 μL, 0.21 mmol) were added. The resulting reaction mixture was stirred at 
35 °C for 4 days. Afterward, EtOAc (10 mL) was added and the mixture washed with a satd. 
solution of NH4Cl (5 mL), a satd. solution of NaHCO3 (5 mL) and H2O (5 mL). The organic layer 
was dried over Na2SO4, filtered and evaporated under vacuum. The residue was purified by 
flash chromatography (pure EtOAc, then MeOH/EtOAc, 1:10; Rf 0.48) affording pure 10 (27 
mg, 55%) as a white solid. 
[α]D
23 –7.6 (c 1.35, CHCl3). 
1H NMR (400 MHz, CDCl3) (major rotamer) δ (ppm): 7.82 (bs, 1 H, 
NH), 7.52 (bs, 1 H, NH), 7.40 (bs, 1 H, NH), 7.06-6.88 (bs, 1 H, NH), 6.51 (s, 1 H, CH Mtr), 6.40-
6.15 (m, 3 H, NHε Arg), 4.71-4.59 (m, 1 H, Hα Asp), 4.56-4.46 (m, 1 H, Hα Arg), 4.34-4.18 (m, 2 H, 
4-H + Hα Gly), 3.81 (s, 3 H, OCH3 Mtr), 3.76-3.58 (m, 4 H, 3-Heq + OCH3), 3.45-3.35 (m, 2 H, 3-Hax 
+ Hα Gly), 3.31-3.17 (m, 2 H, Hδ Arg), 2.80-2.38 (m, 9 H, Hβ Asp + 5-H + 2 x CH3 Mtr), 2.11 (s, 3 
H, CH3 Mtr), 2.04-1.46 (m, 6 H, 5-H’ + 7-H + Hβ Arg + Hγ Arg), 1.41 (s, 9 H, OC(CH3)3), 1.15-1.04 
(m, 1 H, 6-H), 0.82-0.71 (m, 1 H, 7-H’). 13C NMR (100.4 MHz, CDCl3) (major rotamer) δ (ppm): 
173.1 (Cq), 171.5 (Cq), 170.6 (Cq), 170.1 (Cq), 158.4 (Cq), 157.3 (Cq), 156.5 (Cq), 156.4 (Cq), 138.5 
(Cq,arom), 136.5 (Cq,arom), 133.4 (Cq,arom), 124.8 (Carom), 111.7 (CHarom), 81.7 [OC(CH3)3], 55.4 
(OCH3 Mtr), 53.4 (OCH3), 52.6 (Cα Arg), 49.3 (Cα Asp), 47.4 (C-3), 44.1 (Cα Gly), 43.6 (C-4), 40.3 
(Cδ Arg), 37.4 (Cβ Asp), 30.3, 29.7, 29.3, 28.0 [3 C, OC(CH3)3], 26.4, 25.4, 24.1 (CH3 Mtr), 22.7, 
18.3 (CH3 Mtr), 11.9 (CH3 Mtr). MS (ESI) m/z (%): 815 (20) [M + Na]
+, 794 (46), 793 (100) [M + 
1]+. Elemental analysis calcd (%) for C35H52N8O11S (792.90): C, 53.02; H, 6.61; N, 14.13. Found: 
C, 52.87; H, 6.54; N, 13.97. 
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Cyclo[Arg-Gly-Asp-2-(methoxycarbonyl)-4-NHCPA]·TFA [(–)-2] 
Protected tetrapeptide 10 (27 mg, 0.034 mmol) was dissolved in a 95:2.5:2.5 trifluoroacetic 
acid/triisopropylsilane/H2O mixture (2 mL) and the resulting solution was stirred at room 
temperature for 18 h. Afterward, the mixture was evaporated under vacuum and the residue 
was taken up in H2O (3 mL) and washed with Et2O (4 x 1 mL). The aqueous layer was then 
concentrated under vacuum, affording the deprotected cyclic tetrapeptide as a 
trifluoroacetate salt. This crude was purified by semi-preparative HPLC (C18 column, 10 μm, 
250 mm × 10 mm i.d.) using acetonitrile (0.1% TFA) in H2O (0.1% TFA), 5-35% linear gradient 
over 22.5 min at room temperature with a flow rate of 2 mL/min (λ = 223 nm; Rt = 20.6 min). 
The HPLC sample was concentrated under vacuum and lyophilized, affording pure 2 (9.6 mg, 
44%) as a colourless glassy solid. Purity was checked by HPLC analysis (C18 column, 5 μm , 250 
mm x 4.6-mm i.d.), using acetonitrile (0.1% TFA) in water (0.1% TFA) as eluant, 5-35% linear 
gradient over 35 min at room temperature. 
[α]D
23 –16.0 (c 0.25, D2O). 
1H NMR (400 MHz, DMSO-d6) (2:1 mixture of rotamers) (major 
rotamer) δ (ppm): 12.14 (bs, 1 H, COOH), 8.16-8.10 (m, NH Arg), 7.96-7.88 (m, NH CPA), 7.66-
7.60 (m, NH Asp), 7.58-7.46 (m, 1 H, NHε Arg), 7.39 (d, J = 9.3 Hz, 1 H, NH Gly), 7.32-6.64 (m, 3 
H, NHε Arg), 4.56-4.51 (m, 1 H, Hα Asp), 4.42-4.38 (m, 1 H, Hα Arg), 4,31-4.24 (m, 1 H, Hα Gly), 
4.05-3.92 (m, 1 H, 4-H), 3.62-3.48 (m, 4 H, 3-Heq + OCH3), 3.21-3.17 (m, 1 H, Hα Gly), 3.15-3.02 
(m, 2 H, Hδ Arg), 2.98-2.90 (m, 1 H, 3-Hax), 2.65-2.51 (m, 1 H, Hβ Asp), 2.32-2.21 (m, 2 H, 5-H + 
Hβ Asp), 1.92-1.80 (m, 2 H, 7-H + Hβ Arg), 1.73-1.55 (m, 2 H, 6-H + Hβ Arg), 1.48-1.25 (m, 3 H, 5-
H’ + Hγ Arg), 0.60-0.46 (m, 1 H, 7-H’). 
1H NMR (400 MHz, D2O) (3:1 mixture of rotamers) (major 
rotamer) δ (ppm): 4.65-4.60 (m, 1 H, Hα Asp), 4.42-4.35 (m, 1 H, Hα Arg), 4.18 (d, J = 15.6 Hz, 1 
H, Hα Gly), 4.12-4.04 (m, 1 H, 4-H), 3.61 (s, 3 H, OCH3), 3.50-3.44 (m, 1 H, 3-Heq), 3.41 (d, J = 
15.6 Hz, 1 H, Hα Gly), 3.34-3.26 (m, 1 H, 3-Hax), 3.12-3.04 (m, 2 H, Hδ Arg), 2.78-2.66 (m, 2 H, Hβ 
Asp), 2.38-2.30 (m, 1 H, 5-H), 1.88-1.84 (m, 1 H, 7-H), 1.82-1.65 (m, 3 H, 6-H + Hβ Arg), 1.58-
1.41 (m, 2 H, Hγ Arg), 1.18-1.09 (m, 1 H, 5-H’), 0.89-0.80 (m, 1 H, 7-H’). 
13C NMR (100.4 MHz, 
D2O) (major rotamer) δ (ppm): 184.4 (Cq), 174.9 (Cq), 172.0 (Cq), 171.6 (Cq), 171.1 (Cq), 163.1 
(Cq), 162.8 (Cq), 156.7 (Cq), 117.8 (Cq), 53.4 (OCH3), 52.7 (Cα Arg), 49.5 (Cα Asp), 46.7 (C-3), 44.1 
(Cα Gly), 43.2 (C-4), 40.5 (Cδ Arg), 36.6 (Cβ Asp), 28.1, 26.0, 25.1, 24.3, 22.4, 22.2. MS (ESI) m/z 
(%): 526 (29), 525 (100) [M + 1]+. 
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5-[Z-Asp(OtBu)]-2-(methoxycarbonyl)-5-NHCPA-OMe  [(+)-13] 
DEPBT (347 mg, 1.16 mmol) and DIPEA (202 µL, 1.16 mmol) were added to a solution of Z-
Asp(OtBu)-OH·H2O (273 mg, 0.80 mmol) in anhydrous THF (3.5 mL) cooled at 0 °C, under an N2 
atmosphere, and the resulting mixture was allowed to warm to room temperature. After 15 
min this solution was slowly added to a solution of compound 12[chap. 5] (92 mg, 0.40 mmol) in 
anhydrous THF (3 mL) precooled at 0 °C. The resulting reaction mixture was stirred at 35 °C for 
6 days. Afterward, EtOAc (20 mL) was added and the mixture was washed with a satd. solution 
of NH4Cl (10 mL), a satd. solution of NaHCO3 (10 mL) and H2O (10 mL). The organic layer was 
dried over Na2SO4, filtered and evaporated under vacuum. The residue was purified by flash 
chromatography (n-hexane/EtOAc 1:1, Rf 0.23) affording pure 13 (178 mg, 84 %) as a white 
solid. 
M.p. 62.7-66.0 °C. [α]D
21 +16.6  (c 1.40, CHCl3). 
1H NMR (400 MHz, CDCl3) (mixture of rotamers) 
δ (ppm): 7.38-7.30 (m, 5 H, Ph, both rotamers), 7.00-6.90 (m, 1 H, NH CPA, both rotamers), 
6.02-5.90 (m, 1 H, NH Asp, both rotamers), 5.11 (s, 2 H, CH2Ph, both rotamers), 4.55-4.44 (m, 1 
H, Hα Asp, both rotamers), 4.18-4.05 (m, 1 H, 5-H, both rotamers), 3.88-3.81 (m, 1 H, 3-Heq, 
major rotamer), 3.75-3.62 (m, 7 H, 3-Heq minor rotamer + 2 x OCH3 both rotamers), 3.06-2.98 
(m, 1 H, 3-Hax, minor rotamer), 2.94-2.84 (m, 2 H, 3-Hax major rotamer + Hβ Asp both 
rotamers), 2.59 (dd, J = 17.2, 7.4 Hz, 1 H, Hβ’ Asp, both rotamers), 1.97 (dd, J = 10.0, 5.7 Hz, 1 
H, 7-H, minor rotamer), 1.90 (dd, J = 10.1, 5.4 Hz, 1 H, 7-H, major rotamer), 1.68-1.56 (m, 3 H, 
4-H + 4-H’ + 6-H, both rotamers), 1.42 [s, 9 H, OC(CH3)3], 0.92-0.84 (m, 1 H, 7-H’, both 
rotamers). 13C NMR (100.4 MHz, CDCl3) (major rotamer) δ (ppm): 172.2, 171.2, 169.9, 156.9, 
156.1, 135.9 (Carom), 128.6 (2 C, Carom), 128.3 (2 C, Carom), 128.1 (Carom), 82.0 [OC(CH3)3], 67.3 
(CH2Ph), 53.0 (OCH3), 52.5 (OCH3), 50.9 (Cα Asp), 43.1, 38.3, 37.9, 37.7 (Cβ Asp), 29.1, 28.0 [3 C, 
OC(CH3)3], 27.8, 21.3. MS (ESI) m/z (%): 1089 (22) [2M + Na]
+, 556 (100) [M + Na]+. Elemental 
analysis calcd (%) for C26H35N3O9 (533.57): C, 58.53; H, 6.61; N, 7.88. Found: C, 58.64; H, 6.33; 
N, 7.62. 
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5-Fmoc-[2-(Methoxycarbonyl)-5-NHCPA]-Arg(Mtr)-Gly-OBn  [(–)-15] 
Prepared as reported for 6, starting from 14[chap. 5] (100 mg, 0.23 mmol). After flash 
chromatography (pure EtOAc, Rf 0.59), pure 15 (172 mg, 79 %) was obtained as a white solid. 
M.p. 110-130 °C (dec.). [α]D
21 –5.8  (c 0.80, CHCl3). 
1H NMR (400 MHz, CD3OD) (2:1 mixture of 
rotamers) δ (ppm): 8.41-8.36 (m, 1 H, NH Gly, minor rotamer), 8.15 (bs, 2 H, NH Gly + NH Arg, 
major rotamer), 7.90-7.86 (m, 1 H, NH Arg, minor rotamer), 7.76 (d, J = 7.4 Hz, 2 H, Fmoc, both 
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rotamers), 7.60 (t, J = 7.1 Hz, 2 H, Fmoc, both rotamers), 7.37-7.25 (m, 9 H, Fmoc + Ph, both 
rotamers), 6.65 (s, 1 H, CH Mtr, minor rotamer), 6.60 (s, 1 H, CH Mtr, major rotamer), 5.17-
5.12 (m, 2 H, CH2Ph, both rotamers), 4.41-4.35 (m, 3 H, Hα Arg + CH2 Fmoc, both rotamers), 
4.17-4.05 (m, 2 H, Hα Gly + CH Fmoc, both rotamers), 4.02-3.84 (m, 2 H, Hα Gly + 5-H, both 
rotamers), 3.81 (s, 3 H, OCH3 Mtr, minor rotamer), 3.79-3.74 (m, 4 H, 3-Heq both rotamers + 
OCH3 Mtr major rotamer), 3.66 (bs, 3 H, OCH3, both rotamers), 3.23-2.90 (m, 3 H, 3-Hax + Hδ 
Arg, both rotamers), 2.67 (s, 3 H, CH3 Mtr, minor rotamer), 2.66 (s, 3 H, CH3 Mtr, major 
rotamer), 2.61 (s, 3 H, CH3 Mtr, minor rotamer), 2.59 (s, 3 H, CH3 Mtr, major rotamer), 2.11 (s, 
3 H, CH3 Mtr, minor rotamer), 2.07 (s, 3 H, CH3 Mtr, major rotamer), 1.99-1.42 (m, 8 H, 4-H + 4-
H’ + 6-H + 7-H + Hβ Arg + Hγ Arg, both rotamers), 0.81-0.72 (m, 1 H, 7-H’). 
13C NMR (100.4 MHz, 
CD3OD) (major rotamer) δ (ppm): 174.8, 173.8, 171.7, 159.8, 159.1, 158.1, 157.9, 145.3 (2 C, 
Carom), 142.6 (2 C, Carom), 139.5 (Carom), 137.8 (Carom), 137.1 (Carom), 134.8 (Carom), 129.6 (2 C, 
Carom), 129.3 (Carom), 128.7 (2 C, Carom), 128.3 (Carom), 128.1 (Carom), 128.0 (2 C, Carom), 126.1 (2 C, 
Carom), 125.7 (Carom), 120.9 (2 C, Carom), 112.7 (Carom), 68.0 (CH2Ph), 67.5 (CH2 Fmoc), 55.9 (OCH3 
Mtr), 54.6, 53.9 (OCH3), 48.5 (CH Fmoc), 45.2, 44.8, 42.0 (Cα Gly), 41.7, 39.5, 29.8, 29.3, 28.9, 
27.1, 24.4 (CH3 Mtr), 20.8, 18.9(CH3 Mtr), 12.1 (CH3 Mtr). MS (ESI) m/z (%): 1926 (9) [2M + 
Na]+, 974 (100) [M + Na]+. 
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5-[Z-Asp(OtBu)]-2-(methoxycarbonyl)-5-NHCPA-Arg(Mtr)-Gly-OBn [(+)-17] 
Prepared in two steps as reported for 8, starting from 15 (170 mg, 0.18 mmol). After flash 
chromatography (pure EtOAc, Rf 0.40), pure 17 (84 mg, 49 % over two steps) was obtained as a 
white solid. 
16: M.p. 160 °C (dec.). [α]D
19 –3.6  (c 0.92, CH3OH). 
1H NMR (400 MHz, CD3OD) (major rotamer) 
δ (ppm): 7.35-7.30 (m, 5 H, Ph), 6.65 (s, 1 H, CH Mtr), 5.16 (s, 2 H, CH2Ph), 4.42-4.39 (m, 1 H, Hα 
Arg), 4.12-3.90 (m, 2 H, Hα Gly), 3.82 (s, 3 H, OCH3 Mtr), 3.71-3.60 (m, 4 H, 3-Heq + OCH3), 3.35-
3.10 (m, 4 H, 3-Hax + 5-H + Hδ Arg), 2.67 (s, 3 H, CH3 Mtr), 2.61 (s, 3 H, CH3 Mtr), 2.12 (s, 3 H, 
CH3 Mtr), 1.98-1.82 (m, 3 H, 7-H + Hγ Arg), 1.71-1.48 (m, 7 H, 5-H, 4-H + 4-H’ + 6-H + Hβ Arg), 
0.80-0.72 (m, 1 H, 7-H’). 13C NMR (100.4 MHz, CD3OD) (major rotamer) δ (ppm): 174.8, 174.0, 
171.9, 159.8, 158.2, 142.7 (Carom), 139.4 (Carom), 137.8 (Carom), 137.1 (Carom),, 134.8 (Carom), 129.5 
(2 C, Carom), 129.3 (Carom), 128.3 (Carom), 125.7 (2 C, Carom), 112.7 (Carom), 68.0 (CH2Ph), 56.0 
(OCH3 Mtr), 54.5, 53.9 (OCH3), 45.0, 42.0, 41.8, 39.0, 31.4, 30.7, 30.3, 29.3, 27.0, 24.3 (CH3 
Mtr), 20.9, 18.8 (CH3 Mtr), 12.1 (CH3 Mtr). MS (ESI) m/z (%): 1459 (18) [2M + 1]
+, 752 (17) [M + 
Na]+, 731 (42), 730 (100) [M + 1]+. 
17: M.p. 110 °C (dec.). [α]D
21 +22.4  (c 0.84, CHCl3).  
1H NMR (400 MHz, CDCl3) (major rotamer) 
δ (ppm): 7.78 (bs, 1 H, NH Gly), 7.68-7.40 (m, 1 H, NH CPA), 7.36-7.12 (m, 10 H, 2 x Ph), 7.18-
7.05 (m, 1 H, NH Arg), 6.50 (s, 1 H, CH Mtr), 6.28-5.96 (m, 4 H, NHε Arg + NH Asp), 5.16-4.96 
(m, 4 H, 2 x CH2Ph), 4.61-4.40 (m, 2 H, Hα Asp + Hα Arg), 4.26 (bs, 1 H, 5-H), 4.16-3.98 (m, 2 H, 
Hα Gly), 3.90-3.74 (m, 4 H, 3-Heq + OCH3 Mtr), 3.64 (s, 3 H, OCH3), 3.28-2.90 (m, 3 H, 3-Hax + Hδ 
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Arg), 2.75-2.65 (m, 5 H, Hβ Asp + CH3 Mtr), 2.60 (s, 3 H, CH3 Mtr), 2.11 (s, 3 H, CH3 Mtr), 2.04-
1.86 (m, 3 H, 7-H + Hβ Arg), 1.78-1.50 (m, 5 H, 4-H + 4-H’ + 6-H + Hγ Arg), 1.37 (s, 9 H, OC(CH3)3), 
0.72-0.68 (m, 1 H, 7-H’). 13C NMR (100.4 MHz, CDCl3) (major rotamer) δ (ppm): 172.4, 171.6, 
170.2, 169.8, 158.3, 157.5, 156.3, 156.0, 138.4 (Carom), 136.4 (Carom), 136.1 (Carom), 135.1 (Carom), 
135.0 (Carom), 133.3 (Carom), 128.5 (2 C, Carom), 128.4 (2 C, Carom), 128.3 (Carom), 128.2 (2 C, Carom), 
128.1 (2 C, Carom), 127.8 (Carom), 124.7 (Carom), 111.6 (CHarom), 81.4 [OC(CH3)3], 67.0 (CH2Ph), 66.8 
(CH2Ph), 55.3 (OCH3 Mtr), 53.3 (OCH3), 52.8 (Cα Arg), 51.3 (Cα Asp), 42.7 (C-5), 41.1 (Cα Gly), 
40.4 (Cδ Arg), 38.3 (C-3), 37.9 (Cβ Asp), 29.6 (Cβ Arg), 29.1, 28.3 (C-6), 27.8 [3 C, OC(CH3)3], 27.4 
(C-4), 25.1 (Cγ Arg), 24.0 (CH3 Mtr), 20.0 (C-7), 18.3 (CH3 Mtr), 11.8 (CH3 Mtr). MS (ESI) m/z (%): 
1057 (100) [M + Na]+, 1035 (16) [M + 1]+. 
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Cyclo[Arg(Mtr)-Gly-Asp(OtBu)-2-(methoxycarbonyl)-5-NHCPA] (19) 
Prepared in two steps as reported for 10, starting from 17 (84 mg, 0.08 mmol). After flash 
chromatography (EtOAc, then MeOH/EtOAc 1:4, Rf 0.60), 19 (21 mg) was obtained in mixture 
with other unidentified products and as a white solid. 
1H NMR (400 MHz, CD3OD)  (major product, major rotamer) δ (ppm): 6.66 (s, 1 H, CH Mtr), 
4.69-4.61 (m, 1 H, Hα Asp), 4.53-4.43 (m, 1 H, 5-H), 4.30-4.23 (m, 1 H, Hα Arg), 4.07-3.96 (m, 1 
H, Hα Gly), 3.93-3.80 (m, 4 H, 3-Heq + OCH3 Mtr), 3.78-3.63 (m, 3 H, OCH3), 3.46 (d, J = 13.6 Hz, 
1 H, Hα Gly), 3.23-3.07 (m, 2 H, Hδ Arg), 2.94-2.76 (m, 3 H, 3-Hax + Hβ Asp), 2.65 (s, 3 H, CH3 
Mtr), 2.62-2.45 (m, 4 H, Hβ Asp + CH3 Mtr), 2.11 (s, 3 H, CH3 Mtr), 1.96-1.47 (m, 7 H, 4-H + 4-H’ 
+ 7-H + Hβ Arg + Hγ Arg), 1.41 (s, 9 H, OC(CH3)3), 1.33-1.22 (m, 1 H, 6-H), 0.87-0.66 (m, 1 H, 7-
H’).  MS (ESI) m/z (%): 815 (36), 794 (37), 793 (100) [M + 1]+. 
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Cyclo[Arg-Gly-Asp-2-(methoxycarbonyl)-5-NHCPA]·TFA (4) 
Prepared as reported for 2, starting from 19 (21 mg, 0.026 mmol). The crude was purified by 
semi-preparative HPLC (C18 column, 10 µm, 250 mm × 10 mm) using acetonitrile (0.1% TFA) in 
H2O (0.1% TFA), 0-50% linear gradient over 35 min at room temperature with a flow rate of 2 
mL/min (λ = 223 nm; Rt = 25.4 min). The HPLC sample was concentrated under vacuum and 
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lyophilized, affording pure 4 (5.6 mg, 12%, calculated from 18) as a colourless glassy solid. 
Purity checked by HPLC analysis (C18 column, 5 μm , 4.6-250 mm), using acetonitrile (0.1% 
TFA) in water (0.1% TFA) as eluant, 5-35% linear gradient over 35 min at room temperature. 
1H NMR (500 MHz, DMSO) (5:1 mixture of rotamers) (major rotamer) δ (ppm): 8.88 (d, J = 7.6 
Hz, NH Asp), 7.77 (d, J = 8.1 Hz, NH CPA), 7.53-7.47 (m, NH Arg), 7.24-7.20 (m, NH Gly), 7.19-
6.64 (m, 4 H, NHε Arg), 4.52-4.46 (m, 1 H, Hα Asp), 4.16-4.11 (m, 1 H, 5-H), 4.04-3.95 (m, 1 H, Hα 
Gly), 3.86-3.79 (m, 1 H, 3-Heq),  3.66-3.59 (m, 4 H, Hα Arg + OCH3), 3.34-3.26 (m, 1 H, Hα Gly), 
3.12-3.02 (m, 2 H, Hδ Arg), 2.99-2.87 (m, 1 H, 3-Hax), 2.82 (dd, J = 16.5, 9.0 Hz, 1 H, Hβ Asp), 
2.45 (dd, J = 16.5, 6.1 Hz, 1 H, Hβ Asp), 1.99-1.81 (m, 2 H, Hβ Arg), 1.67-1.60 (m, 1 H, 7-H), 1.55-
1.46 (m, 2 H, 4-H), 1.44-1.36 (m, 2 H, Hγ Arg), 1.36-1.29 (m, 1 H, 6-H), 0.83-0.71 (m, 1 H, 7-H’). 
MS (ESI) m/z (%): 526 (26), 525 (100) [M + 1]+. Elemental analysis calcd (%) for C23H33F3N8O10 
(638.55): C, 43.26; H, 5.21; N, 17.55. Found: C, 43.48; H, 5.02; N, 17.23. 
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6.8 Appendix 
 
Appendix 1: Analytical HPLC and Full NMR Characterisation of Ligand 2 
 
HPLC analysis of purified cyclopeptide 2. Column: Acclaim 120 (C18, 5 µ, 4.6-250 mm), 
acetonitrile (0.1% TFA) in water (0.1% TFA), 5-35% linear gradient over 35 min at room 
temperature. 
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-50
0
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150
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250 29_nov_13_d1LS_89_scolonnato #4 [modified by HPLC] UV_VIS_1
mAU
min
1 - 16,073
2 - 16,367
WVL:223 nm
 
 
No. Ret. Time (min) Height (mAU) Area (mAU*min) Rel. Area (%) 
1 16.07 130.677 14.976 98.94 
2 16.37 1.808 0.160 1.06 
Total  132.485 15.136 100.00 
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TOCSY full spectrum (top) and TOCSY NH-α region (bottom) of ligand 2 (DMSO-d6, 400 MHz) 
Results and Discussion: Chapter 6 
 
 
96 
 
 
ROESY full spectrum (top) and ROESY NH-α region (bottom) of ligand 2 (DMSO-d6, 400 MHz) 
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1H and 13C NMR chemical shifts of 2 at 298 K 
 
2 δ, ppm 
1H (DMSO-d6) 
13C (D2O) 
- - C-1 28.1 
H-3 3.62-3.48, 2.98-2.90 C-3 46.7 
H-4 4.05-3.92 C-4 43.2 
H-5 2.32-2.21, 1.48-1.25 C-5 25.1 
H-6 1.73-1.55 C-6 22.4 
H-7 1.92-1.80, 0.60-0.46 C-7 22.2 
OCH3 3.62-3.48 OCH3 53.4 
CPA NH 7.96-7.88 - - 
Gly NH 7.39 - - 
Arg NH 8.16-8.10 - - 
Arg NHε 7.58-7.46, 7.32-6.64 - - 
Asp NH 7.66-7.60 - - 
Gly H-α 4.31-4.24, 3.21-3.17 Gly C-α 44.1 
Arg H-α 4.42-4.38 Arg C-α 52.7 
Arg H-β 1.92-1.80, 1.73-1.55 Arg C-β 26.0 
Arg H-γ 1.48-1.25 Arg C-γ 24.3 
Arg H-δ 3.15-3.02 Arg C-δ 40.5 
Asp H-α 4.56-4.51 Asp C-α 49.5 
Asp H-β 2.65-2.51, 2.32-2.21 Asp C-β 36.6 
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Appendix 2: Analytical HPLC, MS-ESI and Full NMR Characterisation of Ligand 4 
 
HPLC analysis of purified cyclopeptide 4. Column: Acclaim 120 (C18, 5 µ, 4.6-250 mm), 
acetonitrile (0.1% TFA) in water (0.1% TFA), 5-35% linear gradient over 35 min at room 
temperature. 
 
0,0 5,0 10,0 15,0 20,0 25,0 30,0 35,5
-50
100
200
300
450 05_feb_15_d3LS_197-198_controlli_semiprep #2 [modified by HPLC]UV_VIS_1
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WVL:223 nm
 
 
No. Ret. Time (min) Height (mAU) Area (mAU*min) Rel. Area (%) 
1 14.55 303.910 30.711 93.24 
2 14.88 21.836 2.226 6.76 
Total  325.746 32.936 100.00 
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d2LS164_p1_141024105526 #1 RT: 0.00 AV: 1 NL: 1.73E2
T: ITMS + c ESI Full ms [150.00-2000.00]
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MS (ESI) m/z (%) of 4: 526 (26), 525 (100) [M + 1]+. 
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1H-NMR (DMSO-d6, 500 MHz) (top) and gCOSY (DMSO-d6, 400 MHz) (bottom) of ligand 4 
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TOCSY NH-α region (top) and ROESY NH-α region (bottom) of ligand 4 (DMSO-d6, 500 MHz) 
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1H chemical shifts of 4 in DMSO-d6 solutions at 298 K 
 
4 δ, ppm 
Proton 1H Proton 1H 
CPA NH 7.78 Arg NH 7.51 
CPA 5-H 4.14 Asp NH 8.90 
CPA 3-Heq 3.81 Gly H-α 3.96; 3.29 
CPA 3-Hax 2.91 Arg H-α 3.63 
CPA 7-H 1.62 Arg H-β,γ 1.93-1.39 
CPA 4-H (2H) 1.49 Arg H-δ 3.04 
CPA 6-H 1.31 Asp H-α 4.47 
CPA 7-H’ 0.75 Asp H-β 2.80; 2.40 
Gly NH 7.22   
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Appendix 3: Cell Biology Assays (αvβ3) 
 
The RGD peptidomimetic ligands 2 and 4 were tested for their integrin binding affinity towards 
M21 human melanoma cells expressing high levels of αvβ3 heterodimer and low levels of αvβ5 
heterodimer, as shown by flow cytometry analysis below.  
 
αvβ3 (B) and αvβ5 (C) integrin expression in M21 human melanoma cells by flow cytometry 
analysis 
 
 
 
 
 
 
 
 
 
 
Percentage of inhibition of integrin-mediated M21 cell adhesion to vitronectin by compound 2 
(left) and 4 (right). Experiments were conducted in triplicate and repeated at least three times. 
Data are presented as means ±SEM from three independent experiments. 
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Appendix 4:  Cell Biology Assays (α5β1) 
 
The RGD peptidomimetic ligands 2 and 4 were tested for their integrin binding affinity towards 
K562 human erythroleukemia cells expressing high levels of α5β1 heterodimer, as shown by 
flow cytometry analysis below. 
 
 
α5β1 integrin expression (right) in K562 human erythroleukemia cells by flow cytometry 
analysis 
 
 
 
 
Percentage of inhibition of integrin-mediated K562 cell adhesion to fibronectin by compounds 
2 (left) and 4 (right). Experiments were conducted in triplicate and repeated at least three 
times. Data are presented as means ±SEM from three independent experiments. 
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Chapter 7: Conformational Evaluation of a CPA-containing Linear Peptide 
 
7.1 Synthesis of a Model Tripeptide Including a 4-OH-CPA 
Eventually, we wanted to investigate the possibility to employ CPAs to form peptide bonds by 
exploiting the piperidine nitrogen atom, by the same way natural pipecolic acid is usually 
employed in peptide chemistry. 
At the same time, we took the opportunity to assess the conformational features offered by 
CPAs, when used in this way. Specifically, we evaluated the cis/trans isomerism about the 
pipecolic acid peptide bond and we compared it with that of selected published proline- or 
pipecolic acid-containing peptides (see Scope of the work). 
Thus, we chose 4-OH-CPA 1 (see section 4.6) as the central template to build the model linear 
tripeptide Boc-Ala-4-OH-CPA-Gly-OBn (5) (scheme 1). 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1. Reagents and conditions: a) Boc-Ala-OH, DEPBT, DIPEA, THF, RT, 4 d; b) NaOH, 
MeOH, 24 h; c) H-Gly-OBn hydrochloride, DEPBT, DIPEA, THF, 35 °C, 4 d; d) TBAF, THF, RT. 
 
Amino ester 1 was coupled with an excess amount of N-Boc-protected alanine (1.5 eq.) by 
using 3-(diethoxyphosphoryloxy)-1,2,3-benzotriazin-4(3H)-one) (DEPBT) as the coupling 
reagent in THF at 25 °C. As usual, the reaction resulted very slow and required 4 days to reach 
completion, but to our delight it afforded the desired dipeptide 2 in 58% yield. Once again (see 
sections 4.2 and 5.3), treatment of 2 with 1 N NaOH for 24 h at room temperature was 
sufficient for the hydrolysis of the ester group, providing acid 3, which was coupled to O-
benzyl-protected glycine by using DEPBT as the coupling reagent. In such a way, desired 
tripeptide 4 was obtained in 84% yield and cleavage of the TIPS protecting group by TBAF in 
THF afforded final product 5. 
For the preliminary conformational investigation we intended to conduct, we preferred to 
work in organic solvent, so we did not proceed with the exhaustive deprotection of the 
peptide and we performed our NMR studies directly on compound 5. 
 
7.2 NMR Investigation of the Cis/Trans Isomerism 
To determine the cis/trans isomeric ratio, we carried out 1H NMR experiments, which showed, 
as expected, the existence of two parallel sets of signals for every compound from 
intermediate 2 to final product 5. Such sets are correlated to the two possible cis and trans 
rotational isomers, so that the isomeric ratio can be evaluated confronting the integration 
values of two signals (one from each the cis and the trans set) originated by the same selected 
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proton. On the other hand, we employed NOE correlation to assign each set to the 
appropriate rotational isomer. 
At first, we evaluated the change in the cis/trans isomerism along the synthetic path by 
comparing the behaviour of intermediates 2 and 4 with that of the final product 5. 
In the proton NMR spectrum of compound 2 the signals assigned to corresponding protons in 
the two rotamers are markedly separated (by almost 1 ppm). 3-Hax in the major rotamer (69%, 
figure 1, A) resonates at δ=2.7 ppm, whereas in the minor one (31%, figure 1, A) at δ=3.4 ppm. 
The signal of 3-Heq is found at δ=4.4 ppm for the major rotamer, whereas the same proton 
resonates at δ=3.7 ppm in the minor rotamer. In the major rotamer, we do not observe any 
NOE correlation between any of 3-H protons with the α-CH of alanine resonating at δ=4.8 
ppm. Instead, we do observe NOE correlations between the latter and both protons on the 
cyclopropane ring resonating at δ=1.4 and 2.1 ppm, as well as with the ester methyl group. 
Unfortunately, we were unable to record any NOE for the minor rotamer. Nonetheless, we 
could conclude that for intermediate 2 the major rotamer was the cis one (figure 1, A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The cis/trans isomerism about the CPA peptide bond 
 
Interestingly, after the second coupling, the ratio between the cis and trans isomers changed 
to 1:1.4 for intermediate 4 (figure 1, B) with an increase in the relative amount of the trans 
isomer. In 4 the α-CH of alanine resonate at δ=4.42 ppm in the major rotamer and at δ=4.9 
ppm in the minor rotamer. The NOESY 1D study revealed a correlation between the α-CH of 
alanine resonating at δ=4.42 ppm and the 3-Heq in the major rotamer, thereby confirming that 
the major isomer in compound 4 is trans. 
This increment of trans concentration can be explained by the augmented steric hindrance 
with the bigger substituent at C-1 in the cis-peptide isomer. However, a hydrogen bond 
between the glycine NH and the alanine CO that forms a seven-membered cycle should 
stabilize the trans isomer, too (figure 1, B).1 The deshielded signal assigned to the glycine NH, 
which resonates at δ=7.2 ppm, is consistent with the presence of this hydrogen bond, whereas 
in the cis isomer the NH resonates at δ=6.6 ppm. 
Final removal of the TIPS group provided final product 5, in which the cis/trans isomeric ratio, 
despite our expectations (owing to the lack of the sterically encumbered 4-OH protecting 
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group) remained practically unchanged (1:1.2) (figure 1, B). In trans isomer the glycine NH 
proton is still engaged in a hydrogen bond with the CO of the alanine, as suggested by its 
chemical shift at δ=7.43 ppm, so the relatively high amount of the cis isomer must be due to 
increased steric effects with the protons at C-3 caused by the presence of the cyclopropane 
ring. 
 
7.3 Cis/Trans Isomerism in CPA-, pipecolic acid- and proline-containing model peptides 
NMR spectroscopic experiments in water have shown that substitution of a proline residue 
(figure 2, A) with a pipecolic acid residue (figure 2, B) leads to a significant increase in 
population of the cis conformer (although the trans form still predominates) because the 
larger size of the pipecolic acid ring causes unfavourable interactions that are larger in the 
trans conformer.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Cis/trans isomerism in proline-, pipecolic acid- and CPA-containing model peptides 
 
Although our spectra were recorded in CDCl3 and some solvent effect cannot be completely 
ruled out, we can still compare our NMR data with those of tetrapeptides 6 and 7. 
It is immediately clear that substitution of natural pipecolic acid with CPA leads to a further 
increment in cis population (figure 2), following the same trend already observed for the 
substitution of proline with pipecolic acid. On the other hand, the absence of any stabilizing 
hydrogen bond in the trans rotamer of 6 and 7 is in contradiction with the previous 
observation, since peptides 4 and 5 are those with the lower concentration of trans isomer, 
although their trans isomers are the only ones stabilized by hydrogen bonds. Therefore, the 
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intrinsic tendency of CPA to give cis rotamer has to be higher enough to balance and 
overcome the hydrogen bond stabilization. As mentioned above, we speculated that this 
effect could be due to further unfavourable interactions present in the trans rotamer between 
the α-CH of the alanine and the protons at C-3 of the CPA due to piperidine ring distortion 
imposed by the cyclopropane moiety. This is in accordance with data reported for N-acetyl-N’-
methyl pipecolinamide (in water) in which there is an increase in the cis isomer from 28 to 
43% when the ε position of the pipecolic amino acid (which corresponds to C-3 in CPA) bears a 
tert-butyl group.1 
 
 
 
7.4 Experimental 
 
 
N CO2Me
TIPSO
O
NHBoc  
2-(Boc-Ala)-4-(triisopropylsilanyloxy)-CPA-OMe [(+)-2] 
DEPBT (105 mg, 0.35 mmol) and DIPEA (61 µL, 0.35 mmol) were added under an N2 
atmosphere to a solution of Boc-Ala-OH (45 mg, 0.24 mmol) in anhydrous THF (1 mL), cooled 
at 0 °C, and the resulting mixture was allowed to warm to room temperature. After 15 min this 
solution was slowly added to a solution of compound 1[chap. 4] (52 mg, 0.16 mmol) in anhydrous 
THF (500 µL) precooled at 0 °C. The resulting reaction mixture was stirred at room 
temperature for 4 days. Afterward, EtOAc (5 mL) was added and the mixture was washed with 
a satd. solution of NH4Cl (2.5 mL), a satd. solution of NaHCO3 (2 x 2.5 mL), and H2O (2.5 mL). 
The organic layer was dried over Na2SO4, filtered, and evaporated under vacuum. The residue 
was purified by flash chromatography (n-hexane/EtOAc, 4:1; Rf 0.37) affording pure 2 (46 mg, 
58%) as a colourless oil. 
[α]D
21 +1.7 (c 0.9, CHCl3). 
1H NMR (400 MHz, CDCl3) (2:1 mixture of rotamers) δ (ppm): 5.41 (d, 
J = 8.0 Hz, 1 H, NH Ala, minor rotamer), 5.03 (d, J = 9.4 Hz, 1 H, NH Ala, major rotamer), 4.84-
4.76 (m, 1 H, Hα Ala, major rotamer), 4.68-4.58 (m, 1 H, Hα Ala, minor rotamer), 4.36 (dd, J = 
13.1, 4.2 Hz, 1 H, 3-Heq, major rotamer), 4.17-4.15 (m, 1 H, 4-H, minor rotamer), 4.12-4.08 (m, 
1 H, 4-H, major rotamer), 3.75-3.63 (m, 4 H, 3-Heq minor rotamer + OCH3 both rotamers), 3.35 
(dd, J = 13.1, 2.1 Hz, 1 H, 3-Hax, minor rotamer), 2.76 (d, J = 13.1 Hz, 1 H, 3-Hax, major rotamer), 
2.20-2.08 (m, 2 H, 5-H + 7-H, major rotamers), 2.04-1.98 (m, 1 H, 5-H, minor rotamer), 1.96 
(dd, J = 9.6, 4.9 Hz, 1 H, 7-H, minor rotamer), 1.83-1.67 (m, 2 H, 5-H’ both rotamers + 6-H 
major rotamer), 1.64-1.56 (m, 1 H, 6-H, minor rotamer), 1.48 (dd, J = 7.9, 4.8 Hz, 1 H, 7-H’, 
major rotamer), 1.44 [s, 9 H, OC(CH3)3, minor rotamer], 1.40 [s, 9 H, OC(CH3)3, major rotamer], 
1.31 (d, J = 6.8 Hz, 3 H, CH3 Ala, minor rotamer), 1.27 (d, J = 6.4 Hz, 3 H, CH3 Ala, major 
rotamer), 1.20-1.18 (m, 1 H, 7-H’, minor rotamer), 1.04 {s, 21 H, Si[CH(CH3)2]3 + Si[CH(CH3)2]3, 
minor rotamer}, 1.03 {s, 21 H, Si[CH(CH3)2]3 + Si[CH(CH3)2]3, major rotamer}. 
13C NMR (100.4 
MHz, CDCl3) (major rotamer) δ (ppm): 175.8, 172.5, 154.6 (NCO2tBu), 79.2 [OC(CH3)3], 65.4 (C-
4), 52.5 (OCH3), 46.2, 45.7, 38.5 (C-1), 30.0 (C-5), 28.3 [3 C, OC(CH3)3], 24.0, 21.9, 19.2 (CH3 
Ala), 18.0 {6 C, Si[CH(CH3)2]3}, 12.0 {3 C, Si[CH(CH3)2]3}. MS (ESI) m/z (%): 1019 (100) [2M + 
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Na]+, 521 (42) [M + Na]+, 499 (29) [M + 1]+. Elemental analysis calcd (%) for C25H46N2O6Si 
(498.73): C, 60.21; H, 9.30; N, 5.62. Found: C, 59.93; H, 9.31; N, 5.34. 
 
 
N
TIPSO
O
NHBoc
O
H
N
CO2Bn
 
2-(Boc-Ala)-4-(triisopropylsilanyloxy)-CPA-Gly-OBn [(+)-4] 
A 1 N solution of NaOH (140 μL) was added to a solution of 2 (46 mg, 0.092 mmol) in methanol 
(210 μL) and the resulting mixture was vigorously stirred for 24 h at room temperature. 
Afterward, the methanol was evaporated and the remaining aqueous layer was diluted with 
H2O (3 mL). The resulting solution was acidified to pH 6 by adding dropwise a 1 N solution of 
HCl, and the product was extracted with CH2Cl2 (3 x 3 mL). Then the aqueous layer was further 
acidified to pH 3 and the product was extracted again with CH2Cl2 (3 x 3 mL). The combined 
organic layers were dried over Na2SO4 and after filtration and evaporation of the solvent, 
compound 3 (40 mg, 90%) was obtained as a thick colourless oil. 
1H NMR (400 MHz, CDCl3) (2.5:1 mixture of rotamers) δ (ppm): 8.86 (bs, 1 H, COOH), 5.60 (d, J 
= 8.6 Hz, 1 H, NH Ala, minor rotamer), 5.27 (d, J = 9.4 Hz, 1 H, NH Ala, major rotamer), 4.84-
4.77 (m, 1 H, Hα Ala, major rotamer), 4.65-4.61 (m, 1 H, Hα Ala, minor rotamer), 4.38 (dd, J = 
13.0, 4.3 Hz, 1 H, 3-Heq, major rotamer), 4.19-4.16 (m, 1 H, 4-H, minor rotamer), 4.13-4.10 (m, 
1 H, 4-H, major rotamer), 3.75 (dd, J = 13.2, 3.9 Hz, 1 H, 3-Heq, minor rotamer), 3.29 (dd, J = 
13.2, 2.3 Hz, 1 H, 3-Hax, minor rotamer), 2.72 (dd, J = 13.0, 2.2 Hz, 1 H, 3-Hax, major rotamer), 
2.16-2.08 (m, 2 H, 5-H + 7-H, major rotamers), 2.04-1.99 (m, 1 H, 5-H, minor rotamer), 1.96 
(dd, J = 9.7, 4.7 Hz, 1 H, 7-H, minor rotamer), 1.92-1.78 (m, 2 H, 5-H’ both rotamers + 6-H 
major rotamer), 1.76-1.68 (m, 1 H, 6-H, minor rotamer), 1.45 (dd, J = 8.0, 4.9 Hz, 1 H, 7-H’, 
major rotamer), 1.41 [s, 9 H, OC(CH3)3, minor rotamer], 1.40 [s, 9 H, OC(CH3)3, major rotamer], 
1.32 (d, J = 7.1 Hz, 3 H, CH3 Ala, major rotamer), 1.29-1.24 (m, 3 H, CH3 Ala, minor rotamer), 
1.18 (dd, J = 7.6, 4.7 Hz, 1 H, 7-H’, minor rotamer), 1.04 {s, 21 H, Si[CH(CH3)2]3 + Si[CH(CH3)2]3, 
minor rotamer}, 1.02 {s, 21 H, Si[CH(CH3)2]3 + Si[CH(CH3)2]3, major rotamer}. 
13C NMR (100.4 
MHz, CDCl3) (major rotamer) δ (ppm): 175.9 (NCO Ala), 175.8, 155.2 (NCO2tBu), 80.0 
[OC(CH3)3], 65.5 (C-4), 46.7, 45.7, 38.6 (C-1), 30.0 (C-5), 28.5 [3 C, OC(CH3)3], 26.2, 24.0, 19.6 
(CH3 Ala), 18.1 {6 C, Si[CH(CH3)2]3}, 12.1 {3 C, Si[CH(CH3)2]3}. 
DEPBT (50 mg, 0.166 mmol) and DIPEA (58 μL, 0.332 mmol) were added under an N2 
atmosphere to a solution of intermediate 3 (40 mg, 0.083 mmol) in anhydrous THF (1.5 mL) 
cooled at 0 °C, and the resulting mixture was allowed to warm to room temperature. After 15 
min the mixture was cooled again at 0 °C and H-Gly-OBn·HCl (25 mg, 0.125 mmol) was added. 
The resulting reaction mixture was stirred at 35 °C for 4 days. Afterward, EtOAc (2 mL) was 
added and the mixture was washed with a satd. solution of NH4Cl (1 mL), a satd. solution of 
NaHCO3 (1 mL) and H2O (1 mL). The organic layer was dried over Na2SO4, filtered and 
evaporated under vacuum. The residue was purified by flash chromatography (n-
hexane/EtOAc, 2:1; Rf 0.24) affording pure 4 (44 mg, 84 %) as a colourless gummy solid. 
[α]D
22 +2.7 (c 1.25, CHCl3). 
1H NMR (400 MHz, CDCl3) (1.4:1 mixture of rotamers) δ (ppm): 7.38-
7.29 (m, 6 H, NH Gly major rotamer + Ph both rotamers), 6.59-6.56 (m, 1 H, NH Gly, minor 
rotamer), 5.18-5.10 (m, 3 H, NH Ala major rotamer + CH2Ph both rotamers), 4.99-4.96 (m, 1 H, 
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NH Ala, minor rotamer), 4.91-4.85 (m, 1 H, Hα Ala, minor rotamer), 4.51 (dd, J = 12.7, 3.9 Hz, 1 
H, 3-Heq, minor rotamer), 4.46-4.41 (m, 1 H, Hα Ala, major rotamer), 4.28 (dd, J = 17.9, 6.2 Hz, 1 
H, Hα Gly, major rotamer), 4.20-4.10 (m, 2 H, 4-H both rotamers + Hα Gly, minor rotamer), 4.02 
(dd, J = 18.5, 4.8 Hz, 1 H, Hα Gly, minor rotamer), 3.78-3.65 (m, 2 H, Hα Gly major rotamer + 3-
Heq major rotamer), 3.42 (dd, J = 13.2, 3.1 Hz, 3-Hax, major rotamer), 2.68 (d, J = 12.7 Hz, 1 H, 3-
Hax, minor rotamer), 2.23-2.16 (m, 2 H, 5-H major rotamer + 6-H minor rotamer), 2.08-2.03 (m, 
1 H, 5-H, minor rotamer), 1.94-1.86 (m, 2 H, 5-H’ minor rotamer + 7-H major rotamer), 1.76-
1.70 (m, 1 H, 6-H major rotamer), 1.66-1.60 (m, 2 H, 5-H’ major rotamer + 7-H minor rotamer), 
1.44-1.33 [m, 10 H, 7-H’ minor rotamer + OC(CH3)3 both rotamers], 1.31 (d, J = 7.0 Hz, 3 H, CH3 
Ala, major rotamer), 1.28 (d, J = 6.6 Hz, 3 H, CH3 Ala, minor rotamer), 1.11-0.96 {m, 22 H, 7-H’ 
major rotamer + Si[CH(CH3)2]3 + Si[CH(CH3)2]3 both rotamers}. 
13C NMR (100.4 MHz, CDCl3) 
(major rotamer) δ (ppm): 174.8 (Cq), 171.3 (Cq), 169.9 (Cq), 154.5 (NCO2tBu), 135.2 (Cq,arom), 
128.8 (2 C, CHarom), 128.7 (2 C, CHarom), 128.4 (CHarom), 80.3 [OC(CH3)3], 67.4 (CH2Ph), 66.4 (C-4), 
50.5 (C-3), 46.9 (Cα Ala), 41.8 (Cα Gly), 39.8 (C-1), 30.6 (C-5), 28.4 [3 C, OC(CH3)3], 23.5, 23.4, 
21.2 (CH3 Ala), 18.1 {6 C, Si[CH(CH3)2]3}, 12.3 {3 C, Si[CH(CH3)2]3}. MS (ESI) m/z (%): 1285 (79) 
[2M + Na]+, 654 (100) [M + Na]+, 632 (9) [M + 1]+. Elemental analysis calcd (%) for C33H53N3O7Si 
(631.88): C, 62.73; H, 8.45; N, 6.65. Found: C, 62.54; H, 8.32; N, 6.61. 
 
 
N
HO
O
NHBoc
O
H
N
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2-(Boc-Ala)-4-(hydroxy)-CPA-Gly-OBn [(+)-5] 
TBAF (80 µL of a 1 M solution in THF, 0.080 mmol) was slowly added to a solution of 4 (44 mg, 
0.070 mmol) in anhydrous THF (3 mL), under an N2 atmosphere. After 1 h the solvent was 
evaporated under vacuum and the residue was taken up in Et2O (3 mL), then the solvent was 
evaporated again. After purification by flash chromatography (EtOAc; Rf 0.36), pure 5 (19 mg, 
58%) was obtained as a colourless gummy solid. 
[α]D
22 +18.8 (c 0.75, CHCl3). 
1H NMR (400 MHz, CDCl3) (1.2:1 mixture of rotamers) δ (ppm): 
7.43-7.40 (m, 1 H, NH Gly, major rotamer), 7.39-7.29 (m, 5 H, Ph, both rotamers), 6.73-6.68 
(m, 1 H, NH Gly, minor rotamer), 5.18-5.10 (m, 3 H, NH Ala, major rotamer + CH2Ph, both 
rotamers), 4.98 (d, J = 7.5 Hz, 1 H, NH Ala, minor rotamer), 4.78-4.72 (m, 1 H, Hα Ala, minor 
rotamer), 4.56 (d, J = 13.0 Hz, 1 H, 3-Heq, minor rotamer), 4.48-4.40 (m, 1 H, Hα Ala, major 
rotamer), 4.31 (dd, J = 17.9, 7.1 Hz, 1 H, Hα Gly, major rotamer), 4.22-4.10 (m, 1 H, Hα Gly, 
minor rotamer), 4.08-4.02 (m, 2 H, Hα Gly minor rotamer, 4-H both rotamers), 3.77 (dd, J = 
13.2, 3.9 Hz, 1 H, 3-Heq, major rotamer), 3.70 (dd, J = 17.9, 4.7 Hz, 1 H, Hα Gly, major rotamer), 
3.29 (dd, J = 13.2, 2.1 Hz, 1 H, 3-Hax, major rotamer), 2.72 (d, J = 13.0 Hz, 1 H, 3-Hax, minor 
rotamer), 2.30-1.98 (m, 2 H, 5-H both rotamers + OH both rotamers), 1.90 (dd, J = 10.0, 4.7 Hz, 
1 H, 7-H, both rotamers), 1.80-1.72 (m, 2 H, 5-H’ minor rotamer + 6-H both rotamers), 1.66-
1.59 (m, 1 H, 5-H’, major rotamer), 1.40 [s, 9 H, OC(CH3)3, minor rotamer], 1.37 [s, 9 H, 
OC(CH3)3, major rotamer], 1.35-1.25 (m, 3 H, CH3 Ala, both rotamers), 1.04 (dd, J = 7.8, 4.7 Hz, 
1 H, 7-H’, both rotamers). 13C NMR (100.4 MHz, CDCl3) (major rotamer) δ (ppm): 175.5, 171.3, 
169.8, 156.6 (NCO2tBu), 135.6 (Carom), 128.7 (2 C, CHarom), 128.6 (2 C, CHarom), 128.4 (CHarom), 
80.2 [OC(CH3)3], 67.4 (CH2Ph), 64.8 (C-4), 48.6 (C-3), 47.0 (Cα Ala), 41.8 (Cα Gly), 40.2 (C-1), 29.7 
(C-5), 28.3 [3 C, OC(CH3)3], 23.3, 20.8 (CH3 Ala), 16.5. MS (ESI) m/z (%): 973 (100) [2M + Na]
+, 
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498 (41) [M + Na]+, 476 (17) [M + 1]+. Elemental analysis calcd (%) for C24H33N3O7 (475.53): C, 
60.62; H, 6.99; N, 8.84. Found: C, 60.50; H, 6.76; N, 8.55. 
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Chapter 8: Synthesis of Both Enantiomers of Trans 3-Hydroxypipecolic Acid 
 
8.1 General Synthetic Approach for Obtaining Hydroxypipecolic Acids 
Owing to their widespread presence in nature and their significant medicinal potential, there 
has been much interest in the development of new methods for the asymmetric synthesis of 
substituted pipecolic acids.1 In this context, trans- and cis-3-hydroxypipecolic acids 1 and 2 
(figure 1) are no exceptions because a number of syntheses of both compounds have been 
reported, also owing to the fact that 3-hydroxypiperidine is a privileged scaffold in nature.2 
Moreover, 3-hydroxypipecolic acids are further examples of constrained amino acids and can 
be either employed directly as rigid serine analogues for the construction of peptidomimetics, 
or converted into the corresponding 3-aminopipecolic acids. The latter compounds could be 
embedded in cyclic RGD-based ligands similarly to what we reported for CPAs (see chapter 6). 
 
 
 
 
 
Figure 1. 3-Hydroxypipecolic acids. 
 
As recently reviewed, methods based on the use of starting material from the chiral pool or 
that involve enantiomerically enriched reagents or catalysts have been mainly exploited, with 
a few additional tactics centered on the enzymatic resolution of racemic compounds.3 Our 
group recently demonstrated that enantiopure 4-hydroxy-, 5-hydroxy- and 4,5-
dihydroxypipecolic acids can be efficiently prepared from the same enecarbamate esters II 
(scheme 1, A) that we already repeatedly described as intermediates in the synthesis of CPAs 
(see chapters 4 and 5).4-7 By this strategy, racemic or enantiopure lactams III are converted 
into enecarbamate esters II, which are then reduced and deprotected to give target 
compounds I. 
We decided to investigate if an analogous approach, but which entails a Suzuki–Miyaura 
reaction instead of a carbonylative process to form the C–C bond at C-2 (Scheme 1, B), could 
efficiently provide trans-3-hydroxypipecolic acid 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1. Retrosynthetic analysis. 
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After hydroboration/oxidation of coupling product V, an enzymatic kinetic resolution should 
provide enantiopure intermediate IV, which is finally oxidized to target compound 1. 
Lipase-catalyzed resolutions have successfully been exploited for the synthesis of 3-
hydroxypipecolic acids (both cis and trans) on only a few occasions, which involved piperidin-
3-ols with the 2-carboxyxlic group already installed on the piperidine ring.8-12 In our case, the 
resolution will be attempted on a 2-aryl- or heteroaryl-substituted piperidin-3-ol, with the 
advantage of obtaining enantiopure intermediates potentially useful for preparing biologically 
relevant 2-aryl-substituted piperidines.13,14 
 
8.2 Synthesis of Racemic Trans 3-Hydroxypipecolic acid 
The Suzuki–Miyaura coupling of lactam-derived vinyl phosphates and triflates has been 
extensively surveyed in the past mainly by the group of Coudert and Gillaizeau15-19 and by our 
own group,20-27 and has found many applications in the synthesis of natural and biologically 
active heterocyclic compounds.28-33 We decided to use this reaction to install a masked 
carboxylic group at C-2 mainly because α,β-unsaturated esters such as II are not suitable to 
install the 3-OH group by hydroboration. Moreover, we desired to establish a new method to 
introduce the carboxylic function at C-2 alternative to the usual carbonylative approach, which 
requires the availability and the manipulation of a toxic and expensive gas. Of course, this 
strategy involves a further oxidative step not required previously. 
To evaluate the feasibility of our approach, we first coupled vinyl phosphate 4 (scheme 2), 
obtained in 96% yield from commercial N-tert-butoxycarbonyl(Boc)-protected δ-valerolactam 
(3), with phenylboronic acid under conditions that worked best for the corresponding vinyl 
triflate.21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2. First attempt of synthesis of racemic trans 3-hydroxypipecolic acid. Reagents and 
conditions: a) (PhO)2POCl, KHMDS, THF, –78 °C; b) phenylboronic acid, (Ph3P)2PdCl2, Na2CO3 (2 
M), THF, 40 °C; c) BH3·DMS, THF; then H2O2 (35 %), EtOH, NaOH (3 N); d) Et3N, DMAP, Ac2O, 
CH2Cl2; e) NaIO4, RuCl3·xH2O, CCl4/MeCN/H2O, 0 °C. 
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The reaction was carried out at 40 °C in the presence of (Ph3P)2PdCl2 (5 mol-%) in a 
tetrahydrofuran (THF) and Na2CO3 (2 M) mixture and it was complete in 24 h to provide known 
dehydropiperidine 5 in 77% yield after chromatography. Hydroboration of 5 was carried out 
with BH3·DMS at room temperature followed by oxidation with H2O2 in alkaline medium,
35 
which provided racemic alcohol 6 in moderate yield (57 %). The expected trans 
stereochemistry in 6 (and similarly in 10, see later) is easily assigned on the basis of very low 
coupling constant values for protons at C-2 and C-3, which appear as broad singlets at δ = 4.5 
and 5.4 ppm, respectively, in the 1H NMR spectrum because of their equatorial orientation. 
Both the aryl and OH groups are thus axially oriented, the former to remove the A(1,3) strain 
with the N-protecting group.36 
Before attempting the enzymatic kinetic resolution of this alcohol we wanted to test the RuCl3 
catalysed oxidation reaction of the phenyl group and so, after acetylation reaction of the OH 
group, we treated compound 7 under standard oxidative conditions.37 To our disappointment, 
the reaction carried out with a catalytic amount of RuCl3·xH2O and in the presence of NaIO4 (4 
eq.) in a CCl4/acetonitrile/water mixture was sluggish, required the addition of further oxidant, 
and yielded carboxylic acid 8 in a very low yield and in mixture with by-products derived from 
over-oxidation at position 6. The oxidative degradation of unsubstituted phenyl rings on 
similar systems has been reported for N-trifluoroacetyl-protected piperidines only,14,34,38,39 and 
never with N-Boc-protected analogues, which are probably not compatible with the reaction 
conditions. Although pipecolic acid 1 could formally be obtained from 6 after N deprotection 
and trifluoroacetylation,34 to keep our synthesis as short as possible we decided to introduce a 
more easily oxidized substituent at C2 from the beginning. So, we opted for a more electron-
rich furan, which was introduceed by the Pd-catalyzed coupling of N-Boc protected vinyl 
phosphate 4 with 2-furanylboronic acid (Scheme 3). Also in this case the coupling was 
successful and provided 9 in 82% yield after chromatography. Hydroboration of 9 was carried 
out both as reported above and with BH3·THF at 0 °C for 22 h, followed by oxidation with 
trimethylamine N-oxide.40 In both cases (±)-10 was obtained in good yield (83 and 85%, 
respectively), although with the latter method purity of the crude reaction mixture was higher.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3. Optimised synthesis of racemic trans 3-hydroxypipecolic acid. Reagents and 
conditions: a) furanylboronic acid, (Ph3P)2PdCl2, Na2CO3 (2 M), THF, 40 °C; b) BH3·THF, 0 °C, 
THF; then Me3NO, THF, 65 °C; c) BH3·DMS, THF; then H2O2 (35 %), NaOH (3 N), EtOH; d) Et3N, 
DMAP, Ac2O, CH2Cl2; e) NaIO4, RuCl3·xH2O, EtOAc/MeCN/H2O, 0 °C; f) HCl (6 N), reflux, 3 h. 
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After acetylation, we tested the oxidative conditions on compound (±)-11 and were pleased to 
obtain acid (±)-8 in good yield (70% after chromatography) after 10 min at room temperature. 
After exhaustive hydrolysis in HCl (6 N) at reflux temperature, an appropriate work-up allowed 
us to obtain racemic 3-hydroxypipecolic acid (±)-1 in quantitative yield and excellent purity.41 
Despite a further oxidative step being required, the Suzuki–Miyaura coupling strategy proved 
an excellent alternative to the alkoxycarbonylative process on lactam-derived vinyl phosphates 
for the introduction of a C-2 substituent in the synthesis of pipecolic acids. 
 
8.3 Enzymatic Resolution of the Racemic Mixture 
Once established an optimised synthetic procedure, we tackled the enzymatic kinetic 
resolution of racemic intermediate (±)-10, since we were interested in the obtaining of the 
two separated enantiomers of the final product (+)-1 and (–)-1. 
We opted to test three commercially available immobilized lipases, which our group have 
successfully employed in the past for the enantioselective acylation reaction of 4-
hydroxypipecolic acid precursors (see sections 5.1 and 5.2),5 CAL-B (Candida antarctica lipase 
B, supported on acrylic resin, trade name Novozym 435),42-44 CAL-A (C. antarctica lipase A on 
Immobead 150),45 and PS-AMANO-IM (Burkholderia cepacia lipase, immobilized diatomaceous 
earth).46,47 As reported in table 1, only CAL-B proved useful giving an enantiomeric ratio (see 
table 1, note f) around 50 when the resolution was carried out in THF and with vinyl butyrate 
as the acylant (table 1, entry 3). 
CAL-A proved less efficient but immobilized B. cepacia lipase did not appreciably convert 10 
into any of the products even with an excess of acylant. This enzyme was the best in the 
kinetic resolution of 4-hydroxypipecolic acid derivatives (see section 5.2)5 and the same 
enzyme (lipase PS-C, but immobilized on ceramic particles)46,47 provided the best results in the 
transesterification reaction of a methyl 3-hydroxypipecolate.9,12 So, although the different 
immobilization forms resulted in differences, the 2-heteroaryl group could play a role in the 
inefficacy of this enzyme. 
The absolute configuration of residual substrate (–)-10 was determined by converting it, on a 
small scale, into corresponding pipecolic acid (–)-1 (see later) and, by comparison of the 
optical rotation of its HCl salt ([α]D
21 = –14.9, c = 1.4, H2O) with the one reported in the 
literature ([α]D
23 = –13.5, c = 0.3, H2O),
49 we found that CAL-B catalyses the acylation of the 
(2S,3S) substrate. Interestingly, CAL-B is known to preferentially catalyse the acylation of the R 
alcohol in compounds like simple secondary and cyclic allylic alcohols,42-44,50,51 but clearly this 
general rule cannot be extended to our case owing to the presence of a second vicinal 
stereocenter. CAL-A similarly showed a stereopreference for the (2S,3S) enantiomer, whereas 
for the PS-AMANO-IM catalysed resolution, owing to the low conversions, the ee values nor 
the absolute configuration of the resolution products were calculated. 
For the synthesis of (2R,3R)-3-hydroxypipecolic acid (–)-1, resolution of (±)-10 was carried out 
on 200 mg of substrate and was stopped at a 57% of conversion to obtain required (–)-(2R,3R)-
10 in enantiopure form (99% ee, see appendix 2 for enantioselective HPLC analysis) in an 
acceptable yield (38% after chromatography). After the lipase-catalysed resolution, compound 
(–)-10 was acetylated to give (–)-11 (90%) (scheme 4) and then oxidized as usual to afford (–)-8 
in 72% yield after chromatography. Exhaustive deprotection was attained by treatment with 
HCl (6 N) at reflux temperature to give (–)-(2R,3R)-1 as the HCl salt in almost quantitative 
yield.41 
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Table 1. Lipase-catalysed kinetic resolution of (±)-10. 
 
 
 
 
 
 
 
 
Entry Acylanta  Solventb t  
(h) 
Conversion 
 (%)c 
(S,S)-11/12 
ee (%)d 
(R,R)-10 
ee (%)e 
E
f 
CAL-Bg 
1 VA DIPE 19 58 50 75 6 
2 VB DIPE 17 60 42 99 11 
3 VB THF 25 45 91 81 53 
   4h VB THF 19 46 89 75 39 
5    VB TBME 17 57 50 98 12 
CAL-Ag 
6 VB THF  24i 31 89 37 25 
7 VA THF 43 45 83 63 21 
PS “Amano” IMg 
   8h VA DIPE 39i 10 - - - 
9 VB THF 96i 25 - - - 
10 VB TBME 52i 18 - - - 
a VA: vinyl acetate, VB: vinyl butyrate. b Anhydrous solvents were used. DIPE: diisopropyl ether, THF: tetrahydrofuran, 
TBME: tert-butyl methyl ether. c Reaction monitored by GLC and conversion determined by 
1H NMR. d Determined by 
HPLC analysis after hydrolysis to (+)-10 on a HPLC Lux 5µ Cellulose-4 column (250 x 4.60 mm). e Determined by HPLC 
analysis on a HPLC Lux 5µ Cellulose-4 column (250 x 4.60 mm). f  The enantioselectivity in an enzymatic kinetic 
resolution process can be conveniently expressed by E = enantiomeric ratio. The ratio between the specificity 
constants (kcat/KM) of the enzyme for the competing R and S enantiomers: E = (kcat/KM)R/(kcat/KM)S. E was calculated by 
using the formula E = ln[(1 – ees)/(1 + ees/eep)]/ln[(1 + ees)/(1 + ees/eep)], where ees is the enantiomeric excess of the 
substrate and eep is the enantiomeric excess of the product.
48 g Reaction carried out on 0.4 mmol of substrate at 30 °C; 
substrate concentration: 0.8 M; enzyme (mg)/substrate (mmol) ratio: 200 mg/mmol; 3.5 equivalents of acylant. h The 
reaction was carried out at 40 °C. i The reaction did not proceed further and it was stopped. 
 
Its enantiomer was instead prepared by stopping the resolution at a 45% conversion, thus 
obtaining (+)-(2S,3S)-12 in 91% ee (see appendix 3 for enantioselective HPLC analysis) (37% 
yield) and with a suitable protection already installed on 3-OH group. After usual oxidation and 
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exhaustive deprotection (scheme 4), (+)-(2S,3S)-1 was obtained in quantitative yield as the HCl 
salt and with optical rotation ([α]D
21 = +13.7, c = 0.7, H2O) consistent to that reported for this 
enantiomer ([α]D
23 = +14.5, c = 0.4, H2O 
[52] and [α]D
25 = +14.2, c = 0.95, H2O 
[53]).41 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 4. Syntheses of (–)-(2R,3R)-3-hydroxypipecolic acid and (+)-(2S,3S)-3-hydroxypipecolic 
acid. Reagents and conditions: a) Et3N, DMAP, Ac2O, CH2Cl2; b) NaIO4, RuCl3·xH2O, 
EtOAc/MeCN/H2O, 0 °C; c) HCl (6 N), reflux, 3 h. 
 
By treating the residual substrate of the enzymatic kinetic resolution with further CAL-B and 
vinyl butyrate, and by stopping the reaction at a 18% conversion, further enantiopure (–)-
(2R,3R)-10 (32% yield) was provided, which was converted into pipecolic acid (–)-1 as 
described above.41 
 
 
 
8.4 Experimental 
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tert-Butyl 6-[(Diphenoxyphosphoryl)oxy]-3,4-dihydropyridine-1(2H)-carboxylate (4)  
A solution of potassium bis(trimethylsilyl)amide (KHMDS) in toluene (0.5 M, 15.8 mL, 7.89 
mmol) was diluted in anhydrous THF (36 mL) and cooled to –78 °C. A solution of 3 (1.26 g, 6.31 
mmol) in anhydrous THF (15 mL) was then added dropwise, keeping the temperature below –
70 °C, and the resulting mixture was stirred for 1.5 h. A solution of diphenylchlorophosphate 
(1.63 mL, 7.89 mmol) in anhydrous THF (9 mL) was then added dropwise and, after 1 h, the 
mixture was warmed to 0 °C. Aqueous NaOH (10%, 150 mL) was slowly added and the product 
extracted with Et2O (3 x 100 mL). The combined organic extracts were washed with NaOH 
(10%, 50 mL) and dried over K2CO3 for 40 min. After filtration and evaporation of the solvent, 
the crude was purified with a short pad of silica gel (n-hexane/EtOAc, 3:1 with 1% Et3N; 
Rf 0.30) to afford pure 4 (2.61 g, 96%) as a pale yellow oil. 
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1H NMR (CDCl3, 200 MHz) δ (ppm): 7.38–7.15 (m, 10 H, Ph), 5.10 (q, J = 3.3 Hz, 1 H, 5-
H), 3.60–3.55 (m, 2 H, 2-H), 2.35–2.04 (m, 2 H, 4-H), 1.75–1.69 (m, 2 H, 3-H), 1.43 [s, 9 
H, C(CH3)3]. 
 
 
N
Boc
Ph
 
tert-Butyl 6-Phenyl-3,4-dihydropyridine-1(2H)-carboxylate (5)
21
 
Aqueous Na2CO3 (2 M, 14.7 mL, 29.4 mmol), (Ph3P)2PdCl2 (77.9 mg, 0.11 mmol) and 
phenylboronic acid (406 mg, 3.33 mmol) were added to a solution of 4 (958 mg, 2.22 mmol) in 
THF (30 mL). The reaction was stirred at 40 °C for 24 h. The reaction was diluted with H2O (35 
mL) and the product extracted with Et2O (3 x 35 mL). The combined organic layers were dried 
over K2CO3. After filtration and evaporation of the solvent, the crude was purified by flash 
chromatography (n-hexane, then n-hexane/EtOAc, 20:1; Rf 0.30) to afford pure 5 (445 mg, 
77%). 
1H NMR (CDCl3, 200 MHz) δ  (ppm): 7.70–7.16 (m, 5 H, Ph), 5.31 (t, J = 3.7 Hz, 1 H, 5-H), 3.73–
3.68 (m, 2 H, 2-H), 2.26 (dt, J = 6.6, 3.7 Hz, 2 H, 4-H), 1.91–1.78 (m, 2 H, 3-H), 1.05 [s, 9 H, 
C(CH3)3]. 
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tert-Butyl 3-Hydroxy-2-phenylpiperidine-1-carboxylate [(±)-6] 
A solution of (CH3)2S·BH3 in THF (2 M, 375 μL, 0.75 mmol) was added to a solution of 5 (129 
mg, 0.5 mmol) in anhydrous THF (1 mL) at 0 °C and under an N2 atmosphere. The cooling bath 
was removed and the mixture was stirred at room temperature for 5 h. The reaction was 
cooled to 0 °C and EtOH (550 μL), NaOH (3 M, 440 μL) and H2O2 (35%, 200 μL) were added. The 
resulting mixture was heated to reflux for 1 h and, after cooling, it was transferred into a flask 
that contained ice. The product was extract with Et2O (4 x 4 mL) and the combined organic 
extracts were dried over Na2SO4. After filtration and evaporation of the solvent, the residue 
was purified by chromatography (n-hexane/EtOAc, 2:1; Rf 0.26) to give (±)-6 (79 mg, 57%) as a 
white solid. 
1H NMR (CDCl3, 400 MHz) δ (ppm): 7.37–7.34 (m, 2 H, Ph), 7.27–7.25 (m, 1 H, Ph), 7.25–7.19 
(m, 2 H, Ph), 5.37 (bs, 1 H, 2-H), 4.52 (m, 1 H, 3-H), 4.12–4.07 (d, J = 13.3 Hz, 1 H, 6-Heq), 2.87 
(td, J = 13.3, 3.3 Hz, 1 H, 6-Hax), 1.98–1.87 (m, 2 H, 5-H and OH), 1.78–1.73 (m, 1 H, 4-H), 1.66–
1.58 (m, 1 H, 4-H’), 1.48 [s, 9 H, C(CH3)3], 1.43–1.39 (m, 1 H, 5-H’). 
13C NMR (CDCl3, 100.32 
MHz) δ (ppm): 156.3 (CO), 137.8 (Cipso, Ph), 128.4 (2 C, Ph), 126.5 (C, Ph), 126.0 (2 C, Ph), 79.8 
[C(CH3)3], 67.2 (CHOH), 60.0 (CHPh), 39.6 (C-6), 28.1 [C(CH3)3], 25.7 (C-4), 18.6 (C-5). MS (ESI) 
m/z (%): 577 (100) [2M + Na]+, 300 (20) [M + Na]+. Elemental analysis calcd. (%) for C16H23NO3 
(277.36): C, 69.29; H, 8.36; N, 5.05. Found: C, 69.31; H, 8.25; N, 5.26. 
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tert-Butyl 3-(Acetyloxy)-2-phenylpiperidine-1-carboxylate [(±)-7] 
Et3N (70 μL, 0.5 mmol) and 4-dimethylaminopyridine (DMAP, 6.5 mg, 0.053 mmol) were added 
to a solution of alcohol (±)-6 (70 mg, 0.25 mmol) in dry CH2Cl2 (1 mL) under an N2 atmosphere. 
The mixture was cooled to 0 °C and acetic anhydride (43 μL, 0.46 mmol) was slowly added. The 
cooling bath was removed and the reaction was stirred at room temperature for 18 h. After 
dilution with CH2Cl2 (5 mL), a satd. solution of NaHCO3 (5 mL) was added and the aqueous 
phase was extracted with CH2Cl2 (3 x 4 mL). The combined organic layers were dried over 
Na2SO4. After filtration and evaporation of the solvent, the residue was purified by 
chromatography (n-hexane/EtOAc, 8:1; Rf 0.24) to give (±)-7 (75 mg, 94%) as a pale yellow oil. 
1H NMR (CDCl3, 400 MHz) δ (ppm): 7.38–7.34 (m, 2 H, Ph), 7.27–7.24 (m, 2 H, Ph), 5.53–5.51 
(m, 1 H, 3-H), 5.49 (s, 1 H, 2-H), 4.17–4.11 (d, J = 13.3 Hz, 1 H, 6-Heq), 2.88 (td, J = 13.3, 3.3 Hz, 1 
H, 6-Hax), 2.12 (s, 3 H, COCH3), 1.93–1.87 (m, 1 H, 5-H), 1.85–1.80 (m, 1 H, 4-H), 1.69–1.60 (m, 1 
H, 4-H’), 1.45 [s, 9 H, C(CH3)3], 1.43–1.39 (m, 1 H, 5-H’). 
13C NMR (CDCl3, 100.32 MHz) δ (ppm): 
170.5 (COCH3), 156.0 (NCO), 137.6 (Cipso, Ph), 128.7 (2 C, Ph), 127 (C, Ph), 126.3 (2 C, Ph), 79.8 
[C(CH3)3], 70.1 (C-3), 57 (C-2), 39.7 (C-6), 28.4 [C(CH3)3], 23.9 (C-4), 21.3 (COCH3), 19.5 (C-5). MS 
(ESI) m/z (%): 661 (100) [2M + Na]+, 342 (27) [M + Na]+. MS/MS (ESI of [M + Na]+) m/z (%): 342 
(3) [M + Na]+, 286 (100), 242 (9), 182 (11). Elemental analysis calcd. (%) for C18H25NO4 (319.40): 
C, 67.69; H, 7.89; N, 4.39. Found: C, 67.63; H, 7.66; N, 4.69. 
 
 
N
Boc
O
 
tert-Butyl 6-(Furan-2-yl)-3,4-dihydropyridine-1(2H)-carboxylate (9)
21
 
Aqueous Na2CO3 (2 M, 24.4 mL, 48.8 mmol), (Ph3P)2PdCl2 (130 mg, 0.185 mmol) and 2-
furanylboronic acid (621 mg, 5.55 mmol) were added to a solution of 4 (1.6 g, 3.73 mmol) in 
THF (48 mL). The mixture was heated at 40 °C for 2 h, then it was diluted with H2O (68 mL) and 
the product was extracted with Et2O (3 x 68 mL). The combined organic layers were dried over 
K2CO3. After filtration and evaporation of the solvent, the crude was purified by flash 
chromatography (n-hexane/EtOAc, 20:1, then n-hexane/EtOAc, 10:1; Rf 0.48) to afford pure 9 
(755 mg, 82%). 
1H NMR (CDCl3, 200 MHz) δ (ppm): 7.32 (dd, J = 1.8, 0.7 Hz, 1 H, 5’-H), 6.35 (dd, J = 3.3, 1.8 Hz, 
1 H, 4’-H), 6.22 (d, J = 3.3 Hz, 1 H, 3’-H), 5.52 (t, J = 4.0 Hz, 1 H, 5-H), 3.68–3.63 (m, 2 H, 2-H), 
2.26 (td, J = 7.0, 4.0 Hz, 2 H, 4-H), 1.91–1.82 (m, 2 H, 3-H), 1.26 [s, 9 H, C(CH3)3]. 
 
 
N
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OH
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tert-Butyl 2-(Furan-2-yl)-3-hydroxypiperidine-1-carboxylate [(±)-10].  
Method A: A solution of (CH3)2S·BH3 in THF (2 M, 1 mL, 2 mmol) was added to a solution of 9 
(250 mg, 1 mmol) in anhydrous THF (2 mL) at 0 °C under an N2 atmosphere. The cooling bath 
Results and Discussion: Chapter 8 
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was removed and the mixture was stirred at room temperature for 4 h. The reaction was 
cooled to 0 °C and EtOH (1.1 mL), NaOH (3 N, 900 μL) and H2O2 (35%, 390 μL) were added. The 
resulting mixture was heated to reflux for 1 h. The solution was transferred into a flask that 
contained ice and the product was extracted with Et2O (4 x 18 mL). The combined organic 
extracts were dried over Na2SO4. After filtration and evaporation of the solvent, the residue 
was purified by chromatography (n-hexane/EtOAc, 3:1; Rf 0.20) to give (±)-10 (222 mg, 83%) as 
a pale yellow oil. 
Method B: A solution of BH3·THF in THF (1 M, 2.87 mL, 2.87 mmol) was added to a stirred 
solution of 9 (219 mg, 0.82 mmol) in anhydrous THF (40 mL) at –78 °C and under a nitrogen 
atmosphere. After 15 min, the temperature was raised to 0 °C and the reaction was stirred for 
20 h. Then the mixture was warmed to room temperature and Me3NO was added. The 
reaction was heated at 65 °C for 2 h. After cooling, EtOAc (80 mL) was added and the organic 
layer was washed with brine (2 x 40 mL) and dried over anhydrous Na2SO4. Chromatography 
(n-hexane/EtOAc, 3:1; Rf 0.20) afforded pure (±)-10 (187 mg, 85%) as a colourless oil. 
1H NMR (CDCl3, 400 MHz) δ (ppm): 7.35 (dd, J = 1.8, 0.6 Hz, 1 H, 5’-H), 6.33 (dd, J = 3.3, 1.8 Hz, 
1 H, 4’-H), 6.11 (d, J = 3.3 Hz, 1 H, 3’-H), 5.34 (bs, 1 H, 2-H), 4.34 (m, 1 H, 3-H), 4.04–4.00 (d, J = 
13.1 Hz, 1 H, 6-Heq), 2.87 (td, J = 13.1, 3.1 Hz, 1 H, 6-Hax), 2.01 (bs, 1 H, OH), 1.93–1.73 (m, 3 H, 
5-H + 4-H + 4-H’), 1.47 [s, 9 H, C(CH3)3], 1.45–1.42 (m, 1 H, 5-H’). 
13C NMR (CDCl3, 100.32 MHz) 
δ (ppm): 156.1 (NCO), 151.9 (C-2’), 141.7 (C-5’), 110.2 (C-4’), 107.0 (C-3’), 80.2 [C(CH3)3], 66.1 
(C-3), 56.2 (C-2), 40.0 (C-6), 28.4 [C(CH3)3], 26.8 (C-4), 18.8 (C-5). MS (ESI) m/z (%) = 557 (48) 
[2M + Na]+, 290 (100) [M + Na]+. Elemental analysis calcd. (%) for C14H21NO4 (267.32): C, 62.90; 
H, 7.92; N, 5.24. Found: C, 62.64; H, 7.89; N, 5.37. 
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tert-Butyl 3-(Acetyloxy)-2-(furan-2-yl)piperidine-1-carboxylate [(±)-11] 
Prepared as reported for (±)-7, starting from alcohol (±)-10 (178 mg, 0.67 mmol). After 
chromatography (n-hexane/EtOAc, 6:1; Rf 0.21) pure (±)-11 (160 mg, 90%) was obtained as a 
colourless oil. 
1H NMR (CDCl3, 400 MHz) δ (ppm): 7.36 (dd, J = 1.8, 1.0 Hz, 1 H, 5’-H), 6.33 (dd, J = 3.3, 1.8 Hz, 
1 H, 4’-H), 6.15 (dd, J = 3.3, 1.0 Hz, 1 H, 3’-H), 5.44 (bs, 1 H, 3-H), 5.32 (bs, 1 H, 2-H), 4.07 (d, J = 
12.7 Hz, 1 H, 6-Heq), 2.88 (t, J = 12.7 Hz, 1 H, 6-Hax), 2.08 (s, 3 H, COCH3), 1.86–1.73 (m, 3 H, 5-H 
+ 4-H + 4-H’), 1.48–1.42 [s, 9 H, C(CH3)3 and m, 1 H, 5-H’]. 
13C NMR (CDCl3, 100.32 MHz) δ 
(ppm): 170.3 (COCH3), 155.4 (NCO), 151.1 (C-2’), 141.9 (C-5’), 110.3 (C-4’), 107.4 (C-3’), 80.0 
[C(CH3)3], 68.4 (C-3), 53.1 (C-2), 39.7 (C-6), 28.4 [C(CH3)3], 24.7 (C-4), 21.2 (COCH3), 19.5 (C-5). 
MS (ESI) m/z (%): 641 (100) [2M + Na]+, 332 (69) [M + Na]+. MS/MS (ESI of [M + Na]+) m/z (%): 
332 (10) [M + Na]+, 276 (100), 232 (15), 172 (11). Elemental analysis calcd. (%) for C16H23NO5 
(309.36): C, 62.12; H, 7.49; N, 4.53. Found: C, 61.93; H, 7.22; N, 4.69. 
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3-(Acetyloxy)-1-(tert-butoxycarbonyl)piperidine-2-carboxylic Acid [(±)-8] 
RuCl3·xH2O (2 mg, 0.01 mmol) was added to a solution of NaIO4 (734 mg, 3.43 mmol) in EtOAc 
(3.5 mL)/CH3CN (5.7 mL)/H2O (2.8 mL) cooled to 0 °C. The reaction was stirred at 0 °C for 15 
min, then a solution of (±)-11 (153 mg, 0.49 mmol) in EtOAc (2.8 mL) was slowly added. After 5 
min at 0 °C, H2O (12 mL) was added and the product was extract with EtOAc (2 x 16 mL). The 
combined organic layers were dried over anhydrous Na2SO4 and the crude product was 
purified by chromatography (CH2Cl2/MeOH, 40:1 + 0.1% AcOH, Rf 0.50) to give (±)-8 (98 mg, 
70%) as a yellow gummy solid. 
1H NMR (CDCl3, 400 MHz) (1:1 mixture of rotamers) δ (ppm): 10.78 (bs, 1 H, COOH), 5.43 (bs, 1 
H, 3-H, rotamer A), 5.34 (bs, 1 H, 3-H, rotamer B), 5.07 (bs, 2-H, rotamer A), 4.99 (bs, 2-H, 
rotamer B), 4.11 (d, J = 12.5 Hz, 1 H, 6-Heq, rotamer A), 3.97 (d, J = 12.5 Hz, 1 H, 6-Heq, rotamer 
B), 2.97 (t, J = 12.5 Hz, 1 H, 6-Hax, rotamer A), 2.85 (t, J = 12.5 Hz, 1 H, 6-Hax, rotamer B), 2.06 (s, 
3 H, COCH3, rotamer A), 2.04 (s, 3 H, COCH3, rotamer B), 1.94–1.20 (m, 4 H, 4-H + 5-H, both 
rotamers), 1.45 [s, 9 H, C(CH3)3, rotamer A], 1.41 [s, 9 H, C(CH3)3, rotamer B]. 
13C NMR (CDCl3, 
100.32 MHz) (1:1 mixture of rotamers) δ (ppm): 177.3, 173.8 and 170.4 (COOH and COCH3, 
both rotamers), 156.3 (NCO, rotamer A), 155.3 (NCO, rotamer B), 80.7 [C(CH3)3], 67.9 (C-3, 
rotamer A), 67.3 (C-3, rotamer B), 57.9 (C-2, rotamer A), 57.1 (C-2, rotamer B), 41.7 (C-6, 
rotamer A), 40.5 (C-6, rotamer B), 28.3 [C(CH3)3], 25.4 (C-4), 21.1 (COCH3, rotamer A), 20.8 
(COCH3, rotamer B), 18.9 (C-5, rotamer A), 18.8 (C-5, rotamer B). MS (ESI) m/z (%): 597 (100) 
[2M + Na]+, 310 (96) [M + Na]+. MS/MS (ESI of [M + Na]+) m/z (%): 310 (3) [M + Na]+, 254 (100), 
210 (49). Elemental analysis calcd. (%) for C13H21NO6 (287.31): C, 54.35; H, 7.37; N, 4.88. 
Found: C, 54.11; H, 7.19; N, 4.95. 
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3-Hydroxypiperidine-2-carboxylic Acid Hydrochloride [(±)-1·HCl] 
A solution of (±)-8 (93 mg, 0.32 mmol) in HCl (6 N, 9 mL) was heated to reflux for 2 h. The 
reaction was then cooled to room temperature and the solvent was evaporated under 
vacuum. The residue was triturated in Et2O (2 x 5 mL), and the organic phase was discarded to 
obtain (±)-1·HCl (46 mg, 100%) as a pale yellow solid. 
1H NMR (D2O, 400 MHz) δ (ppm): 3.95–3.91 (m, 1 H, 3-H), 3.66 (d, J = 8.2 Hz, 2-H), 3.20–3.15 
(m, 1 H, 6-H), 2.91–2.85 (m, 1 H, 6-H’),  1.86–1.78 (m, 2 H, 4-H + 5-H), 1.59–1.44 (m, 2 H, 4-H’ + 
5-H’). 13C NMR (D2O, 100.32 MHz) δ (ppm): 169.6 (COOH), 65.5 (C-3), 60.7 (C-2), 42.6 (C-6), 
28.9 (C-4), 18.6 (C-5). 
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Kinetic Resolution of (±)-10 with CAL-B 
tert-Butyl (R,R)-2-(Furan-2-yl)-3-hydroxypiperidine-1-carboxylate [(–)-10] 
CAL-B (148 mg) was added to a solution of (±)-10 (200 mg, 0.74 mmol) in diisopropyl ether 
(940 μL) at 30 °C. After 10 min, vinyl butyrate (330 μL, 2.6 mmol) was added and the reaction 
was monitored by GLC. After 17 h, the conversion reached 57% and the reaction was stopped 
by filtration through a thin layer of Celite. After evaporation of the solvent, the crude was 
purified by chromatography (n-hexane/EtOAc, 6:1, then n-hexane/EtOAc, 3:1; Rf 0.21) to 
afford (–)-10 (75 mg, 38%, 99% ee). 
[α]D
18 = –77.3 (c = 1.1, CHCl3). Spectroscopic data identical to those reported above for (±)-10. 
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tert-Butyl (R,R)-3-(Acetyloxy)-2-(furan-2-yl)piperidine-1-carboxylate [(–)-11]  
Prepared as reported above for (±)-11, starting from (–)-10 (70 mg, 0.26 mmol). (–)-11 (72 mg, 
90%) was obtained after chromatography (n-hexane/EtOAc, 6:1, Rf 0.21) as a colourless oil. 
[α]D
21 = –45.9 (c = 1.0, CHCl3). Spectroscopic data identical to those reported above for (±)-11. 
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(R,R)-3-(Acetyloxy)-1-(tert-butoxycarbonyl)piperidine-2-carboxylic Acid [(–)-8] 
Prepared as reported above for (±)-8, starting from (–)-11 (70 mg, 0.23 mmol). (–)-8 (49 mg, 72 
%) was obtained after chromatography (CH2Cl2/MeOH, 20:1 with 0.1% AcOH; Rf 0.19). 
[α]D
22 = –15.7 (c = 1.0, CHCl3). Spectroscopic data identical to those reported above for (±)-8. 
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(R,R)-3-Hydroxypiperidine-2-carboxylic Acid Hydrochloride [(–)-1·HCl]
49
 
Prepared as reported above for (±)-1·HCl, starting from (–)-8 (49 mg, 0.17 mmol). (–)-1·HCl (31 
mg, 96%) was obtained as a light yellow solid. 
[α]D
21 = –14.9 (c = 1.4, H2O). Spectroscopic data identical to those reported above for (±)-1·HCl. 
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Kinetic Resolution of (±)-10 with CAL-B 
tert-Butyl (S,S)-3-(Butyryloxy)-2-(furan-2-yl)piperidine-1-carboxylate [(+)-12] 
CAL-B (400 mg) was added to a solution of (±)-10 (540 mg, 2 mmol) in THF (2.6 mL) at 30 °C. 
After 10 min, vinyl butyrate (889 μL, 7 mmol) was added and the reaction was monitored by 
GLC. After 25 h, the conversion reached 45% and the reaction was stopped by filtration 
through a thin layer of Celite. After evaporation of the solvent, the crude was purified by 
chromatography (n-hexane/EtOAc, 6:1, then n-hexane/EtOAc, 3:1 Rf 0.26) to afford (+)-12 (250 
mg, 37%, ee 91%). 
[α]D
23 = +31.7 (c = 0.82, CHCl3). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 7.36 (d, J = 1.2 Hz, 1 H, 5’-
H), 6.33 (dd, J = 3.1, 2.0 Hz, 1 H, 4’-H), 6.15 (dd, J = 2.0, 1.2 Hz, 1 H, 3’-H), 5.42 (bs, 1 H, 3-H), 
5.34 (bs, 1 H, 2-H), 4.08 (d, J = 12.5 Hz, 1 H, 6-Heq), 2.88 (t, J = 12.5 Hz, 1 H, 6-Hax), 2.32 (t, J = 
7.4 Hz, 2 H, OCOCH2CH2), 1.86–1.76 (m, 3 H, 5-H + 4-H + 4-H’), 1.72–1.60 (m, 2 H, CH2CH2CH3), 
1.47–1.44 [s, 9 H, C(CH3)3 and m, 1 H, 5-H’], 0.97 (t, J = 7.4 Hz, 3 H, CH2CH2CH3). 
13C NMR 
(CDCl3, 100.32 MHz) δ (ppm): 173.0 (COCH2), 155.4 (NCO), 151.2 (C-2’), 142.1 (C-5’), 110.4 (C-
4’), 107.4 (C-3’), 80.0 [C(CH3)3], 68.2 (C-3), 53.3 (C-2), 39.8 (C-6), 36.5 (COCH2CH2), 28.5 
[C(CH3)3], 24.8 (C-4), 19.7 (C-5), 18.6 (CH2CH2CH3), 13.8 (CH2CH3). MS (ESI) m/z (%): 697 (100) 
[2M + Na]+, 360 (28) [M + Na]+. Elemental analysis calcd. (%) for C18H27NO5 (337.41): C, 64.07; 
H, 8.07; N, 4.15. Found: C, 63.78; H, 7.93; N, 4.22. 
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(S,S)-3-(Butyryloxy)-1-(tert-butoxycarbonyl)piperidine-2-carboxylic Acid [(+)-13] 
Prepared as reported above for (±)-8, starting from (+)-12 (190 mg, 0.56 mmol). Product (+)-13 
(114 mg, 65%) was obtained as a yellow gummy solid. 
[α]D
20 = +12.4 (c = 1.1, CHCl3). 
1H NMR (CDCl3, 400 MHz) (1:1 mixture of rotamers) δ (ppm): 
9.17 (bs, 1 H, COOH), 5.45 (bs, 1 H, 3-H, rotamer A), 5.36 (bs, 1 H, 3-H, rotamer B), 5.09 (bs, 2-
H, rotamer A), 5.00 (bs, 2-H, rotamer B), 4.14 (d, J = 12.3 Hz, 1 H, 6-Heq, rotamer A), 3.99 (d, J = 
12.3 Hz, 1 H, 6-Heq, rotamer B), 3.00 (t, J = 12.3 Hz, 1 H, 6-Hax, rotamer A), 2.86 (t, J = 12.3 Hz, 1 
H, 6-Hax, rotamer B), 2.31–2.30 (m, 2 H, COCH2CH2, both rotamers), 1.67–1.60 (m, 2 H, 
CH2CH2CH3, both rotamers), 1.47 [s, 9 H, C(CH3)3, rotamer A], 1.43 [s, 9 H, C(CH3)3, rotamer B], 
1.94–1.20 (m, 4 H, 4-H + 5-H, both rotamers), 0.96–0.93 (m, 3 H, CH2CH2CH3, both rotamers). 
13C NMR (CDCl3, 100.32 MHz) δ (ppm): 173.8, 172.9 and 172.7 (COOH and COCH2, both 
rotamers), 156.1 (NCO, rotamer A), 155.3 (NCO, rotamer B), 80.7 [C(CH3)3], 67.4 (C-3, rotamer 
A), 67.3 (C-3, rotamer B), 57.9 (C-2, rotamer A), 57.1 (C-2, rotamer B), 41.6 (C-6, rotamer A), 
40.3 (C-6, rotamer B), 36.3 (COCH2CH2), 28.2 [C(CH3)3], 25.4 (C-4), 18.9 (C-5, rotamer A), 18.8 
(C-5, rotamer B), 18.5 (CH2CH2CH3, rotamer A), 18.4 (CH2CH2CH3, rotamer B), 13.6 
(CH2CH2CH3). MS (ESI) m/z (%): 984 (100) [3M + K]
+, 669 (70) [2M + K]+, 653 (59) [2M + Na]+, 
338 (19) [M + Na]+. Elemental analysis calcd. (%) for C15H25NO6 (315.36): C, 57.13; H, 7.99; N, 
4.44. Found: C, 57.45; H, 7.81; N, 4.28. 
Results and Discussion: Chapter 8 
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(S,S)-3-Hydroxypiperidine-2-carboxylic Acid Hydrochloride [(+)-1·HCl]
52,53
 
Prepared as reported above for (±)-1·HCl, starting from (+)-13 (100 mg, 0.32 mmol). 
Compound (+)-1·HCl (58 mg, 100%) was obtained as a light yellow solid. 
[α]D
21 = +13.7 (c = 0.7, H2O). Spectroscopic data identical to those reported above for (±)-1·HCl. 
Results and Discussion: Chapter 8 
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8.5 Appendix 
 
Appendix 1: Enantioselective Analytical HPLC of (±)-10 
HPLC analysis of purified (±)-10. Column: Lux 5µ Cellulose-4 (4.6-250 mm), isocratic 10% IPA, 
90% hexane at room temperature. 
 
0,0 5,0 10,0 15,0 20,0 25,0 30,0 35,0 40,0
-10,0
0,0
12,5
25,0
37,5
50,0
70,0 13gen2014risoluzioni3idrossipipecolico #25 UV_VIS_1
mAU
min
1 - 18,627
2 - 29,447
WVL:223 nm
 
 
No. Ret. Time (min) Height (mAU) Area (mAU*min) Rel. Area (%) 
1 18.63 59.224 29.204 50.98 
2 29.45 33.830 28.078 49.02 
Total  93.054 57.281 100.00 
N
Boc
OH
O
(+/-)-10
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Appendix 2: Enantioselective Analytical HPLC of (–)-10 
HPLC analysis of purified (–)-10. Column: Lux 5µ Cellulose-4 (4.6-250 mm), isocratic 10% IPA, 
90% hexane at room temperature. 
 
0,0 5,0 10,0 15,0 20,0 25,0 30,0 35,0 40,0
-10,0
12,5
25,0
37,5
50,0
62,5
80,0 13gen2014risoluzioni3idrossipipecolico #17 [modified by HPLC]UV_VIS_1
mAU
min
1 - 19,000
2 - 30,027
WVL:223 nm
 
  
No. Ret. Time (min) Height (mAU) Area (mAU*min) Rel. Area (%) 
1 19.00 69.312 39.747 99.68 
2 30.03 0.193 0.126 0.32 
Total  69.506 39.872 100.00 
N
Boc
OH
O
(-)-10
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Appendix 3: Enantioselective Analytical HPLC of (+)-10 
HPLC analysis of purified (+)-10. Column: Lux 5µ Cellulose-4 (4.6-250 mm), isocratic 10% IPA, 
90% hexane at room temperature. 
 
0,0 5,0 10,0 15,0 20,0 25,0 30,0 35,0
-10,0
0,0
10,0
20,0
30,0
40,0
50,0
60,0 28nov2013risoluzioniCALB #3 [modified by HPLC] UV_VIS_1
mAU
min
1 - 17,773
2 - 27,807
WVL:223 nm
 
No. Ret. Time (min) Height (mAU) Area (mAU*min) Rel. Area (%) 
1 17.77 3.734 1.929 4.53 
2 27.81 53.527 40.642 95.47 
Total  57.261 42.572 100.00 
 
N
Boc
OH
O
(+)-10
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Conclusions 
 
In conclusion, we have demonstrated that substituted 2-azabicyclo[4.1.0]heptane-1-carboxylic 
acids (cyclopropane pipecolic acids, or CPAs) are suitable to be introduced into linear and 
cyclic peptides to generate a novel class of peptidomimetics for drug discovery. 
First, we have shown that it is possible to efficiently prepare a number of differently hydroxy- 
and amino-substituted CPAs by means of the Pd-catalysed methoxycarbonylation of suitably 
functionalized lactam-derived vinyl phosphates followed by an OH-directed (efficient control 
of the relative stereochemistry of the various group) or a Michael-type cyclopropanation. By 
this approach, enantiopure N-Boc-, N-Cbz-, N-CO2Me- and N-Fmoc-protected cyclopropane 
pipecolic acids bearing a hydroxy group at the 4- or 5-position were prepared in good yields, 
starting from simple commercially available materials. In addition, N-CO2Me-protected 4- and 
5-hydroxy-pipecolic acids were efficiently converted into the correspondent 4- and 5-amino 
derivatives, which were employed for the construction of biologically active cyclic 
peptidomimetics. 
A combined NMR spectroscopic and modelling study on these scaffolds suggests that the 
cyclopropane forces the piperidine ring into a slightly distorted half-chair, with the various ring 
substituents projected along well-determined orientations. 
4-OH-CPA was successfully introduced into a short linear peptide by using standard coupling 
techniques, showing that, compared to natural pipecolic acid, the presence of the 
cyclopropane moiety causes a remarkable shift toward the cis isomer about the pipecolic acid 
peptide bond. 
Furthermore, both 4-NH2-CPA and 5-NH2-CPA with cis relative stereochemistry between the 
carboxylic and the amino groups proved suitable templates to prepare cyclic peptidomimetics 
containing the RGD sequence, which resulted potent ligands of both αvβ3 and α5β1 integrin 
receptors.  
The RGD-containing peptidomimetic built on the 5-amino-CPA displayed an inhibition activity 
toward αvβ3 (IC50 = 2.4 nM) comparable to that of the most potent antagonists reported so far 
and it was also ten times more active than the corresponding ligand derived from the isomeric 
4-amino-CPA. Since the activity of both compounds was in the nanomolar range towards both 
integrins, they can be considered as dual ligands, which could be an advantage in these 
compounds find applications in cancer therapy. These results are encouraging in further 
employing these CPA templates for the synthesis of new integrin binders and, by exploiting 
the scaffold N atom as an anchoring point, for targeted delivery of drugs and diagnostics. 
Indeed, we can affirm that another class of artificial conformationally constrained amino acids 
has made its entrance in peptide synthesis. Hereafter, further peptidomimetics could be 
synthesised to find new biologically active compounds and to enlarge investigations 
concerning the conformational characteristics introduced by CPAs in peptides. 
 
Contemporaneously, a side project led to a new efficient and facile synthesis for both 
enantiomers of trans 3-hydroxypipecolic acid, another constrained amino acid part of the 
pipecolic acid derivatives family. In the process, we also developed a new method for the 
introduction of the carboxylic functional group at the 2-position by oxidizing an aryl moiety 
conveniently introduced by Suzuki-Miyaura cross-coupling on the usual vinyl phosphate 
intermediate. 
Conclusions 
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These compounds, apart from containing the interesting 3-hydroxy-piperidene moiety, can be 
considered as constrained serine analogues valuable for natural amino acids replacement in 
the construction of rigid peptidomimetics. Moreover, they could be converted into the 
correspondent 3-amino derivatives and employed as scaffolds for building further RGD-based 
integrin ligands. 
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